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Mitochondrial vitality is dependent upon continued cooperation between nuclear
(nDNA) and mitochondrial genomes (mtDNA) and defects in either genome can result
in a broad spectrum of human disease.
Leber’s Hereditary Optic Neuropathy (LHON) is an inherited blindness caused by
the selective loss of retinal ganglion cells (RGCs) which predominantly affects young
males. In 90% of LHON, cases harbour one of three primary mutations, m.11778G>A,
m.3460G>A andm.14484T>C,which affect Complex I subunits of the electron transport
chain. mtDNA mutations alone cannot explain the characteristic reduced penetrance,
gender bias and secondary phenotypes of LHON. Recent work on LHON has often,
unsuccessfully, focused on the identification of a nuclear-encoded modifying gene
which would explain these characteristics.
Thus, the aims of this PhD were, i) to improve our estimates of disease penetrance
and investigate other potential disease modifiers, ii) to use LHON patient cell lines to
investigate the effect ofmtDNAmutations on cellular processeswhichmay contribute to
LHONand iii) to evaluate retinal degeneration in amtDNAmutation animalmodel. By
investigating these key components of LHON we hope to improve our understanding
of the disease process.
Using a large familial cohort, we were able to update and improve current LHON
penetrance estimates, with our analysis indicating that the penetrance in females is
much higher than previous estimates. In addition, we were able to show that LHON
cases have differential genetic variants andmethylation patterns, identifying ~45 nDNA
modifier genes that may explain the variable penetrance and gender bias in LHON.
Primary LHON fibroblasts were further characterised across a range of biochemical
mechanisms.
Analysis of an mtDNA mutation mouse has improved our understanding of the
effect of mtDNA mutation on RGC loss. Work in this PhD has identified a technical
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Chapter 1 | Introduction
1.1 MITOCHONDRIA
Mitochondria are complex cellular organelles, responsible for a number of biological
processes and cellular control. Often named, ’the powerhouse of the cell’, they produce
more than 90% of the cells’ energy in mammalian systems by oxidative phosphoryla-
tion (Chance et al., 1979). In addition to providing the vast majority of energy for many
species, they also have a role in many other cellular processes, including, Ca2+ regula-
tion, fatty acid synthesis, haem and iron-sulphur cluster biogenesis, and cell signalling,
particularly within the intrinsic pathway of apoptosis.
In healthy individuals, mitochondria are able to respond appropriately to energy
demands, such as upregulatingmitochondrial biogenesis and Adenosine Triphosphate
(ATP) production via the Electron Tansport Chain (ETC) in individuals who regularly
exercise (Menshikova et al., 2006).
Mitochondria have a key role in managing healthy states, however, in cases of
mitochondrial dysfunction, it often results in debilitating disease, respiratory defects
and death. Different tissue types have differing numbers of mitochondria to handle
varying metabolic demands (Cole, 2016; Okie et al., 2016); with high energy demands,
muscle and neurological tissue are often most severely affected (De Vivo and DiMauro,
1990; Pacheu-Grau et al., 2018;Wang et al., 2010). This project focuses onmitochondrial
dysfunctionwhich leads to retinal and visual defects, predominantly, Leber Hereditary
Optic Neuropathy (LHON).
1.1.1 Mitochondrial Structure
Mitochondria are double membrane bound organelles, evolutionary derived from α-
proteobacteria which developed a symbiotic relationshipwith eukaryotic cells (Wallace
and Fan, 2010). Singular mitochondria are small, oval shaped organelles, typically 1–2
µm by 0.5–1 µm (Tzagoloff, 1982). Mitochondrial morphology does show distinct
specialisation between different tissue types and metabolic demands with most mito-
chondria being either ’mitos’ (thread) or ’chondros’ (grain) shaped (Damirchi, 2012;
Youle and Karbowski, 2005; Youle and van der Bliek, 2012). They exist in a complex
mitochondrial network which is further described in Section 1.3.1.
Mitochondria are highly compartmentalised, with different regions of the mito-
chondria specialising in specific roles. The mitochondria are separated from the cell’s
1
cytoplasm by the outer membrane and within the mitochondria, an inner membrane,
comprised of tightly folded, pleomorphic, cristae separates the central matrix from the
Intermembrane Space (IMS). The mitochondrial matrix is the site of the citric acid cycle
and also contains nucleoids of mitochondrial DNA (mtDNA), ribosomes and gran-
ules containing ions, lipids, and other molecules (Jacob et al., 1994; Mannella, 2006;
Pasquali-Ronchetti et al., 1969).
Figure 1.1: Illustration of a mitochondrion, showing the baffle-shape folded, double membrane bound
structure and internal attributes as labelled. Figure from Song (2013), available under Creative
Commons CC0 1.0 Universal Public Domain Dedication Licensing.
The Mitochondrial Outer Membrane (MOM) is highly porous to molecules below
3,000Dadue to the great expression of Voltage-DependentAnionChannel (VDAC) (Mi-
tochondrial Porin) (Bayrhuber et al., 2008; Benz, 1990). For largermolecules, specialised
mitochondrial translocases are used (Sokol et al., 2014). In contrast, the Mitochondrial
Inner Membrane (MIM) is highly selective, with many membrane-associated proteins
embedded in the MIM, particularly the Oxidative Phosphorylation (OXPHOS) ma-
chinery (Schenkel and Bakovic, 2014). This selectivity results in an electrochemical
Mitochondrial Membrane Potential (ΔΨm) of -180 mV between the matrix and IMS
(Kühlbrandt, 2015).
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While mitochondria are dynamic structures, often undergoing fusion and fission
with other mitochondria in response to biochemical triggers, such as restructuring the
mitochondria between condensed and orthodox (respectively, matrix contracted and
expanded) topologies as required (Mannella et al., 2001), and as further described in
Section 1.3.1, their internal structure is very specific. The matrix contains independent
mtDNA, MIM-bound ribosomes (Pfeffer et al., 2015), tRNAs and associated protein
factors, responsible for synthesising both their own DNA and proteins (Kühlbrandt,
2015), and the outlying IMS has a role in signalling pathways and protein transport
(Herrmann and Riemer, 2010).
1.1.2 mtDNA
More than 99% of the DNAused inmitochondrially associated actions is locatedwithin
the nuclear DNA (nDNA), however, mitochondria still maintain their own individual
genome (Kühlbrandt, 2015).
mtDNA, shown inFigure 1.2, is a 16,569 bp circular genomeencoding 37 overlapping
genes, 2 RNAs, 22 tRNA and 13 polypeptides (Taanman, 1999) organised into ~100
nm spherical nucleoids with Mitochondrial Transcription Factor A (TFAM) coating a
singular mtDNA (Bogenhagen, 2012; Kühlbrandt, 2015; Wang et al., 2013). Alongside
structuring the nucleoids, TFAM is also responsible for supercoiling, transcription
initiation, and mtDNA copy number (Campbell et al., 2012).
mtDNA is extremely gene dense, with overlapping genes and few non-coding re-
gions. mtDNA has both a heavy (H-strand, outer, guanosine rich) and light (L-strand,
inner, cytosine-rich) strand with different origins of replication. There is also a non-
coding region called the D-loop, where the H-strand origin of replication (OH) sits
(Gammage and Frezza, 2019). In some mtDNA molecules, the DNA exists in a triple
helix structure due to the incorporation of 7S DNA, a ~680 bp DNA strand (Anderson
et al., 1981; Nicholls andMinczuk, 2014). ~10% of mtDNA contains the 7S triple strand
in cultured human cells but the proportion varies (Nicholls and Minczuk, 2014).
There are three proposed methods for mtDNA replication: strand displacement,
strand-synchronous and Ribonucleotide Incorporation Throughout the Lagging Strand
(RITOLS), but at present, strand displacement is the favoured methodology for repli-
cation (Anderson et al., 1981; Falkenberg, 2018; Holt et al., 2000; Nicholls andMinczuk,
2014; Yasukawa et al., 2006).
Strand displacement theorises that replication begins at OH (Anderson et al., 1981;
Clayton, 2000) where the H-strand is replicated for ~2/3 of the genome in an anti-
clockwise direction whereafter the L-strand origin (OL) is exposed. The L-strand
synthesis then begins and takes place in a clockwise direction whilst the H-strand
replication continues (Anderson et al., 1981; Falkenberg, 2018).
The number of mitochondria present in each cell and their respective quantity of
mtDNA varies between 102 and 104 between cells (Ye et al., 2014); variation in mtDNA
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Figure 1.2: mtDNA showing mitochondrial coding regions in purple, tRNA in green, ribosomal RNA
in blue and the D-loop in orange. Three primary LHON mutations which account for the majority of
LHON cases are shown in red.
copy number has been linked with a variety of diseases, including neurodegeneration
(Rooney et al., 2015).
As all cells contain multiple mitochondria and each mitochondrion contains mul-
tiple copies of mtDNA, this can result in heteroplasmy, whereby some of the cellular
mitochondria carry a variant which the others do not, or homoplasmy, where all of the
mtDNA is homologous. In clinical settings, heteroplasmy and homoplasmy typically
refer to the presence of a pathogenic mutation and how the patient can be affected
as a carrier. Whilst some mitochondrial mutations commonly exist as homoplasmic
mutations (Yu-Wai-Man et al., 2002), it is common for mitochondrial disease to occur
in heteroplasmic states when the mutant mitochondrial burden exceeds a ’threshold’
whereby the organisms’ ability to compensate for defective mitochondria is exceeded
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and disease onset occurs (Rossignol et al., 2003; Ye et al., 2014).
During cell division, mitochondria are split between the two daughter cells and this
can result in one cell carrying a disproportionately high number of mutant mtDNA
molecules compared to the other. Heteroplasmic mothers can produce egg cells with
differing levels of heteroplasmy (Wallace and Chalkia, 2013), resulting in subsequent
difficulties in prediction of disease transmission.
mtDNA inheritance is matrilineal, and as such, it does not undergo recombination
and can be prone to transmission of pathogenic mutations. Whilst it is believed that
there have been exceptions to the matrilineal inheritance (Luo et al., 2018), this is
likely a result of technical error identifying nuclear mtDNA concatamers as mtDNA
(Balciuniene and Balciunas, 2019). Next-Generation Sequencing (NGSeq) screening
by Professor Patrick Chinnery (University of Cambridge) (manuscript in preparation)
further disproves this inheritance mechanism.
mtDNA has a mutational rate 10x that of nDNA as it is arranged in nucleoids,
without histone protection, and has a close proximity to the genotoxic mitochondrial
chain (Pinto and Moraes, 2014). In addition to this, mtDNA does not have nucleotide
excision repair pathways; instead, only base excision repair, mismatch repair, direct
reversal and single strand break repair have been confirmed to occur (Jeppesen et al.,
2011). It was believed that mtDNA damage could further induce mitochondrial dys-
function, leading to a self-amplifying, ’vicious’ cycle which produces more Reactive
Oxygen Species (ROS) which further damages mtDNA (Jeppesen et al., 2011), however,
recent studies have indicated that ROS is a poor effector of mtDNA damage and that
the mutations actually arise from themode of mtDNA replication rather than oxidative
stress (Gammage and Frezza, 2019). The ’vicious cycle’ model would indicate many de
novomutations arising throughout life when mutant mtDNA tends to instead undergo
clonal expansion (De Grey, 2005; Kowald and Kirkwood, 2013).
mtDNA instability leads to pointmutations, insertions or deletions. It is particularly
prone to mtDNA deletions between 8,469-13,447 bp (Fukui and Moraes, 2009; Phillips
et al., 2014) which spans themajor arc of themtDNA at 10,912-10,994 bp rather than the
minor arc, positioned at 16,528-43 bp (Phillips et al., 2014). This deletion spans several
genes, including MT-ND3 and MT-ND4.
1.2 RESPIRATION
Respiration is the cellular process whereby glucose is converted to energy. In humans,
there are four stages: glycolysis, the link reaction, the citric acid cycle and the ETC.
Respiration occurs under both aerobic and anaerobic conditions which respectively
produce a net of 26 and 2 ATP molecules from each molecule of glucose.
Glycolysis occurs in the cytoplasm and 2 molecules of pyruvate are produced from
each glucose molecule. In anaerobic conditions, pyruvate undergoes conversion into
lactic acid - in a reversible reaction - or in aerobic conditions, pyruvate goes into the
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link reaction, whereby it is imported into the mitochondrial matrix by carrier-mediated
proteins and oxidised to acetyl coenzyme A (acetyl-CoA), losing CO2 as a product
(McCommis and Finck, 2015).
Next, acetyl-CoA joins the citric acid cycle which joins with oxaloacetate and goes
through a cycle of reactions to produce onemolecule of Guanosine Triphosphate (GTP)
from Guanosine Diphosphate (GDP) and reduce both Flavin Adenine Dinucleotide
(FAD) to Dihydroflavine-Adenine Dinucleotide (FADH2) and 3 molecules of Nicoti-
namide Adenine Dinucleotide (NAD+) to NAD +Hydrogen (NADH). CO2 is produced
as waste and a molecule of water is also used in the cycle, which is required to recreate
the oxaloacetate used at the start of the cycle.
The FADH2 and NADH created in the citric acid cycle then move to the MIMwhere
the complexes of the ETC are located.
1.2.1 Oxidative Phosphorylation
The mitochondrial respiratory chain is comprised of five complexes, NADH:CoQ10
oxidoreductase, succinate dehydrogenase, CoQ10-cytochrome c reductase, cytochrome
c oxidase and ATP synthase, also named Complex I:V respectively, amongst other
names. Embedded within the MIM, they are the site of OXPHOS and responsible
for the majority of energy production for the cell. FADH2 and NADH from the citric
acid cycle are oxidised and the H+ ions (protons) are pumped out of the mitochondrial
matrix by complexes I, III and IV into the IMS, with Complex IV creating water as a
byproduct, and setting up a proton motive force across the MIM (Jastroch et al., 2010).
As protons return into the cell through Complex V, these are used to synthesise ATP
from ADP and one Inorganic Phosphate group, (Pi).
The complexes all work together to produce energy, sometimes directly; with Com-
plexes I, III and IV capable of integrating to form respirasomes or respiratory super-
complexes (Signes and Fernandez-Vizarra, 2018).
Complex I
Complex I, as shown in Figure 1.4, is the largest enzyme of the mitochondrial res-
piratory chain at ~980 KDa (Brandt and Zickermann, 2013; Mimaki et al., 2012); as
such, it is vulnerable to sequence mutations and assembly error. It is the first enzyme
of the mitochondrial ETC and comprised of 45 subunits, of which Mitochondrially
Encoded NADH:CoQ10 Oxidoreductase Core Subunit 1 (ND1), Mitochondrially En-
coded NADH Dehydrogenase 2 (ND2), Mitochondrially Encoded NADH Dehydroge-
nase 3 (ND3), Mitochondrially Encoded NADH:CoQ10 Oxidoreductase Core Subunit
4L (ND4L), Mitochondrially Encoded NADH:CoQ10 Oxidoreductase Core Subunit 4
(ND4), Mitochondrially EncodedNADH:CoQ10Oxidoreductase Core Subunit 5 (ND5)
andMitochondrially EncodedNADH:CoQ10OxidoreductaseCore Subunit 6 (ND6) are
mitochondrially encoded (Dieteren et al., 2008; Mimaki et al., 2012) and the remaining
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Figure 1.3: MIM, showing the matrix and IMS with complexes I-V of the mitochondrial respiratory
chain embedded into the MIM. The mitochondrial respiratory chain is used to transport electrons to
generate ATP by usage of an unequal electrical charge on each side of the membrane in a process called
oxidative phosphorylation. Electrons are passed along the respiratory chain from Complex I-IV to
Complex V, which is used to produce ATP from ADP + Pi. Electrons are also lost via proton leak
pathways, which are used to protect from oxidative damage. Figure adapted from Divakaruni and Brand
(2011).
38 are nuclear-encoded.
Three of the proton transfer units in Complex I are comprised of ND4, ND2 and
ND5 with the latter unit comprised of ND1, ND6 and ND4L (Hirst and Roessler, 2015)
which transfer the protons across the MIM (Hirst, 2013). ND3 is also a component of
Complex I, which supports ND1 in the ’L’ shaped structure of the complex (Hirst, 2013).
NADH from the citric acid cycle is oxidised by flavin mononucleotide and a seven-
chain of iron-sulphur clusters transfers electrons from flavin to the quinone binding
site (as seen in Figure 1.4) (Hirst and Roessler, 2015). This reduces CoQ10 to ubiquinol,
producing electrons for the reduction of O2 to water by the rest of the ETC (Hirst, 2013).
This action results in the concurrent translocation of four protons through Complex I
from the matrix to the IMS (Giachin et al., 2016).
During the electron transport, Complex I producesROS, including superoxide (O2•),
hydrogen peroxide (H2O2) and hydroxyl radical (•OH). These are then either used
by the cell or deactivated by antioxidants (Jeppesen et al., 2011) but they may cause
oxidative damage when the mitochondrial NADH/NAD+ ratio rises due to Complex I
catalytic inhibition (Hirst, 2013; Jeppesen et al., 2011).
Complex I exists in two conformational shapes; A-form (active) and D-form (de-
active). D-formation has been used to prevent oxidative damage to the cell and it
can transform back to A-formation with increased energy demand (Wirth et al., 2016).
Complex I is particularly important in cellular respiration, producing ~40% of the
proton motive force used in ATP synthesis (Giachin et al., 2016). It can be inhibited
by treatments, such as rotenone, and mutations in Complex I. This can decrease ATP
synthesis and oxidative phosphorylation which limits the cell’s respiratory capacity
(Haroon et al., 2007). Complex I mutations are known to arise in a number of diseases
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Figure 1.4: Cryo-electron microscopy of mitochondrial Complex I showing the complete enzyme with
the fourteen core subunits of the enzyme in colour. Electron flow is indicated by arrows which directs
electrons from the top of the iron-sulphur clusters to the quinone binding site, generating electrons
which are then transferred into the IMS via four proton transfer domains. Figure from Hirst and
Roessler (2015).
including LHON, Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like
episodes (MELAS) and Alzheimer’s (Giachin et al., 2016).
Complex II
The four components of Complex II are nuclear encoded and targeted to the mito-
chondria (Spinazzola and Zeviani, 2009), with subunits A and B forming the succinate
dehydrogenase activity and subunits C and D anchoring it to the MIM.
Complex II catalyses oxidation of succinate to fumarate and transfers electrons to
the respiratory chain CoQ10 pool. Many molecules ROS species are produced through
reverse electron transfer (Bezawork-Geleta et al., 2017).
Much like Complex I, Complex II is also required for Ca2+ homeostasis, which is
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independent of the ΔΨm (Jaña et al., 2019).
Complex III
Complex III is predominantly nuclear encoded with only one of the eleven sub-
units mitochondrially encoded. It oxidises ubiquinol to transfer electrons and oxidise
Cytochrome c (Cytc) and transfers electrons across MIM in the Q-cycle mechanism
(Fernández-Vizarra and Zeviani, 2015).
TheMIManionicphospholipid, cardiolipin, stabilisesComplexes III and IV (Schenkel
and Bakovic, 2014). Cardiolipin binds the highly basic Cytc by electrostatic and hy-
drophobic bonds (Kalkavan and Green, 2017).
Complex III activity can be inhibited by Antimycin A treatment.
Complex IV
Complex IV is comprised of ten nuclear encoded subunits and three mitochondrially
encoded subunits (Fernández-Vizarra andZeviani, 2015; Spinazzola andZeviani, 2009).
It works with Complex III, sometimes within a respirasome, to catalyse the oxidation of
Cytc and reduce oxygen to water through proton translocation (Signes and Fernandez-
Vizarra, 2018).
Complex IV is the last electron acceptor of the respiratory chain and also indirectly
regulates the stability and activity of Complex I within mammalian and invertebrate
systems (Li et al., 2007; Suthammarak et al., 2009).
Complex V
Complex V is the final complex in the oxidative phosphorylation process which is
comprised of 14 nuclear and 2 mitochondrially encoded subunits (Fernández-Vizarra
and Zeviani, 2015; Spinazzola and Zeviani, 2009).
As eponymously named (ATP Synthase), Complex V uses the CI, CIII and CIV
generated proton motive force to synthesise ATP from ADP +Pi by allowing proton
flux to pass through the central channel back into themitochondrialmatrix (Fernández-
Vizarra and Zeviani, 2015).
Complex V activity can be inhibited by oligomycin A.
1.3 MITOCHONDRIAL INTERACTIONS
Whilst widely known for their role in ATP production, mitochondria are extensively
involved in multiple complex pathways. They are capable of initiating the intrinsic cell
death pathway for apoptosis. Further, crosstalk to the Endoplasmic Reticulum (ER)
regulates calcium homeostasis (Marchi et al., 2014), which in turn acts as a secondary
messenger in many signalling processes. Mitochondria are also involved in β-oxidation
of fatty acids and iron-sulphur cluster biogenesis (Benard and Karbowski, 2009).
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These products and signals are then propagated downstream into further biological
processes, resulting in an intricate web of mitochondrial mechanistic action.
Figure 1.5 shows a representation of the typical structure of a mammalian cell, note
the ER position between the nucleus and mitochondria.
Figure 1.5: Diagram of typical mammalian cell structure. Labels numerically represent organelles as
follows: 1 - Nucleolus, 2 - Nucleus, 3 - Ribosomes (dots), 4 - Vesicle, 5 - Rough ER, 6 - Golgi apparatus,
7 - Cytoskeleton, 8 - Smooth ER, 9 - Mitochondrion, 10 - Vacuole, 11 - Cytosol, - 12 Lysosome, 13 -
Centriole, 14 - Cell membrane. Figure from Song (2012), available under Creative Commons CC0 1.0
Universal Public Domain Dedication Licensing.
1.3.1 Fusion and Fission
Whilst mitochondria are semiautonomous organelles which are able to exist as inde-
pendent, singular units and function as usual without the mitochondrial network, it is
common for mitochondria to regularly migrate along cytoskeletal tracks and undergo
a process of fusion or fission of approximately 5 events hourly (Alexandre et al., 1978;
Twig et al., 2008b; van der Bliek et al., 2013).
Fusion refers to the amalgamation of two distinct mitochondria into one singular
mitochondrion, joining both theirMIM andMOM. Fission is the opposite, with a single
mitochondrion separating both membranes and forming two individual mitochondria
which continue to function as distinct entities.
In healthy states, mitochondrial fusion and fission exist in a state of dynamic equi-
librium to allow the exchange of mitochondrial proteins, molecules and mtDNA (Chen
and Chan, 2006; Youle and Karbowski, 2005); giving more mitochondria to cells with a
higher energy demand, like neurons, which are susceptible during mitochondrial dys-
function and these dynamics could allow for pathogenic mitochondria to be relocated
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and recycled in autophagy (Twig et al., 2008a). Equally, fusion and fission are directly
involved in apoptosis inhibition and activation respectively (Li et al., 2012b).
The balance between mitochondrial fusion and fission is affected by cellular condi-
tion, compartmentalisation andmitochondrial functional state (Benard andKarbowski,
2009).
Fusion
Mitochondrial fusion is regulated by 3 main genes, MFN1, MFN2 and OPA1, respec-
tively encoding GTPase dynamin-like proteins Mitofusin 1 (Mfn1), Mitofusin 2 (Mfn2)
and Optic Atrophy Protein 1 (Opa1) (Ranieri et al., 2014; van der Bliek et al., 2013).
MOMs and MIMs are highly coordinated (Benard and Karbowski, 2009; van der
Bliek et al., 2013), with MOM-bound Mfn1 and Mfn2 initiating tethering between
mitochondria, with Mfn1 particularly responsible due to a much higher dimerisation
affinity than Mfn2 (Benard and Karbowski, 2009; Ishihara et al., 2004). Following
mitochondria:mitochondria binding, Opa1MIM fusion occurs (Benard andKarbowski,
2009).
Mitochondrial fusion requires a large number of interacting proteins to consolidate
the MOM and MIM between mitochondria. Membrane structural components, such
as phosphatidylethanolamine, are also required for mitochondrial fusion and phos-
phatidylethanolamine defects result in mitochondrial fusion defects (Schenkel and
Bakovic, 2014).
Problems with mitochondrial fusion have been identified in a number of neurologi-
cal disorders, including autosomal dominant optic atropy - particularly associatedwith
OPA1 mutations - and Charcot-Marie-Tooth disease type 2A (Ranieri et al., 2014).
Mfn1 and Mfn2 have been shown to bind multiple other proteins, alongside the
Mfn1 and Mfn2 homo/heterotypic complexes (Suen et al., 2008); this includes a num-
ber of pro-apoptotic Bcl-2 family members, particularly Bak and Bax (Suen et al., 2008).
Mfn2 has been shown to interfere with apoptotic Bax activation and trigger protec-
tive mitochondrial fusion (Neuspiel et al., 2005); Bax activation, however, prevents
mitochondrial fusion and induces apoptosis (Karbowski et al., 2004)
Fission
Mitochondrial fission is also regulatedbyanotherGTPasedynamin-likeprotein,Dynamin-
Related Protein 1 (Drp1). Drp1 is a cytosolic protein and is recruited to theMOMwhere
oligomeric Drp1 complexes wrap and constrict the mitochondria to mediate fission
(Losón et al., 2013). An alternate method of mitochondrial fission, focal region vesicle
scission, has also been proposed (Fonseca et al., 2019; Youle and Karbowski, 2005).
Mitochondrial fission is known to be difficult to study (van der Bliek et al., 2013)
and a number of MOM proteins, Fis1, Mid49, Mid51, and Mff, have been proposed to
recruit Drp1, however, there is conflicting evidence in their role and necessity (Losón
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et al., 2013; Otera et al., 2010; van der Bliek et al., 2013). While the mechanism is still not
well understood, theMOM adaptor proteins are known to be responsible for managing
fission and punctate formation (Youle andKarbowski, 2005). Mitochondrial-ER contact
points have also been shown to often be trigger points for mitochondrial fission events
(Friedman et al., 2011).
Mitochondrial fission can be used to specialisemitochondria formetabolic demands
or segregate damaged mitochondria into a consolidated cell which undergoes au-
tophagy to remove the damagedmitochondria from usage (Damirchi, 2012; Karbowski
and Youle, 2003; Ranieri et al., 2013; Wright et al., 2007). Mitochondrial fission is seen
in the early stages of apoptosis and after onset, invariably results in mitochondrial
fragmentation (Suen et al., 2008).
Mitochondrial Outer Membrane Permeabilization (MOMP) is seen in the vast ma-
jority of cell death signal-transduction cascades but mitochondrial fission cell death
can work both independently or downstream of MOMP (Perfettini et al., 2005).
In many instances, mitochondrial fission is seen in apoptosis, but depending on the
upstream signal, mitochondrial fission can prevent cell death; this is specifically seen
when disconnected mitochondria are unable to transmit the Ca2+ wave to propagate
the pro-apoptotic signal (Perfettini et al., 2005).
Whilst associated with apoptosis, a key role of mitochondrial fission is actually
mitochondrial biogenesis. Mitochondria are not independently synthesised, but rather,
inherited from thematernal line and asmetabolic demands increase, themitochondrial
mass increases before undergoing fission and creating new daughter mitochondria
(Wright et al., 2007). This is a natural process during growth, improving metabolic
fitness levels, and following the destruction of unhealthy mitochondria to replace and
restore mitochondria to the cell.
Healthy and diseased states between fusion and fission are not governed by one
particular mechanism, but rather the balance of the two and their ability to respond
appropriately to metabolic demands.
1.3.2 Endoplasmic Reticulum-Mitochondrial Interactions
Mitochondria interact with a number of other cellular components, particularly, the
ER. The ER form a number of contact points of ~10-50 nm gap, namely, Mitochondria-
AssociatedMembranes (MAMs) (Giacomello andPellegrini, 2016). These contact points
are used to transfer molecules which interact in a number of biological signalling
processes.
MAMs have been shown to have a role in cell fate, immune response, glucose
homeostasis, mitochondrial fission andmitophagy, amongst other processes (Friedman
et al., 2011; McLelland et al., 2018; Rieusset, 2018; Tubbs and Rieusset, 2017).
Many proteins are involved in mitochondria-ER tethering; much like mitochon-
drial fusion (as described in Section 1.3.1), Mfn1 and Mfn2 are used to tether the two
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organelles (Basso et al., 2018; de Brito and Scorrano, 2008).
MAMs also have a role in mitochondrial biogenesis by ER mediated mitochondrial
constriction for fission; tubules of the ER have been seen to constrict the mother mito-
chondrion to allow for distribution of nucleoids to daughter mitochondria (Rieusset,
2018).
ER dysfunction has been shown to cause a broad range of disease states, particularly
neurodegenerative conditions (Roussel et al., 2013).
Calcium Regulation
Many cellular processes use Ca2+ ions to signal. Cells generallymaintain a cellular Ca2+
concentration of ~100 nM compared to the much stronger concentration (~2mM) in the
extracellular space (Clapham, 2007). To maintain this concentration gradient, plasma
membrane Ca2+ pumps remove Ca2+ from the cell and Sarcoendoplasmic Reticulum
Ca2+-ATPase (SERCA) sequesters Ca2+ into the ER where it is stored (Clapham, 2007).
Like the ER, the mitochondrial Ca2+ concentration normally exists in the mM range
(Britti et al., 2018) but when this exceeds physiological norm it triggers Mitochondrial
Permeability Transition Pore (mPTP) opening and subsequent cell death.
Due to the abundance of VDAC on the MOM, Ca2+, an ion much smaller than the
3,000 Da limit (Bayrhuber et al., 2008; Benz, 1990), is capable of freely moving into the
mitochondria via VDAC. VDAC exists in both an open and closed state, the latter of
which is a partial close and still allows some molecules to travel into the mitochondria
(Britti et al., 2018; Martel et al., 2014). Ca2+ is particularly favoured in the VDAC closed
state, increasing mitochondrial Ca2+ concentrations relative to other metabolites and
triggering cell death (Tan and Colombini, 2007).
Phospholipase C (PLC) agonist activation is capable of producing three distinct
downstream signals, notably Inositol 1,4,5-Trisphosphate (IP3) (Putney and Tomita,
2012). Cytosolic IP3 can then bind IP3 Receptor (IP3R), located on the ER cytosolic
face, triggering IP3 Receptor opening and Ca2+ release via the transmembrane domain
(Rizzuto et al., 2009).
Mitochondrially connected ER then transmit Ca2+ through the MOM. Ca2+ then
travels through the mitochondrial calcium uniporter into the matrix (Marchi et al.,
2014) where it can then act as a secondary messenger in a number of roles including
hormone secretion, neuronal signalling, gene expression and apoptosis (Rimessi et al.,
2008).
Over-excitation can cause cytoplasmic calcium overload which may enhance ox-
idative stress, increasing the likelihood of a mPTP opening (Haroon et al., 2007), an
ER-Unfolded Protein Response (UPRER), or an intrinsic apoptotic event taking place,
as reviewed in Sections 1.3.2 and 1.3.3. The mPTP is located in the MIM and both
causes the mitochondrion to swell and uncouples the ETC (Halestrap, 2006). There has
been debate regarding the mPTP role in cell death but it now seems to be associated
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with necrotic, rather than apoptotic, pathways (Halestrap, 2006; Kinnally et al., 2011).
Despite this, mPTP can still trigger release of apoptotic factors, including Cytc and
Second Mitochondria-derived Activator of Caspases/Direct IAP-Binding protein with
Low PI (Smac/DIABLO) depending upon the initiation method (Ding and Yin, 2012).
VDAC itself plays a role in cell death (Keinan et al., 2010; McCommis and Baines,
2012) and phosphorylation of different isoforms can affect mitochondrial calcium per-
meability and apoptosis susceptibility by triggering anti- or pro-apoptotic pathways.
Phosphorylation by Glycogen Synthase Kinase 3-Beta (GSK3-β) stimulates VDAC/Bcl-
XL binding which makes the cell both less permeable and prevents VDAC from inter-
acting in pro-apoptotic pathways (Beurel and Jope, 2006; Martel et al., 2014). VDAC
phosphorylation also causes Translocator Protein (TSPO) to deregulate mitochondrial
Ca2+ signalling which subsequently increases cytosolic Ca2+ pools (Gatliff et al., 2017)
VDAC also directly interacts with the ER Ca2+ transmission mechanism via Chap-
erone Glucose-Regulated Protein 75 (GRP75) which directly binds IP3 Receptor and
crosslinks the pathways (Szabadkai et al., 2006).
ER-Mitochondrial interaction has been seen to be disrupted in neurological disease,
particularly Wolfram Syndrome, another mitochondrial disorder which causes visual
degeneration (Angebault et al., 2018; Lee et al., 2018).
Unfolded Protein Response
TheUPRER occurs following ER stress, caused by the burden of unfolded proteins in the
ER lumen. Improperly folded proteins are displayed on the ER surface for proteasome
degradation as part of healthy cell homeostasis and protein Quality Control (QC),
however, displayingmisfolded proteins for extended time periods can trigger apoptosis
(Tabas and Ron, 2011; Walter and Ron, 2011). There are three branches which work in
unison to perform the UPRER.
Inositol-Requiring Protein-1 (IRE1) exists as α and β isoforms, with IRE1-α ubiq-
uitously expressed and IRE1-β in the gastrointestinal and respiratory tracts. IRE1 is
activated by imbalance of ER-displayed unfolded proteins to chaperones which subse-
quently splices X-box Binding Protein 1 (XBP1) mRNA (Tabas and Ron, 2011). XBP1 is
a transcription factor and the IRE1-cleaved isoform then promotes expression of many
UPRER genes (Acosta-Alvear et al., 2007; Lee et al., 2003; Tabas and Ron, 2011).
Protein Kinase RNA-like ER Kinase (PERK) phosphorylates Eukaryotic Initiation
Factor 2 (eIF2) which initially upregulates selective translation of Activating Transcrip-
tion Factor (ATF)-4 by limiting the pool of inhibitive unphosphorylated eIF2. ATF-4
then targets C/EBP Homologous Protein (CHOP) which interacts with transcriptional
regulators to induce the pro-adaptive, ER-stress-corrective signalling pathway, partic-
ularly through Growth Arrest And DNA-Damage-Inducible 34 (GADD34) (Rozpedek
et al., 2016; Tabas and Ron, 2011). GADD34 dephosphorylates phosphorylated eIF2 to
continue the cycle and constant activation results in a change in cellular response to
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trigger the apoptotic branch of the UPRER instead (Bravo et al., 2013; Rozpedek et al.,
2016; Tabas and Ron, 2011; Thuerauf et al., 2007).
ATF-6 is transported to the Golgi apparatus following unfolded protein exposure
where it is cleaved to a short-form which translocates to the nucleus and binds ER
stress promoter regions which signal cell stress and induce apoptotic triggers, such as
promoting CHOP expression (Bravo et al., 2013; Tabas and Ron, 2011; Yoshida et al.,
2000; Yu et al., 2017).
Chronic ER-stress has been shown to induce apoptosis (Szegezdi et al., 2006), poten-
tially through direct interaction, such as pro-apoptotic proteins, Bak and Bax, directly
interacting with IRE1 (Hetz et al., 2006).
1.3.3 Intrinsic Apoptosis
There are three known pathways which induce cellular apoptosis: Intrinsic (mito-
chondrial), extrinsic (death cell receptor) and the perforin/granzyme (cytotoxic T-cell)
pathways (Elmore, 2007). Intrinsic and extrinsic lead to the majority of apoptotic
events with the perforin/granzyme pathway less frequently causative (Elmore, 2007;
Voskoboinik et al., 2015).
As implied, the extrinsic pathway is induced through an extracellular signalling
process, namely, ligands binding to the cell death receptor, such as Fas Ligand (FasL)
and Tumor Necrosis Factor (TNF)-α (Elzey et al., 2001; Furuichi et al., 2012). The
intrinsic pathway, however, is triggered directly through the mitochondria, although
there is some evidence suggesting that the two pathways can interact with each other,
particularly through Caspase-8/tBid interactions (Dewson and Kluck, 2009; Igney and
Krammer, 2002).
The intrinsic pathway is predominantly triggered through intracellular stimuli from
many subcellular compartments, withdrawal of growth factors, or DNA damage from
ROS or radiation (Galluzzi et al., 2014; Hekimi et al., 2016; Wu and Bratton, 2013).
Additionally, it is primarily regulated by members of the Bcl-2 protein family (Shamas-
Din et al., 2013; Westphal et al., 2011).
Bcl-2 class family proteins contain a combination of BCL-2 Homology (BH)1-4 do-
mains alongside a C-Terminal Trans-Membrane Domain (TM) (Lomonosova and Chin-
nadurai, 2008). Depending on their sharing of Bcl-2 homologous domains, Bcl-2 class
family proteins can be split into three broad categories: BH1-3 + TM, which form pores
to permeabilise the MOM, BH3-only + TM proteins which activate the pore-forming
proteins and BH1-4 + TM anti-apoptitic proteins which inhibit the former two groups
(Lomonosova and Chinnadurai, 2008; Shamas-Din et al., 2013).
To initiate apoptosis, there are three models of activation: BH1-3 protein displace-
ment from BH1-4 protein complexes, conformational activation of BH1-3 proteins and
membrane remodelling/insertion (Lomonosova and Chinnadurai, 2008). All models
start with BH1-3 proteins, such as Bad, Bid, NOXA, etc. responding to intracellular
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stress by binding anti-apoptotic BH1-4 proteins’ (e.g. Bcl-2, Bcl-XL, MCL-1, etc.) regu-
latory sites and inhibiting them (Kögel and Prehn, 2013; Lomonosova andChinnadurai,
2008; Shamas-Din et al., 2013; Sinicrope et al., 2008).
Location of BH3-only and BH1-3 proteins depends upon cellular apoptotic state. For
example, BH3-only protein NOXA is in a stable, cytosolic multiprotein complex prior
to apoptotic activation (Matsuura et al., 2016) alongside pro-apoptotic BH1-3 protein
Bax, whereas Bak, another pro-apoptotic BH1-3 protein, resides in the mitochondria.
Following apoptotic activation, many BH3-only and BH1-3 proteins migrate to the
MOM (Gross et al., 1999; Nechushtan et al., 2001; Popgeorgiev et al., 2018; Shamas-Din
et al., 2011; Wolter et al., 1997).
At the MOM, activated pro-apoptotic proteins undergo a conformational change
from their passive α-helical globular structure to oligomerise into higher order struc-
tures (Westphal et al., 2011). These highly oligomerised structures create pores which
cause MOMP (Dewson and Kluck, 2009; Gavathiotis et al., 2010; Lovell et al., 2008).
While there are exceptions, the vast majority of MOMP instances lead to irrevocable
apoptosis (Kalkavan and Green, 2017) by releasing intermembrane space molecules,
such as Cytc and Smac/DIABLO (Muñoz-Pinedo et al., 2006).
Cytc normally acts as a ROS scavenger within the ETC process, between complexes
III and IV (Hüttemann et al., 2011; Kalkavan and Green, 2017), but after exiting the
mitochondria it binds Apoptotic Protease-Activating Factor 1 (APAF1), revealing the
N-terminal Caspase Recruitment Domains (CARDs) (Kalkavan and Green, 2017; Li
et al., 1997; Tait and Green, 2010). This structure, the apoptosome, cleaves procaspase-
9, leading to the initiator caspase-9 form cleaving the executioner caspases-3 and -7,
causing apoptosis (Kalkavan and Green, 2017; Malladi et al., 2009; Roberts et al., 2001;
Tait and Green, 2010).
Smac/DIABLO binds Inhibitor of Apoptosis Proteins (IAPs) (including X-linked-
IAP, c-IAP1, c-IAP2, and ML-IAP), preventing them from their inhibitory role on
caspases (Fu et al., 2003). X-linked-IAP, for example, binds executioner caspases-3
and -7, and alongside c-IAP-1, and c-IAP-2, has been identified to bind procaspase-9
(Deveraux et al., 1998). Following release of the the executioner caspases, apoptosis
then proceeds.
Caspases are proteolytic proteins which work to efficiently and neatly break down
the cell and contents (Youle and Karbowski, 2005).
1.3.4 Autophagy
Autophagy is the process whereby the body ’self-eats’ to degrade unwanted intracel-
lular components. These can include proteins, foreign bodies, or whole organelles (Yu
et al., 2018b). It can occur in both selective and non-selective states depending upon
the upstream stimuli (Ding and Yin, 2012).
It can be broken out into further pathways, including, macroautophagy, microau-
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tophagy, chaperone-mediated autophagy and mitophagy, amongst others (Ding and
Yin, 2012), depending on the substrate and mechanism involved.
This process is useful to destroy unhealthy or pathogenic cellular components,
alongside recycling their materials for further usage.
Autophagy works by surrounding the substrate in a double-membrane autophago-
some vesicle in the cytoplasm, before fusing with lysosomes for degradation (Glick
et al., 2010; Mizushima et al., 2008; Yang and Klionsky, 2009; Yu et al., 2018b).
Autophagy can be triggered by ER stress (reviewed in Section 1.3.2) and dysregula-
tion of autophagy renders cells particularly susceptible to ER stress, favouring down-
stream cell death rather than homeostatically recovering (Liu et al., 2015; Ogata et al.,
2006; Yorimitsu et al., 2006).
Mitophagy
Focusing on the mitophagy pathway, mitochondria are particularly susceptible to or-
ganelle damage due to the proximity to the ETC, ROS exposure and limitedDNA repair
methods (Jeppesen et al., 2011; Pinto and Moraes, 2014). Neurons’ mitochondria are
particularly susceptible to mitophagywhen deprived of nerve growth factor (Xue et al.,
1999).
There are two stages to mitophagy: macroautophagy initiation and subsequent mi-
tochondrial ubiquitination by PTEN-Induced Kinase 1 (PINK1)-PARK2 (Parkin RBR E3
Ubiquitin Protein Ligase) or BCL2 Interacting Protein 3 (BNIP3) pathways for selective
autophagic recognition (Ding and Yin, 2012; Gatliff et al., 2017).
TSPO is capable of inhibiting mitophagy by accumulating ROS to prevent PARK2-
mediated mitochondrial ubiquitination (Gatliff and Campanella, 2015; Gatliff et al.,
2017).
1.3.5 Nuclear-Mitochondrial Interactions
As described in Section 1.1.2, mitochondrial proteins are encoded both by the nuclear
and mitochondrial genome. Whilst mtDNA remains within the mitochondria, nDNA
proteins which are relevant to the mitochondria are co- or post-translationally trans-
ported to the mitochondria. Nuclear genetic background has also been seen to alter
expression of primary mitochondrial disease (Cock et al., 1998; Mossman et al., 2019;
Wei et al., 2017).
Interaction between the two organelles occurs in both anterograde (nuclear to mito-
chondrial) and retrograde (mitochondrial to nuclear) directions. Anterograde is often a
stimulator ofmitochondrial biogenesis, with factors such asNuclearRespiratory Factors
(NRF)-1 and -2 and Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1
(PGC-1)-α, -β and -γ (Guha and Avadhani, 2013; Matilainen et al., 2017; Whelan and
Zuckerbraun, 2013; Xia et al., 2019), whereas retrograde signalling works with other
pathways, such as acmTOR pathways and ER-Ca2+ signalling (Guha and Avadhani,
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2013; Matilainen et al., 2017; Whelan and Zuckerbraun, 2013; Xia et al., 2019).
While the anterograde pathway is often used to co-ordinate biogenesis of the
mtDNA, the retrograde pathway can be used to cause epigenetic modification of the
nDNA mitochondrial genes (Guha and Avadhani, 2013; Matilainen et al., 2017; Whe-
lan and Zuckerbraun, 2013; Xia et al., 2019) with different mitochondrial haplotypes
capable of altering nDNA methylation patterns by S-adenosyl methionine regulation
(Vivian et al., 2017).
Long Noncoding RNAs (lncRNAs) and Micro RNAs (miRNAs) have also been seen
to have a role in signalling between the nucleus and mitochondria (Carden et al., 2017;
Dong et al., 2017)withmiRNAs also found to affect expression ofmtDNA (Sadakierska-
Chudy et al., 2014).
The role, mechanism and result of epigenetic modifications within neurological
norm and neurodegenerative disease has been relatively well characterised (Berson
et al., 2018; Ma et al., 2010; Riccio, 2010; van Heesbeen and Smidt, 2019), however
mitochondrial epigeneticmodification, or ’mitoepigenetics’, has been less characterised.
Initially, it was believed that there was no epigenetic modification of mtDNA due to
lack of histone structure (Ghosh et al., 2015; Iacobazzi et al., 2013), with mitochondrial
CpG sites identified, but the role and possibility of mitochondrial methylation has been
debated (Castegna et al., 2015; Manev et al., 2012; Matilainen et al., 2017; Sanchez et al.,
2006; van der Wĳst and Rots, 2015). TFAM, rather than histones, has since been shown
to also have differential methylation patterns (Rebelo et al., 2009).
ROS modulation of mtDNA methylation has been shown to affect mtDNA expres-
sion and that oxidative stress increases the TFAM:mtDNA ratio, triggering nucleoids
to a more compact state to prevent further mtDNA damage (Noack et al., 2006; Re-
belo et al., 2009; Sadakierska-Chudy et al., 2014), but likely downregulating mtDNA
expression.
Shock et al. (2011) identified that DNA Methyltransferase 1 (DNMT1) translocates
to the mitochondria using an upstream start site of DNMT1 to allow for mitochondrial
targeting; mtDNMT1 plays a regulatory role during oxidative stress (van der Wĳst
and Rots, 2015). Additionally, Chestnut et al. (2011) found DNA Methyltransferase 3
(DNMT3)-α in human brain and spinal cord and that enforced expression of DNMT3-α,
but not DNMT1 induced apoptosis in motor neurons. Methylation patterns of mtDNA
have been shown to be conserved between tissue types (Ghosh et al., 2014).
It has been suggested that mtDNA methylation is overestimated at CpG sites (Liu
et al., 2016), however, mitochondria are of α-proteobacteria origin as opposed to the
mammalian origin (Wallace and Fan, 2010); exclusively looking at CpG sites overlooks
the presence of non-CpGmethylation within the mitochondrial genome (Bellizzi et al.,
2013).
Further, 5-Hydroxymethylcytosine (5hmC) 5-Methylcytosine (5mC) was found to
affect nucleoid structure in mammalian mtDNA (Kukat et al., 2011) and H1, H2A, H2B,
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H3 and H4 histone family members are found as integral mitochondrial membrane
proteins which may form complex ‘viaprotein-protein’ interactions as they bind the
D-loop (Choi et al., 2011).
More recently, Ghosh et al. (2014, 2015) identified variable methylation density in a
regionwhich encodesMT-ND6. In LHON,MT-ND6m.14484T>Cmutations account for
~14% of patients and mitoepigenetics have now been reviewed for neurodegenerative
disease, particularly forD-loop regionmethylation impairment (Coppedè and Stoccoro,
2019).
1.4 VISUAL PATHWAYS
The retina (Figure 1.6) is a complex structure derived from the embryonic forebrain. It
is capable of transmitting information about photons of light to the brain via the optic
nerve where it may then be integrated and visually reconstructed as an image.
Light passes to the outer segment layer at the back of the eye where photosensitive
rod and cone cells are located. The rod and cone cells are bordered by pigmented
epithelia which contain melanosomes that also absorb photons to prevent light reflec-
tion back into the retina and supplement the rods and cones with nutrients (Nickla
and Wallman, 2010; Strauss, 2005). Rod cells have a low resolution, however, they are
capable of generating electrical impulses from a single photon of light. Cone cells are
less sensitive but have a higher resolution and different forms of cone cells differentiate
between photons of different electromagnetic wavelengths due to the variation in the
photosensitive pigment between the cells - allowing for colour perception (Berg et al.,
2002; Purves et al., 2001). The electrical impulses are then transmitted through the
Outer Nuclear Layer (ONL) and into the Outer Plexiform Layer (OPL) where the rod
and cone cells’ synaptic terminal connects to horizontal or Bipolar Cells (BCs). Hori-
zontal cellsmay connect to the BCs’ dendrites or directly to the BCs in the InnerNuclear
Layer (INL), which are then responsible for transmission directly to Retinal Ganglion
Cells (RGCs) in the Inner Plexiform Layer (IPL) or via INL amacrine cells.
In summary, to reach the RGCs, electrical signals from the Photoreceptors (PRs)
are transmitted down the vertical (via BCs) or lateral (via horizontal cells to BCs then
amacrine cells) pathways.
The RGCs are located in the Ganglion Cell Layer (GCL) but their dendrites extend
into the IPL. Both the RGCs and BCs can be classified as either ON-centre or OFF-
centre cells (Neumann et al., 2016; Pavlidis et al., 2006; Pickard and Sollars, 2012) with
BCs also being organised by their level of stratification (as reviewed by Euler et al.,
2014), where typically, the ON-centre stratify to the retina’s distal IPL or OFF-centre if
the dendrites extend only to the proximal IPL. ON-centre bipolar cells become more
depolarised when PRs in the centre of the receptive field (as shown in Figure 1.7) are
stimulatedwith lightwhereas this has the inverse response inOFF-centre cells; similarly
in darkness OFF-centre cells are more depolarised whereas ON-centre hyperpolarise
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Figure 1.6: Illustration of retinal organisation, showing RPE, the PR layer, the OLM, ONL, OPL, INL,
IPL, GCL, NFL and ILM. Light approaches towards the bottom of the diagram, passing the cell layers
until it reaches the photoreceptive layer where rod and cone cells detect it and initiate signal
transduction towards the RGCs. Figure from Goldman (2014).
(Neumann et al., 2016).
ON-centre BCs signal to ON-centre RGCs and OFF-centre BCs signal OFF-centre
RGCs (Kolb and Marshak, 2003) with stimulated ON-centre RGCs increasing firing
rate, however, OFF-centre cells work in the opposite way, as hyperpolarised BCs trigger
fewer action potentials from OFF-centre RGCs. Both ON- and OFF-centre RGCs send
more action potentials from greater graded potential signals from the bipolar cells.
RGCs (and some amacrine cells) are the first retinal neurons to initiate action potentials
rather than graded potentials (Field and Chichilnisky, 2007).
LHON arises from loss of RGCs - primarily those in the papillomacular bundle (Yu-
Wai-Man et al., 2009). The papillomacular bundle is comprised of a range of different
types ofRGCs, namely: parasolRGCs (M-cells, TypeAcells),midgetRGCs (P-cells, Type
B cells), small bistratified cells (Pavlidis et al., 2006), Intrinsically Photosensitive Retinal
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Figure 1.7: Illustration of retinal cells, indicating ON- and OFF-centre BC cell types in green;
ON-centre BCs are stimulated when light is detected by central PRs and inhibited when light is detected
by the surrounding PRs. OFF-centre BCs work in the opposite way, where central light is inhibitory
and surrounding light stimulatory. Figure from Watson and Breedlove (2012).
Ganglion Cells (ipRGCs) and Melanopsin-containing RGCs (Pickard and Sollars, 2012)
as shown in Figure 1.8.
RGCs cells are highly varied from species to species (Kolb et al., 1981; Masland,
2001), however, it is estimated that 10-20 morphologically different cell subtypes exist
in humans.
The combination of phototransduction signalling between the photoreceptive cells
to the RGCs allows for complex parallel processing of informationwhich permits for the
complex image of the visual field to be generated through the differing informational
inputs from different points of the retina with the variation across the retina being
considered a ’mosaic’ due to the complex networking interactions and preferential
relay of different information via particular cellular pathways (Rossi et al., 2011;Wassle,
2004). For example, an OFF-centre midget BC innervates a singular OFF-centre midget
RGC - which are used to relay action potentials - whereas ON-centre midget RGCs are
innervated bymultiple ON-centre BCs, with an input of 9-12 photoreceptive cells being
relayed to the ON-centre RGC (Kolb and Marshak, 2003).
The RGCs then extend to form the optic nerve, resulting in the ’blind spot’ where
it leaves the eye, and continues to the brain. Different RGC types innervate different
regions of the brain with ipRGCs innervating a large range (Do and Yau, 2010). Parasol
ganglion cells - which transmit non-opponent light responses - project to the parvocel-
lular layers of the Lateral Geniculate Nucleus (LGN) and midget ganglion cells - which
transmit colour and fine detail perception – project to the parvocellular layers of the
LGN (Kolb and Marshak, 2003; Pavlidis et al., 2006).
The LGN receives information from both eyes as shown in Figure 1.9 with informa-
tion in G1, G4 and G6 being contralateral and layers G2, G3 and G5 ipsilateral. Small
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Figure 1.8: Illustration of retina structure showing PRs in the outer segment layer (OS), and outer
nuclear layer (ONL) with innervations to BCs in the outer plexiform layer (OPL). The BCs stretch
across the INL where dopaminergic amacrine cells (DA) also receive bipolar input from the “off” IPL
sublamina. Similarly, OFF-centre RGCs traditionally synapse in the “off” sublamina and ON-centre in
the “on” sublamina with RGCs located in the ganglion cell layer (GCL) with variations of RGC species.
BC innervation of RGCs is shown with black cells representing parasol, midget and small bistratisfied
cells with three forms of ipRGCs shown in orange. Figure from Pickard and Sollars (2012).
bistratified RGCs project to the koniocellular layers, in between the parvo- and magno-
cellular layers of the LGN (Kolb and Marshak, 2003; Pavlidis et al., 2006); collectively,
the layers allow for parallel processing (Wassle, 2004) and most RGCs synapse with the
parvocellular, magnocellular and koniocellular cells in the LGN (Xu et al., 2001).
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Figure 1.9: Illustration of LGN, showing parvocellular, koniocellular and magnocellular layers. Layers
K1-K6 are koniocellular which receive information from small bistratified RGCs. The G1 layer receives
information from the contralateral eye and G2 ipsilateral with both in the magnocellular region,
innervated by parasol cells. Layers G3, G4, G5 and G6 are parvocellular, innervated by parasol cells and
alternate eye input with G3 and G5 ipsilateral but G4 and G6 contralateral.
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1.5 LEBER HEREDITARY OPTIC NEUROPATHY
1.5.1 Phenotype
LHON is a rare genetic disorder which results in severe loss of visual acuity via uni-
lateral degeneration of the optic nerve with bilateral degeneration occurring simulta-
neously or within 6-8 weeks in 75% of cases (Yu-Wai-Man et al., 2009).
Following from the first clinical report of a patient suffering LHON, by von Graefe
(1858), the disease was then further characterised by its namesake, Theodore Leber, a
German ophthalmologist who identified LHON in 16 families in 1871 (Leber, 1871).
Clinical Phenotype
Patients first experience painless visual clouding, and sometimes impaired colour per-
ception, before the characteristic development of a central scotoma (defect of central
fixation) or centrocaecal scotoma (defect of central fixation and area between the blind
spot to fixation point) by loss of predominantly RGCs, as shown in Figure 1.10. This
causes loss of central vision, with 25% of cases presenting simultaneous bilateral visual
loss (Yu-Wai-Man et al., 2009) but 75% sequential with onset in a singular eye first
before bilateral involvement, typically 1.8 months after the initial singular eye onset
(Sadun and Kim, 2010). Visual acuity deteriorates within 4-6 weeks with vision typi-
cally settling at or below 20/200 (Sadun and Kim, 2010; Yu-Wai-Man et al., 2009) before
full optic atrophy at six months (Sadun and Kim, 2010; Yu-Wai-Man et al., 2009).
Compared to other mitochondrial disorders, LHON is generally considered to have
a very mild phenotype. Typical other mitochondrial diseases include MELAS and
Leigh Syndrome, both of which are severe and the latter of which usually results in
childhooddeath. In LHON, life quality rather than expectancy is generallymore greatly
affected, however, LHON has been seen to double mortality risk ratio through strokes
and quadruple dementia risk alongside other conditions (Orssaud, 2018; Riordan-Eva
et al., 1995). Rare cases of visual recovery have been reported, particularly associated
with m.14484T>C mutations but most cases do not recover after visual loss (Oostra
et al., 1994; Riordan-Eva et al., 1995).
Visual Pathophysiology
The complexmosaicismof the eye is necessary for colour and edge perception, however,
in LHON, the loss of RGCs of the papillomacular bundle results in preferential removal
of visual circuitry which is more common within the predominantly affected region,
but other regions are less affected, and hence, different cell populations. This can
account for why central vision and red-green colour perception are primarily affected
(Yu-Wai-Man et al., 2009).
Red and green light is initially detected by M-cone and L-cone, respectively, which
are named in accordance with their ability to detect medium (green) and long (red)
wavelengths of light. Similarly, S-cones detect short wavelength blue light, however,
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Figure 1.10: llustration of retinal light input showing eyes’ respective vision. In LHON, visual defects
cause central scotomas where the vision of the fixation point deteriorates or centrocaecal scotoma where
vision deteriorates from the fixation spot to the blind spot.
the S-cone phototransduction pathway is lower resolution with few S-cones present in
the foveal pit and unlike the midget pathways of M- and L-cones, it uses non-midget
BCs connecting to a small bistratified blue/yellow RGC (Kolb and Marshak, 2003). In
LHON, the S-cone pathway is normally unaffected by the disease (Sadun et al., 2000;
Ventura et al., 2005).
Studies in the optic nerve have shown the depletion of the central optic nerve, where
axons of midget RGCs are located (Sadun et al., 2000), which is in concordance with the
loss of cells from the papillomacular bundle where midget cells are, again, primarily
located (Pavlidis et al., 2006; Sadun et al., 2000). Midget RGCs vastly outnumber parasol
RGCswithin the central retina, with a 20-30 times prevalence (Dacey andPetersen, 1992;
Pavlidis et al., 2006) and small bistratified cells and ipRGCs account for significantly
less of the cell types in the whole of the GCL (Pavlidis et al., 2006; Pickard and Sollars,
2012). In LHON, midget cells are primarily affected, however, the direct mechanism
which causes this is not yet determined.
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RGCs are particularly susceptible to mitochondrial dysfunction due to their high
metabolic demand (Ito and Di Polo, 2017) and as comparatively small cells, midget cells
may be less capable of surviving metabolic distress with lower energy reserves. This
smaller size also creates difficulty in mitochondrial transport and mitochondria are
normally strategically distributed along the long axons in unmyelinated gap junctions
(Carelli et al., 2004). Yang et al. (2020) found an increase of retrograde mitochondria
and decrease of stationary mitochondria in affected axons alongside an increase of ROS
in human Induced Pluripotent Stem Cells (iPSCs).
RGC cell lines have also been shown to produce superoxides at a rate of one fifth
of brain mitochondria (Levin, 2007). This tighter control could indicate that they
are particularly susceptible to oxidative stress which results in RGC death through
apoptosis given the increased ROS production in LHON (Lin et al., 2012; Yang et al.,
2020; Zhuo et al., 2012).
Variation of LHON Phenotype
There are some incidents of ’LHON Plus’, or Harding’s Disease, which is LHON with
further multiple sclerosis-like comorbidity, including demyelination, tremors, epilepsy
and dementia, amongst others (Carelli et al., 2001; Joshi and Kermode, 2019; Nikoske-
lainen et al., 1995). LHON Plus occurs more commonly in female LHON patients than
male (2.1:1) and often presents with a longer interval time (1.66 years) from unilateral
to bilateral onset (Pfeffer et al., 2013). Co-occurrence of multiple sclerosis and LHON
mutations are likely by chance but the co-occurrence results in a phenotype which is
painless but also more aggressive and irreversible (Pfeffer et al., 2013).
Another variant is ’Childhood LHON’ where the patient typically develops LHON
before age 12, which is half the median Age of Onset (AOO) (Chinnery, 2000; Majander
et al., 2017). ChildhoodLHONdisease development is quite different to classical LHON
and is seen to have a better prognosis, however, sample size is limited and 1/5 patients
remain legally blind (Barboni et al., 2006; Majander et al., 2017).
There are few cases of Childhood LHON’ but some evidence has suggested that
the more severe m.3460G>A mutation is more common (18%) within a cohort of hy-
pothetical Childhood LHON cases (Barboni et al., 2006). Childhood LHON exhibits
diffuse optic disc atrophywithout microangiopathy in acute bilateral LHON but a vari-
able degree of atrophy and microangiopathy in acute unilateral LHON (Barboni et al.,
2006). Childhood LHON which exhibited a slowly progressive course had limited bi-
lateral optic atrophy within the temporal sector of the optic disc and variable degree of
microangiopathy (Barboni et al., 2006).
There are a few cases of concurrent LHON mutation inheritance (Cruz-Bermúdez
et al., 2016; Howell et al., 2002; Kerrison et al., 1995; Mimaki et al., 2003), across a
range of mtDNA mutations, including concurrent LHON associated mutations with
another mtDNA mutation and multiple LHON associated mutations - both primary,
and primary and rare variant combinations.
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Case numbers are limited, and whilst phenotype has been seen to vary (Kerrison
et al., 1995; Mimaki et al., 2003), this could arise concomitantly, given the variation in
the mutations, rather than synergistically as a triple concomitant LHONmutation case
showed no evidence of mutation synergistic effect on mitochondrial activity (Cruz-
Bermúdez et al., 2016). It is possible for some mutations that LHON is an isolated
disease and the LHON plus phenotype arises from inheritance of additional mutations
which modify the phenotype into a compounded form of dual disease expression
(Morgia et al., 2008; Pfeffer et al., 2013).
1.5.2 Epidemiology
LHON is the most common primary mitochondrial disorder (Chinnery and Turnbull,
2001), harbouring mutations in the mtDNA with prevalence depending upon region
and haplogroup background, such as 3.22 per 100,000 in the North East of England
(Yu-Wai-Man et al., 2003) and 2.06 per 100,000 in Finland (Puomila et al., 2007) with
foundermutations contributing to population frequency of disease and disease causing
variant (Macmillan et al., 2000a).
LHON is complicated by incomplete penetrance and a marked sex bias, with 50%
of males harbouring a primary LHON mutation developing the disease but only 10%
of females (Yu-Wai-Man et al., 2003). Median onset age is 24 years old (Chinnery,
2000), however, the age can vary greatly and carriers are generally considered at risk of
developing LHON until over 50.
Globally, three primary mutations account for ~90% of LHON cases (Brown et al.,
1997; Jurkute et al., 2019; Taylor et al., 2003; Yu-Wai-Man et al., 2003, 2014), namely
m.11778G>A, m.3460G>A and m.14484T>C which respectively cause point mutations
inMT-ND4,MT-ND1 andMT-ND6 genes (Gorman and Taylor, 2011; Yu-Wai-Man et al.,
2003), all ofwhich encode subunits of Complex I of themitochondrial respiratory chain.
These mutations may be found both in heteroplasmy and homoplasmy (Yu-Wai-Man
et al., 2003).
Further mutations, such as m.10663T>C, which is associated with mitochondrial
haplogroup J (Brown et al., 2002), can also cause LHON alongside the three more com-
mon variants. m.3460G>A is a phylogenetically older mutation, randomly distributed
within haplogroups (Torroni et al., 1997). To date, as seen in Figure 1.1, MITOMAP lists
19 primary LHON mutations (Lott et al., 2013). This indicates that the mutations have
been confirmed to be inherited in pedigrees of families, with multiple cases of LHON
patients with the same mtDNA background.
While the majority of LHON mutations affect Complex I subunits, other genes
affecting other molecules have also been implicated, such as MT-CYB, MT-CO3, and
MT-ATP6 (Yu-Wai-Man and Chinnery, 2000).
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m.11778G>A ND4 R340H 100% 69% 33-60%
m.3460G>A ND1 A52T 91% 13% 14-75%
m.14484T>C ND6 M64V 31% 14% 27-80%
m.3376G>A ND1 E24K 98% Rare NA
m.3635G>A ND1 S110N 93% Rare 29%
m.3697G>A ND1 G131S 100% Rare NA
m.3700G>A ND1 A112T 93% Rare NA
m.3733G>A ND1 E143K 100% Rare 24-30%
m.4171C>A ND1 L289M 93% Rare 46%
m.10197G>A ND3 A47T 96% Rare NA
m.10663T>C ND4L V65A 89% Rare 56%
m.13051G>A ND5 G239S 98% Rare 56%
m.13094T>C ND5 V253A 100% Rare NA
m.14459G>A ND6 A72V 89% Rare NA
m.14482C>A ND6 M64I 31% Rare NA
m.14482C>G ND6 M64I 31% Rare NA
m.14495A>G ND6 L60S 100% Rare NA
m.14502T>C ND6 I58V 78% Rare 10%
m.14568C>T ND6 G36S 87% Rare NA
1.5.3 Diagnosis
As a rare disease, LHON is often initially difficult to diagnose without known familial
history, and a number of initial neuroimaging tests are frequently used to characterise
the phenotype before specific genetic testing. This may include optic disc examination,
visual field testing, an Electroretinography (ERG), or Magnetic Resonance Imaging
(MRI) or Computerised Tomography (CTPR) scans (LHON Society, 2020; Traboulsi,
2012). An ERG measures retinal electrical responses and a CTPR scan can typically
exclude other mechanisms of optic neuritis or optic nerve inflammation but anMRI can
provide additional information (LHON Society, 2020; Traboulsi, 2012). In some cases,
lumbar punctures or steroids may be ordered in cases of suspected central nervous
system infection or optic neuritis respectively (LHON Society, 2020).
Following from suspected LHONdiagnosis, a blood sample is usually collected and
a targeted genetic test is typically performed. The Genetic Testing Registry presently
lists 57 clinical tests for LHON at labs across the world (National Institutes of Health
(NIH), 2020), however, more perform this test than those registered on this list. The
majority of tests are either targeted variant analysis or coding region sequence analysis.
The targeted analyses often only check for m.11778G>A, m.3460G>A and m.14484T>C
mutations resulting in~10%ofLHONcases failing tobediagnosed through thismethod
and requiring further diagnoses.
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1.5.4 Susceptibility Factors and Disease Triggers
Abroad range of susceptibility factors and disease triggers have been studied in LHON,
however, cause of disease onset is still widely unknown.
Susceptibility factors relate to features which increase risk of disease onset in a
susceptible person whilst disease triggers are features which directly cause disease
(Yeatts et al., 2006). For example, a range of mutations and environmental factors have
been investigated in LHON, this includes smoking, alcohol consumption and many
others (Kirkman et al., 2009; Newman, 2009; Sadun et al., 2003) to account for variable
penetrance, but these do not directly cause LHON. A LHONmutation makes a person
greatly susceptible to LHON but it does not trigger disease onset, again, environmental
influences affect the likelihood that a person with a genetic background for LHON
will develop the disease, but they do not directly cause LHON. The susceptibility
factors may indirectly trigger LHON disease onset by a presently unconfirmed trigger
mechanism, such as oxidative stress, which results in the LHON phenotype of RGC
cell death.
Genetics
As a primary mitochondrial disease, mitochondrial mutations are an obvious factor.
Many investigations have also sought to find nDNA factors which affect LHON devel-
opment as the majority of mitochondrial genes are located in the nucleus.
Alongside the 19primaryLHONmutations shown inTable 1.1,MITOMAPpresently
also recognises a further 18 secondary LHON mutations (Lott et al., 2013). Secondary
mutations occur in individual patients within a LHON family with one of the pri-
mary mutations and they are hypothesised to be a causative factor in the likelihood
for developing the disease. Secondary variants are defined as further genetic variants
which affect genes encoding neither function nor production of the OXPHOS proteins
or environmental factors (Niyazov et al., 2016); they can also be acquired instead of
inherited (Niyazov et al., 2016) and are often mutations which affect mtDNA outside
of the primary 19 LHONmutations.
There is some debate over whether secondary variants are pathogenic or not as
further rare mutations have also been identified (Chalmers and Schapira, 1999; Chin-
nery et al., 2001; Fauser et al., 2002a; Howell et al., 1993; Johns and Berman, 1991) and
additional testing is necessary to determine whether they are pathogenic or harmless
polymorphisms which are observed by chance.
Extensive in-house studies have sought to identify novel LHON genetic variants
which could predict disease onset or identify a causative pathway which is directly
responsible, but both these and published data have yet to pinpoint a root genetic cause
for why some carriers develop and others do not (Fauser et al., 2002b; Phasukkĳwatana
et al., 2010; Rosenberg et al., 2016; Vilkki et al., 1991).
Mitochondrial haplogroup is one factor which is capable of further modulating ex-
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pression of disease. This results in further difficulty to discern the underlying genetic
cause of LHON. Some ’pathogenic’ variants only cause disease within certain mito-
chondrial genetic backgrounds, making it harder to attain sample numbers and power
within the same haplogroups to identify why those variants act as modifiers (Ji et al.,
2012; Strauss et al., 2013). B5a1, J1b and J2c haplogroup backgrounds have been shown
to increase penetrance of the m.11778G>A and m.14484T>C LHONmutations (Carelli
et al., 2006; Hudson et al., 2007; Kaewsutthi et al., 2011).
As stated in Section 1.1.2, mtDNAdoes not undergo recombination, andhaplogroup
refers to the clonal manner of mitochondrial inheritance. Rather than tracking re-
combination between generations, haplogroups describe the accumulation of various
mutations through the matrilineal inheritance across populations (Elson et al., 2001;
Soares et al., 2011). It has been suggested that non-pathogenic missense mtDNA poly-
morphisms can result in an accumulation of mutations which accumulate to create a
sufficient mutational burden which triggers LHON (Caporali et al., 2018). Wei et al.
(2017) hypothesise that oldermtDNAhaplogroups have naturally selected against these
mutations, leading to different disease penetrances by haplogroup - or ethnogeograph-
ics - as these mutations are not necessarily non-pathogenic, as originally believed, and
could directly accumulate to cause disease or interfere with mitochondrial-nuclear
crosstalk (Chinnery and Gomez-Duran, 2018).
With the crosstalk between the nuclear andmitochondrial genome, it is possible that
any modifier genes could occur on either nuclear or mitochondrial genome and these
could directly affect the system, or act as a trans-acting variant whichmodifies a distant
gene. Further, with environmental factors known to affect LHON onset, epigenetic
modification of either genome could be causative in disease onset.
Mitochondrial copy number has also been identified as neuroprotective in LHON
carriers, with LHON patients unable to implement the same neuroprotective mito-
chondrial biogenesis (Bianco et al., 2017, 2015, 2018), however, Finsterer and Zarrouk-
Mahjoub (2018) challenged the study design and belief that mtDNA biogenesis is
protective, rather than a result of the condition, alongside other points. Within LHON,
no other research group has presently, independently proven that mitochondrial copy
number is protective rather than as a result of LHONmutations. In broader mitochon-
drial defects, mtDNA copy number has further been shown to ameliorate pathogenic
burden of mtDNA defects, such as Filograna et al. (2019), who found that elevated
mtDNA copy number partially rescues cardiomyopathy and Complex IV (Cytochrome
Oxidase) (COX) deficiency within a m.5024C>T + m.13715C>T heteroplasmic mouse.
Sex-Bias
As mentioned in Section 1.5.2, LHON predominantly affects males, with ~5x incidence
rate when compared to the female disease incidence.
This has resulted in a number of theories for the bias, however, at present it is not
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fully understood. Two main theories presently lead to explain this aspect to disease
progression: X-linked modifier genes and hormonal disease suppression.
Many different X-linked genes have been identified and presented as a causative
factor in disease onset, however, often a subsequent paper refutes the accuracy of the
named variant (Chen and Denton, 1991; Hudson et al., 2005; Phasukkĳwatana et al.,
2010; Qu et al., 2010; Shankar et al., 2008; Vilkki et al., 1991).
It is possible that within alternate studies, their hypothetical gene is causative but
that it is only relevant within the specific haplogroup backgrounds captured within
that study and that it does not influence penetrance in other haplogroup backgrounds
(Ji et al., 2012; Strauss et al., 2013).
The alternate theory is that oestrogen plays a neuroprotective role in LHON dis-
ease onset by doubling Mitochondrial Antioxidant Manganese Superoxide Dismutase
(MnSOD) efficacy and as a result, minimising ROS activity (Pedram et al., 2006).
Estrogen Receptor β (ERB) is now being targeted for LHON treatment as it has been
shown to increase mitochondrial copy number, prevent ROS production and improve
cell viability (Pisano et al., 2015), therapy for this pathway is further reviewed in Section
1.5.5.
ROShas been shown to be apoormediator ofDNAdamage, however, so it is possible
that oestrogen is protective by other means (Brawn and Fridovich, 1981; Gammage and
Frezza, 2019; Halliwell and Aruoma, 1991).
Age
Few LHON patients develop disease in childhood. When they do, this tends to be
the childhood LHON form, with a different clinical progression (Barboni et al., 2006;
Majander et al., 2017). The likelihood of developing LHON continues to increase with
a median age onset of 24 (Chinnery, 2000), whereafter the odds ratio of development
eventually reduces and plateaus around age 50 with 95% of those affected developing
disease before this point (Yu-Wai-Man and Chinnery, 2000).
The body undergoes multiple different hormonal changes throughout life. In ad-
dition to this, genes are regularly switched on and off throughout different sections of
life to adjust to demands of growth, systems repair and eventual senescence. There is a
broad range of years whereby LHON onset is likely to occur, however, so it is difficult
to associate it with any particular biological age response.
Smoking
Smoking has been seen to have a direct impact on LHON onset; Kirkman et al. (2009)
found a penetrance of 93% in male smokers compared to male non-smokers’ 66% pen-
etrance; female smokers, however, were only affected with 33% penetrance (Kirkman
et al., 2009). Further, visual acuity has been seen to decrease with smoking (Karanjia
et al., 2014).
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It has also been shown that smoking is a causative factor in LHON by depressing
mtDNA copy number and oxidative phosphorylation, only compensated by efficient
ROS detoxification (Giordano et al., 2015; Tsao et al., 1999). Further, smoking has been
shown to induce epigenetic modifications (Breitling et al., 2011; Monick et al., 2012)
which could be a further influence in disease development by nuclear-mitochondrial
interactions, as described in Section 1.3.5.
Cigarette smoke is highly poisonous and genotoxic (DeMarini, 2004; Talhout et al.,
2011). Some chemical compounds within it only affect local tissue, however, some, like
nicotine, are absorbed where they can then be transmitted around the body and cause
effects elsewhere.
Nicotine has been found to act both in a neuroprotective and neurotoxic manner,
depending on the situation (Ferrea and Winterer, 2009; Ma et al., 2017). While iso-
lated nicotine can be neuroprotective, there are hundreds of chemicals which could
be concurrently absorbed and which could be responsible for the detrimental effect of
smoking on LHON onset.
Alcohol Consumption
Alcohol is believed to possibly affect LHONdisease onset, however, this trendwas only
seen with heavy alcohol intake (Kirkman et al., 2009). Morris and Votruba (2012) also
reported a case where a male recovered 5 months after disease onset following lifestyle
change where he quartered smoking intake and ceased alcohol intake from 60 weekly
units.
While alcohol has been seen to increase likelihood of disease onset, it has also been
associated with better visual acuity following disease onset (Karanjia et al., 2014).
1.5.5 Treatment Strategies
Atpresent, there is no cure nor guaranteedprevention strategy for LHONand treatment
options are both very limited and often expensive. Additionally, as time progresses
from AOO, the potential for visual recovery becomes increasingly less viable. In Eng-
land, treatments are limited to clinical trials and lack of options results in some patients
choosing to self medicate through Internet purchases, based on experimental research.
These strategies are not always confirmed to be beneficial and could cause a number
of complications; whilst one of the supplements, Idebenone, has shown improvements
in patients (Klopstock et al., 2011), it does not guarantee that online purchases are of
medical grade.
A number of different treatment options are in consideration, as well as lifestyle
aids which help LHON patients manage their illness. As summarised in Table 1.2,
ClinicalTrials.gov (National Institutes of Health, 2020) lists 19 interventional studies
for LHON, of which 8 are complete, 3 are recruiting and 4 are presently active but
not recruiting. The remaining 4 have been terminated, withdrawn or are of unknown
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status. Presently ongoing clinical trials have also been described by Jurkute et al. (2019).
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Table 1.2: Summary table of active or complete interventional clinical trials on LHON from ClinicalTrials.gov (National Institutes of Health, 2020).
Status Study Treatment





Safety and Efficacy Study of Gene Therapy for The Treatment of Leber’s
Hereditary Optic Neuropathy
Drug: rAAV2-ND4
Completed A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide
(MTP-131) Topical Ophthalmic Solution for the Treatment of Leber’s Hereditary
Optic Neuropathy
Drug: Elamipretide (MTP-131) 1%
topical ophthalmic solution
Recruiting Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber’s
Hereditary Optic Neuropathy
Drug: Injection of scAAV2-P1ND4v2
Active, not
recruiting
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy
(LHON) Patients
Genetic: GS010
Completed Study to Assess Efficacy, Safety and Tolerability of Idebenone in the Treatment of




Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects




Study to Assess the Efficacy and Safety of Raxone in LHON Patients Drug: Idebenone
Completed A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber’s
Hereditary Optic Neuropathy (LHON)
Drug: Curcumin
Recruiting New Non-invasive Modalities for Assessing Retinal Structure and Function Device: LSFG-NAVI
Recruiting Stem Cell Ophthalmology Treatment Study II Procedure: Arm
Completed Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year
From Onset in LHON Due to the ND4 Mutation (REVERSE)
Biological: GS010
Completed Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From
Onset in LHON Due to the ND4 Mutation
Biological: GS010
Completed Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve
Atrophy and Recent Onset NAION Patients
Drug: QPI-1007 at various doses
Completed Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of




Idebenone (Raxone/Catena) is an antioxidant which inhibits lipid peroxidation and
facilitates electron flux to bypass Complex I (Klopstock et al., 2011). It is a short-
chain analogue of CoQ10 which works in the same manner but is more bioavailable in
neurological tissue and mitochondria due to the structural modification (Jurkute et al.,
2019). It has been used in a number of trials (Cortelli et al., 1997; Klopstock et al.,
2011; Yu-Wai-Man et al., 2013) and does appear to improve visual acuity, however,
application is limited and it is possible that it ameliorates Complex I dysfunction in
some RGC species but the midget cells do not recover (Klopstock et al., 2011). Some
RGCs could potentially be functionally suppressed but respond favourably to treatment
if treated quickly (Jurkute et al., 2019).
Idebenone has been approved in the European Union under "exceptional circum-
stances" under "orphan designation" from Santhera Pharmaceuticals GmbH (Deutsch-
land) (European Medicines Agency, 2015) and it is available in Scotland to LHON
patients who do not yet meet the UK criteria to be registered as severely sight impaired
(Scottish Medicines Consortium, 2017).
While the response to Idebenone has been variable, such as only specific cell lines
responding to treatments (Yu-Wai-Man et al., 2017), and NHS England not offering
Idebenone as a treatment to LHON, Idebenone is safe and well tolerated with original
treatments of 270 mg·day-1 (Carelli et al., 2011) and rising up to 900 mg·day-1 in later
studies which indicate that Idebenone has a favourable clinical outcome in LHON
treatment (Llòria et al., 2017; Lyseng-Williamson, 2016; Zhao et al., 2020). The RHODOS
clinical trial did not find an improvement in visual acuity recovery (Klopstock et al.,
2011) but post hoc and follow up analysis found an improvement in best visual acuity
(Klopstock et al., 2013, 2011). Further studies also found an improvement in visual
acuity, field and evoked potential (Lyseng-Williamson, 2016; Pemp et al., 2019; Zhao
et al., 2020) alongside increased clinically relevant recovery in both recent and chronic
LHON (Carelli et al., 2011; Lyseng-Williamson, 2016; Pemp et al., 2019).
In addition to this, EPI-743, a para-benzoquinone therapeutic related to Vitamin E,
has been shown to have a clinically favourable response (Sadun et al., 2012).
Minocycline has beenused as a neuroprotective agentwhich blocksmPTP formation
and acts as an antioxidant (Haroon et al., 2007). MTP-131 increases OXPHOS efficiency
and reduces ROS generation (Koopman et al., 2016) and it is presently undergoing
phase 2 clinical trials as Ocuvia™ (Stealth BioTherapeutics Inc., 2019); it has also been
seen to associate with cardiolipin, a molecule known for stabilising Complexes III and




Recent treatments have looked at targeting ERB to reduce apoptosis, induce mito-
chondrial biogenesis and reduce ROS in LHON (Giordano et al., 2011; Pisano et al.,
2015). They suggest that the hormonal dimorphism between sexes could factor into the
reduced penetrance in females, further implicating ERB as a beneficial target.
No present clinical trials involve treating with oestrogen to target the ERB, however,
it is being considered as a mechanism in preventing onset (Giordano et al., 2011; Pisano
et al., 2015). There are concerns in treating with oestrogen given the number of side
effects of hormonal treatments, however, both oestrogens and androgens have been
investigated in therapy across a range of mitochondrial diseases (Mohajeri et al., 2019).
G protein-coupled oestrogen receptor has also been seen to act in a neuroprotective
manner against Complex I neuronal insult (Yuan et al., 2019) and crosstalk between
both G protein-coupled estrogen receptors and ERB and Estrogen Receptor α (ERA) has
been observed (Romano and Gorelick, 2018). This research is still at an early stage but
could lead to a promising treatment.
Mitochondrial Biogenesis
Mitochondrial biogenesis has been implicated with hormonal treatments as the at-
tributing factor for why ERB treatment has been particularly effective (Giordano et al.,
2011; Pisano et al., 2015).
In addition to this, cigarette smoke, a known causative factor of LHON onset,
discussed in Section 1.5.4, has been shown to depress mtDNA copy number within
patient fibroblasts (Giordano et al., 2015), indicating that smoking could increaseLHON
onset likelihood by reducing mitochondrial biogenesis.
Some contention has been raised towards these studies by Finsterer (2017), with Yen
et al. (2002) finding that all LHON carriers’ copy number is increased when compared
to wild type controls. This contradiction between the results questions whether mito-
chondrial biogenesis is truly neuroprotective, or rather, a result of LHON development
and at best a potential biomarker of disease onset which arises as a result of carrying a
LHONmutation.
Improved mitophagy also appears to improve cell survival by reducing mutant
mtDNA burden in cybrid cell lines (Sharma et al., 2018). Ketogenic treatment has also
been shown to reduce mutant mtDNA burden in cybrid heteroplasmic cell lines whilst
upregulating mitochondrial copy level in homoplasmic cell lines (Emperador et al.,
2019).
Gene Therapy
Gene therapy by Recombinant Adeno-Associated Virus 2 (rAAV2) allotopic expression
of MT-ND4 has been trialled with LHON patients (Wan et al., 2016), showing some
improvement in visual acuity and field but no improvement to the GCL.
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GenSight have also performed rAAV2 allotopic expression ofMT-ND4, calledGS010
(GenSight Biologics, 2019). Week 48 of the RESCUE Phase III had no difference com-
pared to the sham placebo in the temporal retinal nerve fiber layer, papillomacular
bundle thickness or ganglion cell volume. Week 96 REVERSE Phase III clinical trials
similarly show no statistical significance in the effect of GS010 in visual acuity or con-
trast sensitivity, however, there is a clinically relevant improvement and treatment was
well tolerated (Bouquet et al., 2019).
Other studies of rAAV2 allotopic expression have generally found treatment to be
safe in humans (Guy et al., 2017; Vignal et al., 2018) but no trial has been marked as
statistically successful yet - possibly due to small sample sizes - as clinical improvement
has been identified across multiple studies (Zhang et al., 2018).
Stem Cells
Conversion of patients’ cells to iPSCs and reprogramming to RGCs before editing the
mtDNA and transplanting back to the patient has also been strategised (Kim et al.,
2018; Wong et al., 2017). There are a number of difficulties with this method at present,
particularly with reprogramming and transplantation, however there has been some
success in retinal disease with iPSC treatment. Mandai et al. (2017) used autologous
iPSCs to transplant new RPE cells to a neovascular age-related macular degeneration
patient and the same team also treated another patient with age-related macular de-
generation with cells from an anonymous donor (Cyranoski, 2017). Another Japanese
group have also recently announced iPSCs transplant to treat corneal epithelial stem
cell deficiency, with the patient showing improvement without problems (The Japan
Times, 2019).
There are still concerns on the safety of iPSC treatment (Singh et al., 2019) but despite
this, it is seen as a positive development in therapeutic treatments, with a number of
studies looking at iPSC treatments across a range of optic neuropathies (Maeda et al.,
2019).
Wong et al. (2017) has suggested Clustered Regularly Interspaced Short Palindromic
Repeats (CRISPR) reprogramming of iPSCs, however, despite the increasing popularity
of the gene editing tool, it is probably not a good strategy for treating LHON. Given
the difficulties of targeting CRISPR to mtDNA, treatments should instead focus on
Transcription Activator-Like Effector Nucleases (TALENs) and Zinc-Finger Nucleases
(ZFNs) (Gammage et al., 2018a).
Mitochondrial Donation
While mitochondrial donation will not cure any LHON patients, it could prevent the
transmission of LHON mutations through the maternal lineage.
The UK became the first country in the world to legalise mitochondrial dona-
tion/mitochondrial replacement therapy in 2015 (United Kingdom Houses of Parlia-
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ment, 2015) with countries, such as Singapore, also looking to legalise this option
(Singapore Bioethics Advisory Committee, 2018). The response in some other coun-
tries, like theRepublic of Ireland, have been less favourable, with theRepublic of Ireland
proposing a bill to expressly prohibit all forms ofmitochondrial replacement (An Roinn
Sláinte Department of Health, 2017).
Three methods of mitochondrial donation persently exist: pronuclear transfer, ma-
ternal spindle transfer and polar body transfer with the former two methods legalised
in the UK (Craven et al., 2010; Tachibana et al., 2009; Wang et al., 2014).
The technique varies but the end effect is that the nDNA comes from two parents
whilst themtDNAcomes froma thirddonor parentwhodoes not carrymtDNAdisease.
There have been successes with mitochondrial donation (Zhang et al., 2017), how-
ever, as it is a new technique, long-term risk has not been ascertained.
Lifestyle Aids & Assistive Technology
Whilst a cane or Braille has classically been used to support the visually impaired,
newer technology aims to specifically support LHON patients.
Specialised computer software, such as JAWS or ZoomText act as screen readers
or magnifiers (Freedom Scientific Inc, 2019a,b) which can support LHON patients.
Modern mobile features, such as Apple’s Voiceover and Android’s Talkback allow
people to interact with their phones despite being visually impaired.
Both classical magnifying glasses and CCTV magnifiers (CCTV camera recording
projecting amagnification onto a new screen) can be beneficial, whilst some specialised
assistive eyewear, namely NuEyes and eSight, aim to directly use LHON patients’
remaining peripheral vision to see and translate text to speech (eSight Corp, 2019;
NuEyes, 2019).
A lot of the specialised technology is extremely expensive, however, and the cost of
buying lifestyle aids and assistive technology adds to the cost burden that comes with
loss of eyesight and abilities that LHON causes.
1.6 PROJECT AIMS
Given the limited success in treatment options with LHON, this project has identified
three target investigation routes to develop a greater understanding of LHON genetic
risk factors and disease mechanisms in mitochondrial optic neuropathies.
Firstly, this project seeks to improve our estimates of disease penetrance and inves-
tigate other novel genetic and epigenetic modifiers which could contribute to disease
onset. Chapter 2, ’LHON Disease Penetrance’, recalculates disease penetrance in a
large, modern cohort and investigates the statistical probability of an X-linked modi-
fier gene being involved in LHON disease onset. It also seeks novel nDNA variants
which modulate disease penetrance through both genetic and epigenetic molecular
investigation.
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Secondly, this project seeks to characterise specific LHON patient fibroblast cell
lines of the three most common mtDNA mutations, m.11778G>A, m.14484T>C or
m.3460G>A, to directly investigate cellular processes which could act as a LHON trig-
ger mechanism. In addition to this, as retinal tissue is not available from patients,
accurate characterisation of cell lines could allow for future work to determine whether
affected biological pathways improve as a result to drug treatment. Chapter 3, ’Func-
tional Characterisation of LHON Fibroblasts’, evaluates mtDNA copy number, ATP
production, cellular oxygen consumption, calcium homeostasis, mitochondrial mem-
brane potential and mitochondrial network structure and interactions with the ER in
isolated tests to gauge whether these pathways affect LHON expression and whether
fibroblast cell lines exhibit quantifiable differences in cases to controls.
Thirdly, given the limitations of cell work, this project finally seeks to develop a
technical framework to evaluate retinal degeneration in a m.5024C>T + m.13715C>T
mutation mouse model. This holistic approach will allow for evaluation of retinal de-
generation both at a systems level and specifically within the affected tissue type. It
opens future options for drug testing and application of the methodology in specific
LHON mouse models. Chapter 4, ’Retinal Characterisation of Mitochondrial Disease
Mouse’, investigates mitochondrial heteroplasmy level across the mouse, and charac-
terises cellular organisation in both sections and whole mounts of retinal tissue.
Overall, we hope to identify genetic variants which influence LHON expression,
improve our understanding of the disease process and develop methods which would
allow for drug evaluation.
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Chapter 2 | LHON Disease Penetrance
2.1 INTRODUCTION
As present disease onset is not accurately predictable, this chapter seeks to further
characterise disease penetrance to ascertain any predictor variable which could aid in
diagnostics. There is a discrepancy between known genetic aetiology and phenotype
development. As such, there are likely currently unknown genetic links and disease
risk factors which have yet to be characterised.
LHON results in a diminishing life quality and awareness of relative disease risk al-
lows for informed decision processes regarding reproductive choices and life-planning,
such as preparing career optionswhich do not require great visual acuity. Additionally,
our lack of understanding in disease onset raises difficulties in strategising options for
both potential gene therapy treatments and drug design.
As discussed in Section 1.5.4, a number of factors influence disease onset. Whilst
~90% of LHON cases carry m.11778G>A, m.14484T>C or m.3460G>A mutations (Yu-
Wai-Man and Chinnery, 2011), this is not a guarantee of disease and a number of other
factors influence disease onset but both the factors and the effect size of each is presently
undetermined.
As further described in Section 1.5.4, mitochondrial haplogroup, and accumulation
of non-pathogenic missense mtDNA mutations which could accumulate to trigger
LHON disease onset or interfere with mitochondrial-nuclear crosstalk (Chinnery and
Gomez-Duran, 2018), affect LHON penetrance. These known factors contribute to
penetrance, but at present, they do not fully explain disease onset and this chapter
investigates novel genetic mechanisms which could further influence it.
More than 99% of the mitochondrially associated actions are encoded in the nDNA
(Kühlbrandt, 2015), as such, it is likely that nuclear background further modulates
any additive model for disease penetrance. In ethnically homogeneous populations, it
can be assumed that the nuclear and mitochondrial background evolved together and
that they are optimised to work most efficiently in conjunction; in cases of admixture,
the mtDNA background will only match the nDNA background from one parent and
will not have evolved to work so efficiently with the nuclear background of the other
parent. The impact of this mismatch depends on several factors: the distance between
the co-evolution and whether the mtDNA is aligned with the dominant nDNA alleles
which the mtDNA co-evolved with, if genetically distant alleles are dominant in nDNA
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encoding, and whether the proteins of the nuclear-encoded mitochondrial respiratory
chain work effectively with the mitochondrially-encoded proteins. Nuclear-mtDNA
mismatch has been confirmed to increase disease risk (Crawford et al., 2018; Gaweda-
Walerych andZekanowski, 2013; Rishishwar and Jordan, 2017; Zaidi andMakova, 2019)
with nuclear-mtDNA background matching considered as a factor in mitochondrial
replacement therapy (Rishishwar and Jordan, 2017).
This further indicates that nuclear variants can alter disease expression in primary
mitochondrial disease. As such, bioinformatics tools are used to evaluate potential
candidate nuclear variants which influence LHON penetrance, both within families to
ascertain whether nuclear background affects penetrance and for the statistical proba-
bility that an X-linked modifier gene can affect LHON expression.
Additionally, nuclear genes are investigated for differences between LHONpatients
and unaffected carriers for both sequence-level and also epigeneticmodifications, given
that age, sex, and environmental factors influence LHON expression, as described in
Section 1.5.4. Cases of LHONwithout an obvious primary mitochondrial disease have
also been discovered, questioning whether LHON can also arise solely from a nuclear
disease background (Abu-Amero et al., 2005).
At present, there has been limited success in identifying nuclear modifier genes
in LHON and whilst epigenetic modifications are known to have a causative role in
complex mitochondrial disease (Wallace and Fan, 2010), there has been no system-
atic study of the role of epigenetics in LHON. Epigenetic factors have been identified
and investigated in patients, however, sequence methylation and nuclear epigenetic
modifications have not been directly investigated within LHON. This chapter seeks
to determine further genetic modifiers to explain some of the missing heritability of
LHON. This includes exome analysis and nuclear methylation investigation. Given
the disease penetrance differences between male and female LHON primary mutation
carriers and also genome-wide variation between male and female methylation values
(Singmann et al., 2015), methylation patterns were to be specifically investigated as a
potential cause of disease onset. In addition, this chapter aims to calculate statistical
probabilities for a modifier gene being X-linked and to also update penetrance mea-
surements in a large, modern cohort LHON for differences in penetrance by primary
mutation or country of origin.
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2.2 METHODOLOGY
2.2.1 Familial Disease Penetrance
Multiple generations of family pedigrees were collected from 82 families as shown in
Table 2.1. Pedigrees ranged from 1-5 generations with 1-34 mothers within the full
pedigree. All offspring below the age of 30 (6 years after median AOO (Chinnery,
2000)) were excluded to minimise likelihood of misassignment of disease status by
asymptomatic carriers developing at a later age. Within another dataset consisting of
133 Italian and 111 British affected LHON patients, 73.77% of affected LHON patients
develop by age 30; counts are shown in Figure S1. Whilst thresholding later would
prevent erroneous LHONdisease status classification, themajority of LHONcases have
developed by age 30 and raising the threshold further would remove many pedigrees
from the study.
Disease penetrance was then calculated for male and female offspring, after strati-
fying the mothers as affected or unaffected (asymptomatic) carriers. This project was
undertaken in collaboration with Professor Valerio Carelli (University of Bologna) who
previously identified that disease penetrance in offspring is greater in children of af-
fected mothers than unaffected mothers (data unpublished).
This was further segmented by LHON causativemutation and the country in which
the family resided.
Table 2.1: Table of the cohort analysed for differential offspring penetrance, showing the 1001 offspring
from all mothers then stratifying by mother’s disease status.
Offspring Male Female
All Mothers Affected 219 103Unaffected 266 413
Affected Mothers Affected 65 30Unaffected 43 52
Unaffected Mothers Affected 154 73Unaffected 223 361
2.2.2 X-Linked Modifier Gene
Following from the pedigrees collected tomeasure LHONdisease penetrance in Section
2.2.1, statistical analyses were replicated based on the work by Bu and Rotter (1991)
to determine the validity of a two locus causative model and feasibility of an X-linked
modifier gene accounting for part of the variability in disease penetrance.
The dataset is limited to the maternal line as offspring will share mtDNA lineage
and the disease penetrance reflects segregation of nDNA locus, reducing dimension of
the model from two loci (nDNA + mtDNA) down to one (nDNA).
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The Bu and Rotter (1991)methodology has two hypotheses: the X-linked hypothesis
and the X-inactivated hypothesis. AHaldane correctionwas not applied as Burton et al.
(2000) found that ascertainment bias adjustments with heterogeneity often results in
biased parameter estimates which do not match those in the sample or original pop-
ulation. Due to the advances of computational power, exact p-values were calculated
and Fisher’s exact test was replaced by ANOVA analysis of deviance for evaluation of
heterogeneity.
The X-linked hypothesis restricts mothers in the pedigrees to those which are ob-
ligate heterozygotes and calculates an X-linked goodness-of-fit test for male offspring
and assumes a binomial distribution of inheritance for the affected X chromosome
from the mother to her son, giving a segregation ratio, T, of 0.5. This is then tested in
pooled sibships through Chi-Squared testing and individual male sibships through the
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The X-Inactivation hypothesis also limits the pedigrees to obligate heterozygous
mothers and calculates T, the segregation ratio; q, the population frequency of an
allele and K, the probability of a heterozygous female being affected (penetrance). It
then calculates the proportion of affected, female LHON patients who develop LHON
due to X-inactivation and those who are homozygous for the mutant allele on both X
chromosomes.
2.2.3 Nuclear DNA Variants
A cohort of 30 patients were chosen for nDNAmethylation analysis, as shown in Table
2.2. The nDNA methylation cohort covered 4 families and a total of 30 LHON family
members. 16 carried m.11778G>A mutations, 3 m.14484T>C and 11 m.3460G>A. 9 of
the 30 members were unaffected carriers.
Whole blood was collected and DNA was extracted and bisulphite converted by
Doctor Hannah Elliot (University of Bristol, formerly, Newcastle University), who sent
samples to Illumina (Illumina, Inc., San Diego), where samples were loaded onto an
Illumina Infinium HumanMethylation27 BeadChip microplate for amplification, frag-
mentation, precipitation and resuspension. Samples were then transferred to an array
for hybridisation and Xstaining before loading into an Illumina scanner and imaging.
Data was returned as .idat files and decrypted in Illumina® GenomeStudio 2011 +
v1.9.0 Methylation module before exporting to R version 3.3.2 (2016-10-31), Platform:
x86_64-w64-mingw32/x64 (64-bit), Running under: Windows 7 x64 (build 7601) via
methylumi_2.20.0.
Two samples which failed on the chip (F1B_3460_M_U_38 and F1C_3460_M_A_38)
were excluded. A detection threshold of p=0.01 and a minimum of 3 beads per probe
44
were then set to remove low quality probes and poorly covered genes before quantile
normalisation (rescales distribution of pooled intensities of methylated and unmethy-
lated probes to be identical). Normalised methylation beta methylated and unmethy-
lated values were then used to calculatemethylationM-values (log2 ratio of methylated
and unmethylated probe intensity), indicating whether or not a gene was methylated
at the probe position. Beta-values are prone to severe heteroscedasticity in the high
and lowmethylation range making it inappropriate for statistical analysis; the M-value
is more homoscedastic and thus suitable for subsequent analysis (Du et al., 2010).
limma_3.30.2 (Ritchie et al., 2015) performed 80 combinations of covariates (Status +
Gender + Age +Mutation + Batch + Never Smoked + CPD) in a linear regression across
the full data set - using 20/28 samples which contained metadata for Never Smoked
and CPD (this excludes all children who are legally too young to smoke). Data was
then stratified into females and affected patients only and running 32 combinations on
the females then another 40 combinations (Gender + Age + Mutation + Batch + Never
Smoked + CPD) on the affected patients.
Significant genes were grouped from the full data set and females with a non-
adjusted p-value <0.05 which occur in >95% of tests to identify hyper- and hypomethy-
lated genes.
Genes were further cross-matched against in-house exome sequencing data. 25
affected patients and 3 unaffected carriers described in Table 2.3 had whole blood
samples taken and DNA extracted. Exome data was captured using Nextera Rapid
Exome Capture 37Mb and Illumina TruSeq 62Mb. 17,403 genes 62Mb were captured
by probes and samples were sequenced on an Illumina HiSeq2000. BWA (v0.7.10) (Li
and Durbin, 2009) aligned paired-end reads to Human Reference Genome, GRCh38
(Schneider et al., 2016) with Ensembl gene annotations. Samtools (v.01.18) (Li et al.,
2009) compressed and generated indexes for the alignments and Picard (v1.85) (Broad
Institute, 2016) removed duplicate reads. Variants were detected by Varscan (v2.3.8)
(Koboldt et al., 2012) and annotated by ANNOVAR (v529) (Li and Wang, 2017).
Exome data was cleaned by removal of probes which failed exome sequencing and
given the number of variants across any site, dominant and recessive models were
performed against the exome dataset to identify differential variants between LHON
patients and carriers. These were then cross-matched against the list of hyper- and
hypomethylated genes to identify genes which contained both differential methylation
and exome variants.
Genes were analysed through Gene Set Enrichment Analysis (GSEA) with cross-
matched genes against Molecular Signatures Database (MSigDB) gene sets (Mootha
et al., 2003; Subramanian et al., 2005) to calculate overlap against MSigDB’s C2 curated
gene sets of chemical and genetic perturbations and MSigDB’s C5 GO gene sets of
biological processes; gene sets larger than 500 and smaller than 15 were excluded.
The full cross-matched gene list of exome variants and LHON hyper- and hy-
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pomethylated genes thenunderwent PANTHER14.1OverrepresentationTest (Released
20190711) (Mi et al., 2018; Mi and Thomas, 2009) against GO gene sets of biological pro-
cesses by Fisher’s Exact Test, restricting to False Discovery Rate (FDR) p < 0.05.
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Table 2.2: Samples in nDNA methylation arrays; gender indicating if male (M) or female (F), status indicating whether they are affected (A) or unaffected carriers (U
(C)). CPD indicates Cigarettes Per Day, current.






CPD AOO Smoker Before
AOO
1 F1A_3460_F_A_38 A38_A 61 F 1 m.3460G>A A NA NA NA NA 12 NA
2 F1B_3460_M_U_38 A38_B 42 M 1 m.3460G>A U (C) NA NA NA NA NA NA
3 F1C_3460_M_A_38 A38_C 39 M 1 m.3460G>A A Yes No 16 35 6 No
4 F1D_3460_F_A_38 A38_D 37 F 1 m.3460G>A A Yes No 14 40 20 Yes
5 F1E_3460_F_A_38 A38_E 40 F 1 m.3460G>A A Yes No 14 20 7 No
6 F1F_3460_M_A_38 A38_F 19 M 1 m.3460G>A A NA NA NA NA 13 NA
7 F1G_3460_F_A_38 A38_G 15 F 1 m.3460G>A A NA NA NA NA 11 NA
8 F1H_3460_F_U_38 A38_H 20 F 1 m.3460G>A U (C) NA NA NA NA NA NA
9 F1I_3460_F_A_38 A38_I 15 F 1 m.3460G>A A NA NA NA NA 7 NA
10 F1J_3460_F_A_38 A38_J 12 F 1 m.3460G>A A NA NA NA NA 3 NA
11 F1K_3460_F_A_38 A38_K 16 F 1 m.3460G>A A NA NA NA NA 6 NA
12 F2A_11778_M_A_38 A38_L 72 M 2 m.11778G>A A No No 17 7.143 16 No
13 F2B_11778_M_A_40 A40_A 79 M 2 m.11778G>A A No No 15 30 57 Yes
14 F2C_11778_M_A_40 A40_B 80 M 2 m.11778G>A A No No 20 7.143 22 Yes
15 F2D_11778_F_U_40 A40_C 76 F 2 m.11778G>A U (C) No Yes NA 0 NA NA
16 F2E_11778_F_U_40 A40_D 48 F 2 m.11778G>A U (C) No Yes NA 0 NA NA
17 F2F_11778_M_A_40 A40_E 46 M 2 m.11778G>A A No No 15 30 16 No
18 F2G_11778_M_A_40 A40_F 39 M 2 m.11778G>A A Yes No 15 10 17 No
19 F3A_14484_F_U_40 A40_G 58 F 3 m.14484T>C U (C) No Yes NA 0 NA NA
20 F3B_14484_M_A_40 A40_H 31 M 3 m.14484T>C A No No 15 10 20 Yes
21 F3C_14484_M_U_40 A40_I 30 M 3 m.14484T>C U (C) No No 13 5 NA NA
22 F4A_11778_M_A_40 A40_J 54 M 4 m.11778G>A A No No 18 20 18 No
23 F4B_11778_F_U_40 A40_K 64 F 4 m.11778G>A U (C) No Yes NA 0 NA NA
24 F4C_11778_F_A_40 A40_L 71 F 4 m.11778G>A A Yes No 15 20 NA No
25 F4D_11778_F_A_41 A41_A 71 F 4 m.11778G>A A No Yes NA 0 54 NA
26 F4E_11778_M_A_41 A41_B 40 M 4 m.11778G>A A No Yes NA 0 22 NA
27 F4F_11778_F_U_41 A41_C 38 F 4 m.11778G>A U (C) NA NA NA NA NA NA
28 F4G_11778_M_A_41 A41_D 49 M 4 m.11778G>A A No Yes NA 0 5 NA
29 F4H_11778_M_A_41 A41_E 48 M 4 m.11778G>A A Yes No 14 40 NA Yes
30 F4I_11778_F_U_41 A41_F 42 F 4 m.11778G>A U (C) Yes No 15 20 NA NA
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Table 2.3: Samples in nDNA exome sequencing; gender indicating if male (M) or female (F), status
indicating whether they are affected (A) or unaffected (U (C)).
Sample UNIQUE_ID Gender Family LHONMutation Status
1 F1B_3460_M_U_38 M 1 m.3460G>A U (C)
2 F1C_3460_M_A_38 M 1 m.3460G>A A
3 F1F_3460_M_A_38 M 1 m.3460G>A A
4 F1F_3460_M_A_38 M 1 m.3460G>A A
5 F1I_3460_F_A_38 F 1 m.3460G>A A
6 F1L_3460_M_A M 1 m.3460G>A A
7 F1M_3460_M_A M 1 m.3460G>A A
8 F1N_3460_F_A F 1 m.3460G>A A
9 F1O_3460_F_A F 1 m.3460G>A A
10 F1P_3460_M_A M 1 m.3460G>A A
11 F2A_11778_M_A_38 M 2 m.11778G>A A
12 F2B_11778_M_A_40 M 2 m.11778G>A A
13 F2E_11778_F_U_40 F 2 m.11778G>A U (C)
14 F2G_11778_M_A_40 M 2 m.11778G>A A
15 F3B_14484_M_A_40 M 3 m.14484T>C A
16 F3D_14484_M_U M 3 m.14484T>C U (C)
17 F3E_14484_M_A M 3 m.14484T>C A
18 F3F_14484_M_A M 3 m.14484T>C A
19 F4E_11778_M_A_41 M 4 m.11778G>A A
20 F4J_11778_M_A M 4 m.11778G>A A
21 F5A_3460_M_A M 5 m.3460G>A A
22 F5B_3460_M_A M 5 m.3460G>A A
23 F6A_11778_M_A M 6 m.11778G>A A
24 F6B_11778_M_A M 6 m.11778G>A A
25 F7A_14495_M_A M 7 m.14495A>G A
26 F7B_14495_M_A M 7 m.14495A>G A
27 F8A_11778_M_A M 8 m.11778G>A A
28 F8B_11778_M_A M 8 m.11778G>A A
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2.3 RESULTS
2.3.1 Familial Disease Penetrance
Pedigrees of 82 families were collected and analysed for differential penetrance in
offspring between affected and unaffected mothers. Data set is summarised in Fig-
ure 2.1; this clearly shows that the majority of LHON pedigrees only had a single
mother and most data came from unrelated pedigrees. However, some were large
multi-generational pedigrees, of up to 34 mothers passing QC across their generational
pedigree. The majority of captured offspring are female and a greater proportion of
the male offspring are affected than female. The majority of mothers captured are
asymptomatic, from the UK cohort, and m.11778G>A carriers. Within the total cohort,
haplogroup H is most common, however, the majority of families have not had their
haplogroup determined.
Figure 2.2 further segments the samples, by familial mutation and cohort, looking
at the percentage affected in offspring; sons and daughters.
Table 2.4 shows differences in the mother’s disease status and how this affects
their children’s likelihood of developing LHON. This looks at the entire cohort then
segments by LHON causative mutation and the country that the recruited family lived
in. Offspring age was thresholded at 30 years old, so this assumes that the majority of
offspring have developed LHON by this point if they are to develop, however, this is
likely a slight under-representation of the lifetime LHON penetrance as some who are
older than 30 could still develop beyond the date of this study.
Cohorts were further described in Figure 2.3, which shows the breakdown of mu-
tation in offspring by the cohort. m.11778G>A was the most prevalent mutation in all
countries with the Finnish cohort only containing m.11778G>A and m.3460G>A, and
the Tasmanian cohort only containing m.11778G>A and m.14484T>C. The Tasmanian
cohort seems to have a lower percentage of offspring affected, as seen in Figure 2.2 B;
stringent thresholding was applied on the pedigrees to improve sample quality, how-
ever, the pedigrees did appear to be biased to recording female offspring and male
offspring had not been included in some of the generations which were excluded. Fe-
male offspring were recorded for all generations and given the lower rate of affected
females, it is possible that the lowermale affected rate is also an accurate representation
of the dataset. The Tasmanian cohort has a greater proportion of m.14484T>C which is
the most mild LHONmutation and could be the reason for the lower penetrance.
m.14495A>G andm.12719T>A are single familymutationswhich only appear in the
UK population and metadata describing the pathogenic LHON mutation was missing
for some samples in the UK cohort. m.12719T>A is also a single family mutation, not
presently recognised in MITOMAP (Lott et al., 2013) and needs validation as causative
for LHON.
Whilst all countries have a largeproportionofm.11778G>Aoffspring, thedifferences
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seen between penetrance in the Finnish and Tasmanian cohort (Figure 2.4) could be due
to the difference in mutation burden rather than nuclear background. Table S1 does
show that the penetrance in m.3460G>A and m.14484T>C is significantly different
(sons p = 5.05e-03; daughters p = 3.66e-04) whilst testing for all mutations, a significant
difference is found (sons p = 2.599e-12; daughters p = 1.82e-04). In the cohorts, no
significant difference is found between sons’ penetrance (p = 0.092) whilst daughters’
has some significance (p = 1.051e-05).
There are significant differences in the penetrance of LHON in offspring between
affected and unaffected mothers. As shown in Table S1, total offspring significance is p
= 8.43e-09, with female offspring more affected by mothers’ status (p = 7.62e-05) than
male offspring (p = 5.60e-04).
This continues to be true in m.11778G>A carriers with affected mothers more likely
to have affecteddaughters andoffspring in general (p = 0.008 andp= 0.001 respectively).
m.3460G>A carriers are more affected by mothers’ disease status with offspring 28.6%
more likely to be affected if their mother is affected (p = 0.001) and both sons and
daughters are affected by mothers’ status (p = 0.025 and p = 0.046 respectively).
Both UK and Finnish offspring are more likely to be affected by mothers’ status (p
= 0.002 and p = 5.43E-05), however, this is predominantly for sons in the UK (p = 0.014)
whilst both sons and daughters are affected in Finland (p = 0.041 and p = 0.001), with
daughters more influenced than sons.
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Figure 2.1: The characterised cohort of LHON families. Number of mothers within each family (A), total number of offspring by gender and disease status (B), number
of mothers by disease status (C), total number of generations by country (D), number of mothers within the cohort by LHON mutation (E) and total number of
generations by haplogroup (F).
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Figure 2.2: The characterised cohort of LHON families showing penetrance in all offspring, sons and
daughters, stratifying by familial mutation (A) and country of collection (B).
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Figure 2.3: The characterised cohort of LHON families showing the proportions of each mutation
within the sampled cohort.
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Table 2.4: Pedigrees of 82 families with a LHON mutation; 348 generations of mothers penetrance in
offspring, stratifying by offspring sex, mother’s disease status and familial LHON mutation or cohort. n











Total 32.17% 45.15% 19.96%
Affected 50% 60.19% 36.59%
Unaffected 27.99% 40.84% 16.82%
m.11778G>A
(n = 656)
Total 31.71% 43.95% 20.47%
Affected 44.63% 53.03% 34.55%
Unaffected 28.79% 41.53% 17.77%
m.3460G>A
(n = 176)
Total 40.34% 55.42% 26.88%
Affected 60.00% 73.33% 44.00%
Unaffected 31.40% 45.28% 20.59%
m.14484T>C
(n = 92)
Total 21.74% 34.69% 6.98%
Affected 25.00% 25.00% -
Unaffected 21.59% 35.56% 6.98%
m.14495A>G
(n = 7)
Total 57.14% 75.00% 33.33%
Affected 100% 100% -
Unaffected 25.00% 0.00% 33.33%
m.12719T>A
(n = 8)
Total 25.00% 25.00% 25.00%
Affected - - -
Unaffected 25.00% 25.00% 25.00%
UK
(n = 501)
Total 31.54% 48.33% 16.09%
Affected 47.44% 66.67% 25.00%
Unaffected 28.61% 44.44% 14.67%
Finnish
(n = 326)
Total 37.11% 44.05% 29.33%
Affected 55.95% 56.86% 54.55%
Unaffected 30.34% 38.46% 22.22%
Hungarian
(n = 83)
Total 37.35% 42.86% 31.71%
Affected 47.83% 57.14% 33.33%
Unaffected 33.33% 35.71% 31.25%
Tasmanian
(n = 99)
Total 15.15% 31.43% 6.25%
Affected 0.00% 0.00% 0.00%
Unaffected 15.96% 32.35% 6.67%
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Table 2.5: Pedigrees of 56 families with a m.11778G>A LHON mutation; 312 generations of mothers












Total 29.57% 42.07% 18.23%
Affected 43.04% 48.84% 36.11%
Unaffected 25.56% 39.67% 13.79%
UK
(n = 276)
Total 31.16% 48.84% 15.65%
Affected 37.93% 64.29% 13.33%
Unaffected 30.36% 46.96% 15.91%
Finnish
(n = 247)
Total 35.22% 41.86% 27.97%
Affected 50.75% 50.00% 51.85%
Unaffected 29.44% 38.20% 20.88%
Hungarian
(n = 72)
Total 37.50% 42.86% 32.43%
Affected 45.00% 54.55% 33.33%
Unaffected 34.62% 37.50% 32.14%
Tasmanian
(n = 61)
Total 13.11% 28.57% 5.00%
Affected - - -
Unaffected 14.29% 30.00% 5.56%
Table 2.6: Pedigrees of 46 British families with a LHON mutation; 224 generations of mothers
penetrance in offspring, stratifying by offspring sex, mother’s disease status and familial LHON











Total 32.17% 45.15% 19.96%
Affected 50% 60.19% 36.59%
Unaffected 27.13% 39.73% 16.37%
m.11778G>A
(n = 357)
Total 28.85% 41.67% 17.46%
Affected 42.50% 54.55% 27.78%
Unaffected 28.79% 41.53% 17.77%
m.3460G>A
(n = 99)
Total 48.48% 63.04% 35.85%
Affected 61.22% 76.00% 45.83%
Unaffected 36.00% 47.62% 27.59%
m.14484T>C
(n = 73)
Total 21.92% 33.33% 8.82%
Affected 0.00% 0.00% -
Unaffected 22.86% 36.11% 8.82%
m.14495A>G
(n = 7)
Total 57.14% 75.00% 33.33%
Affected 100% 100% -
Unaffected 25.00% 0.00% 33.33%
m.12719T>A
(n = 8)
Total 25.00% 25.00% 25.00%
Affected - - -
Unaffected 25.00% 25.00% 25.00%
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2.3.2 X-Linked Modifier Gene
Following from pedigree collection in Section 2.3.1, to measure LHON disease pene-
trance, statistical analyses, based upon thework of Bu andRotter (1991), were replicated
to determine the validity of a two locus causative model and feasibility of an X-linked
modifier accounting for part of the variability in LHON disease penetrance.
X-Linked Hypothesis
Data was restricted to obligate heterozygotes and the new dataset is summarised in
Figures 2.4 and 2.5. Compared to Figures 2.1 and 2.2, limiting to obligate heterozygotes
has clearly limited the number of mothers within each pedigree (Figure 2.5 A). Fewer
female offspring are included and a larger proportion of male offspring are affected.
Whilst there are fewer mothers, the ratio of affected to unaffected does not significantly
change and nor do the cohort or mutation proportions. There are fewer mothers of
haplogroup H, however, the relative proportions do not shift greatly. The percentage
affected in the m.12719T>A mutation has greatly increased while the m.14495A>G
mutation has been removed; these mutations occurred in single families so penetrance
proportions are readily influenced by sample removal. Aside from this, the mutation
percentage affected did not greatly change, with the largest change seen within the
Tasmanian families (Figure 2.5).
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Figure 2.4: The characterised cohort of LHON obligate heterozygote mothers’ families. Number of mothers within each family (A), total number of offspring by gender
and disease status (B), number of mothers by disease status (C), total number of generations by country (D), number of mothers within the cohort by LHON mutation
(E) and total number of generations by haplogroup (F).
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Figure 2.5: The characterised cohort of LHON obligate heterozygote mothers’ families showing
penetrance in all offspring, sons and daughters, stratifying by familial mutation (A) and country of
collection (B).
The X-linked goodness-of-fit test for males was first calculated in the pooled and
individual sibships (the former split by cohort and latter by cohort and sibship size), as
shown in Tables 2.7 and 2.8 respectively. Given thatH0 =Male offspring develop LHON
depending upon their inheritance of the wildtype or mutant X-linked allele and H1 =
Male offspring LHON penetrance is not caused by their equal likelihood inheritance
of the wildtype or mutant X-linked allele, it appears that the null hypothesis must
be rejected in some populations, including the entire dataset as a whole (p = 0.036).
In the pooled male groups, the null hypothesis must also be rejected for Tasmania
and the UK (p = 0.033 and p = 0.010) respectively. After splitting by sibship size and
calculating individual expected affected sample frequencies, the Finnish population
must also reject the null hypothesis (p = 0.041), but the other countries pass using this
methodology.
As the null hypothesis was rejected, it must be assumed that male offspring LHON
penetrance is not caused by the equal likelihood inheritance of the wildtype or mutant
X-linked allele.
Despite the Bu and Rotter (1991) methodology stating that their male goodness-of-
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fit test used obligate heterozygote mothers, a further filtration was carried out given
the appearance of their data in comparison to ours, whereby only unaffected mothers
with one or more affected sons was considered, as shown in Table 2.9. In this dataset,
the p-value does not reach significance and as such, it can instead be said that male
offspring develop LHON depending upon their inheritance of the wildtype or mutant
X-linked allele.
Table 2.7: Values and significance of pooled goodness-of-fit test for males.
Cohort Observed Expected χ2 P
All 174 155.5 4.402 0.036
Finnish 50 53.5 0.458 0.499
Hungarian 14 12.5 0.360 0.549
Tasmanian 11 7.0 4.571 0.033
UK 99 82.5 6.600 0.010
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Table 2.8: Values and significance of individual goodness-of-fit test for males. s = sibship size, ns =
number of families.
s ns Observed Expected χ2 P
Finnish
1 12 8 12.000
2 17 20 22.667
3 3 4 5.143
4 5 6 10.667
5 2 6 5.161
6 1 2 3.048
8 2 4 8.031
Total 29 42 50 66.716 4.188 0.041
Hungarian
1 6 5 6.000
2 3 3 4.000
3 3 4 5.143
4 1 2 2.133
Total 10 13 14 17.276 10.621 0.431
Tasmanian
1 7 6 7.000
2 2 3 2.667
3 1 2 1.714
Total 6 10 11 11.381 0.013 0.910
UK
1 37 36 37.000
2 34 37 45.333
3 12 17 20.571
4 3 5 6.400
5 1 1 2.581
7 1 3 3.528
Total 22 88 99 115.413 2.334 0.127
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Table 2.9: Values and significance of individual goodness-of-fit test for males whilst limiting to
unaffected mothers with one or more affected sons. s = sibship size, ns = number of families.
s ns Observed Expected χ2 P
Finnish
1 8 8 8.000
2 13 18 17.333
3 2 2 3.429
4 4 6 8.533
5 2 6 5.161
6 1 2 3.048
8 1 3 4.016
Total 29 31 45 49.520 0.413 0.521
Hungarian
1 5 5 5.000
3 2 3 3.429
4 1 2 2.133
Total 8 8 10 10.562 0.030 0.863
Tasmanian
1 6 6 6.000
2 2 3 2.667
3 1 2 1.714
Total 6 9 11 10.381 0.037 0.848
UK
1 36 36 36.000
2 30 35 40.000
3 8 11 13.714
4 2 2 4.267
5 1 1 2.581
7 1 3 3.528
Total 22 78 88 100.089 1.460 0.227
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X-Inactivation Hypothesis
Data was further restricted to unaffected mothers with one or more affected sons and
the new dataset is summarised in Figures 2.6 and 2.7. Compared to Figures 2.4 and 2.5,
again, limiting sample size further clearly limits the number of mothers within each
pedigree (Figure 2.6 (A)). All affected mothers are excluding by this filtration (Figure
2.6 (C)) but the general proportions do not seem to have been largely affected. There has
been little change in percentage affected bymutation or cohort, although theHungarian
penetrance does slightly decrease (Figure 2.7).
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Figure 2.6: The characterised cohort of LHON unaffected mothers, with one or more affected sons, families. Number of mothers within each family (A), total number of
offspring by gender and disease status (B), number of mothers by disease status (C), total number of generations by country (D), number of mothers within the cohort
by LHON mutation (E), total number of generations by haplogroup (F).
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Figure 2.7: The characterised cohort of LHON unaffected mothers, with one or more affected sons,
families showing penetrance in all offspring, sons and daughters, stratifying by familial mutation (A)
and country of collection (B).
T, the segregation ratio, was calculated, as shown in Table 2.10, and cohorts were
tested for heterogeneity by Analysis of Deviance (p = 0.960) by comparing each country
T to the global measurement, indicating that there is not heterogeneity between the
cohorts.
K, the probability that a heterozygous female will be affected (penetrance), was then
calculated using the global T value (as there were no significant differences in cohort
heterogeneity). This used the obligate heterozygote mothers described in Figures 2.4
and 2.5. Analysis of deviance was performed (p = 0.9877) and no significant difference
was found in the measurements of K, as shown in Table 2.11.
q, the frequency of the abnormal X-linked gene, was finally calculated to be q = 0.283,
using the global T and K values. Affected LHON females were then calculated to be
homozygous carriers of the X-linked gene in 61.62% instances whilst the other 38.38%
of LHONaffected females are heterozygoteswho develop the disease by X-inactivation.
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2.3.3 Nuclear DNA Variants
Figure 2.8 shows the abnormal grouping of two samples by PCA, phylogenetic distance,
M-Value intensity and Log2-Intensity of CPG sites, indicating their outlier status. Re-
view of control probes shows that these samples had poor specificity and failed both
bisulphite conversion and negative control checks. Samples F1B_3460_M_U_38 and
F1C_3460_M_A_38 were removed and individual probe quality was then assessed as
in Figure S2. A quality threshold of p = 0.01 was then set as shownwith low confidence
probes excluded. Aminimumof 3 beads per probewas also set, with final probe counts
per chromosome described in Table S2. 27,220 probes remained of the original 27,578.
Final sample detection P-value confidence is shown in Figure S4. Sample
F2A_11778_M_A_38 does appear to be increased compared to other samples, how-
ever, this is still below acceptable levels for sample P-value quality.
Samplesunderwentquantile normalisation at aprobe level to standardise themethy-
lated and unmethylated probes intensity between different samples. Colour density
distribution of the two channels are shown in Figure S5 and phylogenetic trees of
methylation status are in Figure 2.9.
Linear regressions of all permutations of y ∼ Status+Gender+Age +Mutation+
Famil y + Batch + NeverSmoked + CPD were analysed. To choose variables, linear
regressions were performed with all available metadata variables, and those which
significantly affected the output gene list results were incorporated into the model;
mutation + family + batch were all included as the sample loading pattern does not
allow for differentiation between these variables. Regressions were performed on the
full dataset where metadata was available, and split into further segmentations with
limited input variables depending uponmetadata availability. Males and females were
analysed separately as differences were seen between male and female methylation
patterns (Figure S6), with females having a greater proportion of methylated sites than
males. Whilst standard practice often disregards the 23rd chromosome, this would not
be effective for LHON given the potential for an X-linked modifier gene. Comparisons
of genematches are shown in Figure 2.10, indicating that gender and smoking variables
influence methylation patterns most significantly.
Hyper- and hypomethylated genes identified by linear regression are then shown
in Tables S3 and S4 respectively.
Figures S7 and S8 respectively show matches of the hyper- and hypomethylated
genes against MSigDB’s C2 curated gene sets of chemical and genetic perturbations,
and MSigDB’s C5 GO gene sets of biological processes.
Exome analysis of dominant and recessive models was undertaken and 3,833 genes
were identified which contain variants which exclusively occur within affected or un-
affected LHON carriers in either dominant or recessive models. Models were defined
as variants which existed exclusively within affected or asymptomatic carriers which
were not present within the reciprocal group with dominant models being a single
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allele and recessive models as combinations of homozygous alleles or heterozygous
combinations of minor alleles in case of compound heterozygosity. This resulting gene
list was cross-matched against the LHON hyper- and hypomethylated genes. Results
are shown in Tables 2.12 and 2.13 respectively.
Figures 2.11 and 2.12 respectively showmatches of the cross-matched genes against
LHON hyper- and hypomethylated genes against MSigDB’s C2 curated gene sets of
chemical and genetic perturbations, and MSigDB’s C5 GO gene sets of biological pro-
cesses. All of the listed gene sets have a minimum FDR q-value of 0.05; full significance
shown in Tables S5 and S6 respectively.
PANTHER14.1 Overrepresentation Test of the 45 cross-matched genes showed that
pathways for generation of neurons and neurogenesis were overrepresented at an
FDR-q = 0.027 and p = 0.020 respectively. No other pathways reached significance for
over-representation after FDR correction. Genes which contributed to these pathways
are described in Table S7.
Figure 2.8: Reviewing raw dataset sample quality by PCA clustering (A), phylogenetic clustering (B),
probe density across M-value (C) and CpG site Log2 Intensity (D).
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Figure 2.9: Phylogenetic tree of sample nuclear methylatio relations based on 27,220 probes; before (A)
and after (B) quantile normalisation.
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Figure 2.10: Comparisons of different genes included in different linear model combinations; comparing % match between y 1 + Status to y 1 + Status + Variable on
X axis (A), then y 1 + Status to y 1 + Status + Variable on X axis +, Gender (B), Age (C), Batch (D), Family (E), Mutation (F), CPD (G) and Never Smoked (H),
indicating the difference which incorporating an additional variable has on the gene list compared to the gene list prior to inclusion.
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Table 2.12: Differentially hypermethylated genes in LHON patients compared to unaffected carriers,
which also contain genetic variants that are unique to either patients or carriers in either dominant or
recessive models of alleles captured in exome sequencing. Mitochondrial genes identified from
MitoCarta 2.0 (Calvo et al., 2016; Pagliarini et al., 2008) and retinal genes identified from TIGEM






ADCY2 YES YES NA YES
AIRE YES YES NA NA
BMP8A YES YES NA NA
CMTM6 NO YES NA YES
ECT2 NO YES NA YES
FGF20 YES YES NA NA
FZD1 YES YES NA NA
GNAI1 NO YES NA YES
GPM6A NO YES NA YES
GPR157 YES YES NA NA
GRB10 NO YES NA YES
HGF NO YES NA YES
IPO9 NO YES NA YES
IRF6 NO YES NA YES
ITGA1 YES YES NA YES
LAMC2 YES YES NA NA
MEGF10 YES YES NA YES
NETO1 NO YES NA YES
NIPA1 YES YES NA YES
PCDHGC4 NO YES NA YES
RAB32 NO YES YES YES
RBP4 NO YES NA NA
SCN4B YES YES NA YES
SCUBE3 NO YES NA NA
SLC25A36 NO YES YES YES
THRB NO YES NA YES
TLX2 NO YES NA YES
TSPAN32 YES YES NA NA
ZNF273 NO YES NA YES
70
Table 2.13: Differentially hypomethylated genes in LHON patients compared to unaffected carriers,
which also contain genetic variants that are unique to either patients or carriers in either dominant or
recessive models of alleles captured in exome sequencing. Mitochondrial genes identified from
MitoCarta 2.0 (Calvo et al., 2016; Pagliarini et al., 2008) and retinal genes identified from TIGEM






COPB2 NO YES NA NA
DNAJB13 YES YES NA NA
DNASE1L1 YES YES NA NA
EFNB1 NO YES NA NA
EVL NO YES NA NA
GPR37L1 NO YES NA NA
IDH3G YES YES YES YES
IGSF8 NO YES NA NA
IQSEC1 NO YES NA NA
LINS1 YES YES NA NA
NANP NO YES NA NA
PHYH YES YES YES YES
RAB32 NO YES YES YES
RUNX3 YES YES NA NA
SLC6A18 YES YES NA NA
TFAP4 NO YES NA NA
TNS3 YES YES NA NA
Figure 2.11: Matches of exome cross-matched LHON hypermethylated (red) and hypomethylated
(genes) in MSigDB’s C2 curated gene sets of chemical and genetic perturbations (3302 gene sets).
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Figure 2.12: Matches of exome cross-matched LHON hypermethylated (red) and hypomethylated (genes) in MSigDB’s C5 GO gene sets of biological processes (7350
gene sets).
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Table 2.14: Pathways in GO C5 Biological Process Complete overrepresented by gene list identified as













14 3.38 4.15 + 3.45E-06 0.027
Neurogenesis 15 3.59 4.17 + 1.26E-06 0.020
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2.4 DISCUSSION
2.4.1 Familial Disease Penetrance
The familial disease penetrancewas an expansionof previous calculations of penetrance
in LHON families looking at male and female offspring, then stratifying by mothers’
disease status, LHON mtDNA mutation and country of collection.
As seen in Table 2.4, penetrance estimates in our sampled cohort are higher than
those which were seen previously, particularly in females, where it was estimated to
have a penetrance of 10% (Yu-Wai-Man et al., 2003, 2009), whilst our cohort shows a
penetrance of 19.96% in all female offspring. The male penetrance is 45.15% which
is not a significant deviation of the 50% previously described (Yu-Wai-Man et al.,
2003, 2009). Our cohort contains all pedigrees previously identified by Yu-Wai-Man
et al. (2009) with additional generations and families. Given that families require an
affected familymember to be diagnosed, penetrance values are likely artificially inflated
by ascertainment bias and smaller families skew towards penetrance inflation whilst
our expanded cohort is more representative of true penetrance. Counteracting this
inflation, 26.23% of LHON cases develop after age 30, indicating that a number of our
’unaffected’ carriers would develop LHON at a later age. As seen in Figure 2.1, the
majority of our cohort aremultigenerational pedigreesmeaning that the true percentile
which go on to develop LHON at a later date would actually be much lower than this
percentile. As a whole, the biases in ascertainment and late onset disease onset act
in opposite directions and our penetrance estimates are likely an improvement from
previous measures.
The increase of penetrance seen in females could be attributed to improved genetic
diagnostics within the last decade; whilemales were classically diagnosedwith LHON,
given the lower likelihood of being affected, females could have previously had lower
positive diagnoses.
We segmented the data further into m.11778G>A mutations by country of collec-
tion in Table 2.5 and British families by mutation in Table 2.6. We found it is probable
that mutation has a greater influence on offspring’s penetrance than country of origin,
particularly in males (sons p = 2.60e-12; daughters p = 1.82e-04). Country of origin
does seem to influence penetrance in females (p = 1.051e-05) but not males (p = 0.092),
however, this could be indirectly measuring the differences in LHON causative mu-
tation pathogenicity as the sampled mutant variant proportions differ by country of
collection (Figure 2.3).
Phylogenetically speaking, the Finnish and Hungarian cohorts are likely to be most
related, with the UK also quite closely related (Duda and Jan Zrzavý, 2016). Whilst
only tracking the maternal line, Finnish pedigrees contained members of haplogroups
H, J1, X, J2 and V while Hungarian pedigrees contained members of H, J1, X, K and U.
Many of the UK cohort did not have haplogroup data, however, those covered were of
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H, J, K and U haplogroups.
Tasmanian pedigrees are expected to have the most divergent nDNA background
(whilst haplogroup directly assesses mtDNA ancestry, it indirectly also covers the
maternal nDNA lineage to a less accurate degree), however, most of the country are
not indigenous (Australian Bureau of Statistics, 2016) and it is likely that this cohort is
comprised of some European ancestry family members, although this would still likely
be most divergent. Given that the haplogroups of the Tasmanian families are H and
J2, European ancestry is likely. H is extremely common in Europe while J2 is more
commonly found within Near Eastern (Arabic and North Eastern Africa) regions and
some European subclades (Pala et al., 2012; Roostalu et al., 2006).
In addition to haplogroup data and ethnogeographic data, indicating that our pedi-
grees are likely all of European descent (Richards et al., 2002), clinical notes indicate
that the Tasmanian pedigrees were from families who emigrated from Britain and are
related to the UK cohort. No data showing direct pedigree relation was available,
however.
Finland andHungary have themost similar LHONpenetrancemeasurements (least
squares), however, they also have the most similar proportions of LHON primary mu-
tations (Figure 2.3) and it is likely that this effect is greater than the nDNA background
effect.
This is further compounded by restricting data to the m.11778G>Amutation (Table
2.5); there is no difference in proportions of penetrance by country of collection in male
offspring (p = 0.057), however, females are more affected (p = 7.055e-06), indicating that
there is an effect of country of origin, albeit, not as significant as the mutation specific
penetrance. Restricting data to the UK cohort (largest dataset, with all greatest range
of LHON causative mutations), as seen in Table 2.6, further shows that mutation has a
significant impact (sons p = 2.616e-14; daughters p = 1.627e-05).
The data also shows that the mothers’ disease status greatly affects penetrance in
offspring. This was extremely significant (total p = 9.43e-09) in the total population,
particularly as the 2-sample test used Yates Correction, which is extremely stringent
and has been argued that it is so stringent that it should not be used regardless of data
normality (Hitchcock, 2009; Thompson, 1988). With our data, it was determined that
Yates Correction should be used as the sample size was not extremely small and data
washeteroskedastic. The sample sizewas, however, not so large that all populations and
mutation groups could be tested. Only stratifications of m.11778G>A and m.3460G>A
couldbe tested, alongside theUKandFinnish countrygroups. All testedmeasurements
were significant, with the exception of UK daughters andm.11778G>A sons, indicating
that these two groups were not affected bymothers’ disease status, or more likely given
the other results, were inadequately powered to detect significance at that sample
stratification.
As such, we can confidently state that mothers’ disease status greatly affects LHON
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penetrance in offspring. This could be due to the environment in which the children
are raised, as LHON is known to have an environmental influence to onset (a number
of which are discussed in Section 1.5.4), or a secondary genetic loci which could be
passed from mother to child (as discussed in Section 2.4.2 for X-linked loci).
If a secondary genetic loci exists on any autosomal chromosome, in a recessive
model, an affected homozygous mother would have a 100% likelihood of passing this
onto the child, alongside the mtDNA mutation, whilst a heterozygous mother would
have a 50% chance of transmitting the mutant secondary loci allele. In a dominant
model, an affected mother could be homozygous or heterozygous, each which would
again be transmitting the mutant allele at 100% and 50% likelihood.
In terms of the 23rd chromosome, male children would receive a mutant allele from
a heterozygous mother at 50% likelihood or 100% from a homozygous mother. When
assuming the father does not carry the mutant allele on his X-chromosome, the odds of
developing LHON by inheriting a mutant allele from a carrier mother are reduced as
she could be affected by X-inactivation of the healthy allele within retinal tissue. If the
father does carry the mutant allele on his X-chromosome, female offspring will receive
this X chromosome from the father, whichmay ormay not be inactivated in optic tissue,
leaving the mother’s X chromosome active in the eye.
This is greatly influenced by the prevalence of any abnormal allele at a secondary
loci within the population.
2.4.2 X-Linked Modifier Gene
Following from thework by Bu andRotter (1991), this project sought to test the X-linked
hypothesis and the X-inactivated hypothesis in a newer data set and determinewhether
the results which Bu and Rotter (1991) found hold true nearly three decades later. The
overarching hypothesis is that a hypothetical X-linked gene could be responsible for
the difference in penetrance seen between male and female LHON carriers and this is
further broken down into the X-linked hypothesis and the X-inactivation hypothesis.
Males only have one X chromosome which they inherited off their mother, whereas
females have two X chromosomes, one off each parent, and one of which undergoes
X-inactivation for gene dosage purposes (Panning, 2008).
As such, males can be more susceptible to X-linked disease onset as they only have
one X chromosome whereas females have two. All females are chimeras, being that
X-inactivation does not occur at a single cell level but rather approximately at the 8
cell stage (Shvetsova et al., 2019), leading to some tissues having the X chromosome
from one parent inactivated whilst other tissues can inactivate the X chromosome from
the other parent. X-chromosome inactivation is not equally balanced, with skewed
X-inactivation common in the general population (Shvetsova et al., 2019). Given the
penetrance dimorphism between males and females, specific X-linked models were in-
vestigated rather than autosomalmodelswhichweremore likely to be directly captured
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by investigating nuclear DNA variants, as discussed in Section 2.4.3.
Unlike Bu and Rotter (1991), who found that the p-value was > 0.05 in all samples,
which supported their H0 theory that the X-linked and mitochondrial model was accu-
rate, as seen in Tables 2.7 and 2.8, some of the χ2 measurements in our cohort were large
leading to a p-value below 0.05 and the rejection of the null hypothesis. Unusually, in
this instance Bu and Rotter (1991) described a "straightforward χ2 test", however, they
use Equation 2.2.
χ2  2




This is double the standardChi-Squared equation for the pooled goodness-of-fit test
for males, Table 2.7. There is no indication why this is performed and χ2 is inherently a
two-tailed test which tests in both directions for differences between the observed and
expected; doubling the classical χ2 test does would create a four-tailed test while only a
single dimensionality is tested. In practical terms, it increases the χ2 value and increases
the chances that the H0 should be rejected, as happened in the total dataset and both
the Tasmanian and UK Cohorts. If using a classical χ2 formula, no probabilities are
significant.
Despite this, Table 2.8, which does use a classical χ2 formula, does have significant
measurements for the Finnish population - which was not significant in the pooled
cohort.
Bu and Rotter (1991) define an obligate heterozygote to be an unaffected mother
with one or more affected sons, or an affectedmother with one or more unaffected sons
but as seen in Table 2 of their paper, where s = 1, all pedigrees show an observed value
equal to ns, indicating that all obligate heterozygous mothers within their study of s =
1 must have been an unaffected mother with one affected son rather than any affected
mothers with one or more unaffected sons. As such, the dataset was further limited to
unaffected mothers with one or more affected sons as seen in Table 2.9.
Limiting to unaffected mothers with affected sons removes the bias in the expected
offspring formula (Equation 2.1) which demands that when s = 1, that the number
of expected affected offspring = 1. It is further skewed towards smaller family sizes
expecting to have a higher penetrance than larger ones, with a penetrance of 67.7%
when s = 2 and 57.1%when s = 3. This approaches 50% penetranceWhen s = 10, where
penetrance becomes 50.0%. In Table 2.9 the χ2 test never returns a significant p-value
and this is likely amore accurate test given themanner of deriving the expected number
of male offspring.
As such, significance in Table 2.9 are the recommended measurements for the
individual goodness-of-fit test, despite the apparent stated methodology, given the
reparations to the bias in the lower sibship size families. In this model the male
offspring develop LHON depending upon their inheritance of the wildtype or mutant
X-linked allele.
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This reduction of sample size lowers the χ2 test’s power to detect significant differ-
ences, however, only 20 of 174 mothers are excluded by this limitation. Further, whilst
using a standard χ2 test rather than the Bu and Rotter (1991) equation, described in
Equation 2.2 for pooled cohorts, there is no significance of the χ2 measurement either.
This supports the statement that male offspring develop LHON depending upon their
inheritance of the wildtype or mutant X-linked allele.
Where affected males = 0, it is a truncated distribution which was not corrected for
aswith cohorts containing unmodelled heterogeneity, Burton et al. (2000) found that as-
certainment bias adjustments results in biased parameter estimates which do notmatch
those in the sample or original population. As such, whilst these calculations are not
true to the global population, they remain correct for our sampled participants. Bu and
Rotter (1991) did not explicitly state their mechanism of ascertainment bias correction
beyond "the Haldane method" which has a number of different implementations, so
this methodology could not be directly replicated.
The X-Inactivation Hypothesis states that an affected female must be homozy-
gous mutant or a heterozygous mutant with the healthy allele having undergone
X-inactivation of the healthy allele in optic tissue.
To calculate T, the segregation ratio, data was restricted to unaffected mothers who
have one or more affected sons. These are obligate heterozygotes and a larger cohort
than affected mothers with one or more unaffected sons. This removes families with
no male affected offspring, however, as T looks at the female offspring, the T ratio will
be unaffected by this selection method.
T is shown in Table 2.10 with a range of 0.125-0.583 and a global value of 0.230. No
significance was found by analysis of deviance or equality of proportions so the global
value is an accurate representation of the full dataset. T = 0.230 is different from the
value found by Bu and Rotter (1991) (T = 0.093), indicating that our cohort had a higher
proportion of affected females.
K, the probability that a heterozygous femalewill be affected (penetrance; a higherK
indicates a lower disease threshold) was then calculated as the ratio of affectedmothers
in the obligate heterozygote population (Table 2.11). It ranged from 0.100-0.385 with
a global measurement of K = 0.176. The global measurement was used as analysis of
deviance and equality of proportion tests found no significant differences between the
cohorts. Bu and Rotter (1991) found K = 0.111 which was similar to our measurement.
Using global T and K values, q, the frequency of the affected X-linked allele, was
then calculated. Bu and Rotter (1991) found q = 0.076 whilst our cohort found q =
0.283. This indicates that the our cohort either has a greater proportion of mutant
X-linked modifier alleles in the population by chance, or that the prevalence of q in the
population has shifted to favour the abnormal X-linked modifier allele. Calculations
for q assume that q is a singular loci on the X-linked allele, however, it could also
be a combination of multiple loci on the X chromosome which are inherited together
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through linkage disequilibrium.
Given that only one human generation has passed since Bu and Rotter (1991), it is
more likely that this is by chance or that our cohorts have different nuclear backgrounds
to the samples captured by Bu and Rotter (1991), or that clinical diagnostics have
improved. Improved true positive diagnoses of female LHON patients would alter
K, the probability that a heterozygous female will be affected. As shown in Section
2.4.1, we did find a much higher penetrance in females which subsequently affects the
calculation of q, the X-linked affected allele.
This methodology indirectly looks at the effect of nuclear background to a limited
degree. By splitting by cohort and assuming that families within the same country
have a closer nuclear background than those in different countries we did calculate
individual measurements for T and K but found no significant difference between
cohorts. It does not take into account that mutation specific burden could have a
greater impact on penetrance and instead equates all 5 individual LHON mutations
as the same loci with equal effects. It also assumes that X-inactivation is random,
however, this has been shown to not be true, with preferential silencing of abnormal X
chromosomes (Shvetsova et al., 2019). Additionally, as discussed in Section 2.4.1, our
pedigrees are all European and some are related to each other, indicating that nuclear
variation within cohorts could be greater than variation between select cohorts, e.g.
Tasmanian and UK.
As q = 0.283 (affected X-linked allele frequency), this is comparatively higher than
the q calculated by Bu and Rotter (1991) (q = 0.076). This methodology is based on the
assumption that the mutant X allele comes from the maternal line and when q = 0.283,
a high proportion of the population would carry the allele by chance, including the
father - who was assumed to be a wildtype, selected by chance and not a carrier.
Following from the calculation of q, the proportion of affected females heterozygous
at X-linked locus was 38.38% whilst the other 61.62% are assumed to be homozygous
mutant. This proportion is close to the inverse of the 60% and 40% respectively found
byBu andRotter (1991). This is likely a result of the greatly increased q value, indicating
that any abnormal X-linked gene is common, rather than rare, within the population.
Following from work by Bu and Rotter (1991), we found that within our cohort, it
does statistically indicate that penetrance could occur as a result of an X-linkedmodifier
gene. Unlike their indication that it is rare in the population (q = 0.076) we found the
allele to be common in the population (q = 0.283), which could explain why it has been
undetected at present. With rare population variants, it can be assumed that carriers
would also be LHON affected, however, with it common in the population, it could
be inherited from the paternal, rather than just the maternal, line to affect daughters.
Further, common alleles require more samples to create a statistical test strong enough
to identify the mutant allele within the population. With rare disease, studies often
struggle to capture sufficient sample numbers and hence study power to prove common
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variants as pathogenic.
This higher penetrance is more explanatory towards the disease patterns seen in the
large multi-generational LHON families, however. If q is small, it would be expected
that LHON onset would cease within a few generations of the maternal lineage pro-
gression as each generation brings a new X chromosome from each father - who could
be assumed to not carry the abnormal X-linked gene at q = 0.076. At q = 0.283 there
is a larger chance that the X-linked abnormal allele could be inherited from either the
mother or father and disease transmission would continue down the pedigree - as is
often seen.
2.4.3 Nuclear DNA Variants
Data from Illumina Infinium HumanMethylation27 BeadChips were first analysed to
identify differential methylation between LHON affected patients and carriers. The
HumanMethylation27 BeadChip is an older array which has been followed by the
Infinium HumanMethylation450 BeadChip and Infinium MethylationEPIC BeadChip
more recently. The difference between chips relates to the number of probes on the chip
(~27,000, ~450,000 and ~850,000, respectively) and the type of chemistry involved on
the probes. TheHumanMethylation27 BeadChip only contains Type I probeswhilst the
HumanMethylation450 and MethylationEPIC BeadChips also contain Type II probes -
thus the chemistry, and analysis, of arrays differs.
The programming language R was chosen to analyse the BeadChips, as present
gold standard analysis pipelines predominantly use packages available through R and
Bioconductor (Huber et al., 2015; Morris and Beck, 2015; Wang et al., 2018).
BeadChip analysis pipelines have extensive QC processing to ensure that technical
error isminimised throughout the analysis process. Processing standards have changed
since the release of theHumanMethylation27 BeadChip and some of the recommended
pipeline processes are built to directly handle theHumanMethylation450BeadChip and
later (Morris and Beck, 2015; Touleimat and Tost, 2012; Wang et al., 2018). As such,
while some packages do directly handle the data (Davis et al., 2017; Du et al., 2008),
they do not have all of the recommended procedures, such as removal of low quality
and poorly sampled probes, so these were specifically written into R to implement a
more robust analysis than using a historic package and pipeline.
There is a significant effect of batch effect on microarray data (Price and Robin-
son, 2018), and this effect is directly visible within control probes (Figure S3). When
samples were prepared, they were loaded into the BeadChip by family groupings and
not randomised which led to difficulty in differentiating between familial, batch and
mutation effects. Further variance is seenwhen assays are performed on different days,
however, our samples were performed on the same day with only one additional ar-
ray between our samples. Had sample order been randomised during loading of the
arrays, this batch effect could have been controlled for, but due to the ordered nature
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of the samples, any normalisation of the batch effect would also normalise methylation
patterns between LHONmutation and familial patterns. This sample arrangement had
a detrimental result on our confidence of the analysis but despite this, while noticeable,
the batch effect has not prevented identification of candidate differentially methylated
genes.
Genotype is also known to affect methylation patterns (Gertz et al., 2011; Grimm
et al., 2019) and as genotype runs in families, methylation patterns are affected. Sim-
ilarly, whilst debated, it is believed that transgenerational epigenetic modifications
further occur within families, either as marks which are directly inherited from par-
ents, or as a result of being brought up in a similar environment (Horsthemke, 2018;
Kaati et al., 2007; Nilsson et al., 2018).
Samples initially appeared to be grouping by mutation status (Figure 2.9), however,
quantile normalisation will have reduced the batch effect and possibly removed any
familial/causative mutation methylation significance during this process as quantile
normalisation is very stringent.
As metadata regarding smoking status was missing from several samples, different
groupings of linear regressions were performed to optimise the available data. For
those which contained smoking metadata, cigarettes per day and having ever smoked
did greatly impact methylation status, alongside gender. Of the independent variables
tested, age had the least impact on methylation status as incorporating it into the
regression had minimal impact.
During the QC process, the two samples which failed to pass QC were a male
unaffected carrier and his affected brother. This resulted in only 1 of the remain-
ing 8 unaffected carriers being male and the other 7 all female; there are significant
methylation differences between males and females (Hall et al., 2014; Nino et al., 2018),
particularly on the X-chromosome to account for gene dosage. Due to this, it is common
for X-chromosome probes to be fully removed from methylation analysis; given that
there is a difference betweenmale and femalemethylation patterns and that only 1male
unaffected carrier passedQC and that it is predicted that LHON could be affected by an
X-Linked gene (Bu and Rotter, 1991; Chen and Denton, 1991; Hudson et al., 2005; Pha-
sukkĳwatana et al., 2010; Qu et al., 2010; Shankar et al., 2008; Vilkki et al., 1991), datawas
split into male and female cohorts and analysed separately rather than excluding the
X-chromosome or comparing male autosomal chromosomes to unaffected autosomal
chromosomes which are heavily skewed towards female methylation patterns.
44 genes were found to be hypermethylated and 23 hypomethylated in LHON
patients when compared to controls, with some sex differences between males and
females (Tables S3 and S4).
Exome analysis identified 3,833 genes which exclusively occurred in either LHON
patients or carriers in both dominant and recessive models. The exome array captured
information on 17,403 genes indicating that 22.02% of the genes had unique variants
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and this was too large to accurately identify any novel LHON disease causing variants.
These unique exome variants were then cross-matched against the list of differen-
tially methylated genes, resulting in 29 hypermethylated and 17 hypomethylated genes
which contained unique variants between the LHON patients and carriers - that could
be either causative or protective.
They then underwent pathway analysis to identify gene sets which could indicate
novel pathways which affect LHON expression. Most of the chemical and genetic per-
turbations gene sets were from cancer data sets, relating to cell survival. Interestingly,
they mapped to the gene set which is identified to become hypermethylated in breast
progenitor cells pre-exposed to estradiol (Cheng et al., 2008), which is a sex hormone
that targets ERA and ERB, the latter of which has been investigated for a target in
LHON treatment (Giordano et al., 2011; Pisano et al., 2015).
Themost significantmatcheswithin the C5 Biological Process Complete gene set list
are from pathways involved in neurogenesis, neuron differentiation and development.
LHON results in RGC cell death, a type of neuronal cell (Kirches, 2011; Maresca, 2011;
Wong et al., 2002; Yu-Wai-Man and Chinnery, 2000; Yu-Wai-Man et al., 2009) and of our
identified list of 45 candidate genes, these were over-represented in neuronal gene sets,
indicating that these variants and methylation patterns could implicate novel genes as
modifier geneswhich are either causative or protective towards LHON.Whilstmethyla-
tion can occur as a result of LHON onset, the genotype is upstream, meaning that these
genes are more likely to be causative rather than develop changes as a result of LHON
onset. The identification of neuronal gene sets as significant was further confirmed by
the more stringent Fisher’s Exact Test used by PANTHER’s Overrepresentation Test.
Additional neuronal gene sets were also identified within the C5 Biological Process
Complete gene set database, significantly, gene sets relating to regulation of oxidative
stress induced cell death, cell death in response to oxidative stress, and further cell
death and oxidative stress pathways. Oxidative stress triggers nucleoids to fold to a
more compact state (Noack et al., 2006; Rebelo et al., 2009; Sadakierska-Chudy et al.,
2014) and could down-regulate mitochondrially encoded genes which are required for
OXPHOS. LHON cells are particularly susceptible to oxidative stress (Battisti et al.,
2004; Meyerson et al., 2015), which also increases free radical production, and this can
directly result in cell death (Ott et al., 2007; Ryter et al., 2006; Zhuo et al., 2012).
This work seems to identify novel genes which interact in pathways which realisti-
cally could be related to the LHONphenotype, and potentially, these genes could act as
modifiers to explain some of the variable expression and unpredictable disease onset
of LHON.
Directly reviewing specific gene function, a number of genes seem to directly re-
late to mitochondrial, neuronal or retinal function, including FGF20, FZD1, GPM6A,
GPR157, GPR37L1, GRB10, IDH3G, LAMC2, MEGF10, NIPA1, PCDHGC4, PHYH,
RAB32, RBP4, SLC25A36 and SLC6A18.
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All gene functions are reviewed within Section 5.4 and some genes present func-
tional features which are particularly relevant to LHON.
FZD1, which is associated with exudative vitreoretinopathy (Kaykas et al., 2004), a
condition which prevents peripheral retinal angiogenesis and causes a diverse range
of phenotypes within a familial lineage, with some patients asymptomatic carriers
(National Library of Medicine (US), 2019). Additionally, PHYH mutations are found
within 90% of patients clinically diagnosed with Refsum disease, another retinal dis-
order which causes retinitis pigmentosa (Patterson and Percy, 2015). Severe autosomal
recessive retinitis pigmentosa has also been found to be caused by RBP4 mutations
(Cukras et al., 2012).
MEGF10 also has a role in retinal neuron mosaic distribution, particularly for star-
burst amacrine cells and horizontal cells (Kay et al., 2012). Interruptions in supporting
neuronal cell types could induce cell death in dependent cells.
IDH3G encodes isocitrate dehydrogenase, a mitochondrial matrix protein which
catalyses oxidative decarboxylation of isocitrate into α-ketoglutarate within the citric
acid cycle (Smolková and Ježek, 2012). SLC25A36 has an essential role in mtDNA
and mtRNA synthesis and breakdown through pyrimidine transport (Di Noia et al.,
2014) and RAB32 has a role in both autophagy (Wang et al., 2012) and apoptosis via
mitochondrial fission control (Bui et al., 2010). Rab32 is upregulated throughout mul-
tiple sclerosis disease progression and causes ER stress with mitochondrial cell death
in primary neurons (Haile et al., 2017). Multiple sclerosis-like symptoms are often
seen in Harding’s disease (LHON-plus) (Carelli et al., 2001; Joshi and Kermode, 2019;
Nikoskelainen et al., 1995). Of note, RAB32 is significantly methylated in different re-
gions of the 6:146905888-146907189 locus, with opposingmethylation patterns between
affected LHON patients and asymptomatic carriers, with one region hypermethylated
in patients when compared to carriers, whilst another region is hypomethylated when
compared to carriers across multiple probes.
Both results from pathway analysis and individual gene investigation look promis-
ing for LHON novel candidate genes. Three of the identified 45 genes directly relate to
retinal disease, a further 3 affect mitochondrial function and many affect neurogenesis,
as identified through over-representation of genes within gene set pathway analysis.
Given the thousands of genes investigated and functional results, our candidate gene
list warrants further investigation.
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Chapter 3 | Functional Characterisation of LHON
Fibroblasts
3.1 INTRODUCTION
LHON is a disease that predominantly affects RGCs, however, they exist within the
eye’s retina and their axons extend to form the optic nerve. As such, this tissue is not
readily available for study from live patients and another model must be used. Bahr
et al. (2020); Jankauskaitė et al. (2017) reviewed cellular and animal models of LHON
and after consideration of resources and the ability of themodel to accurately represent
LHON, a primary fibroblast model was selected.
Primaryfibroblasts have longbeenused in abroad rangeof scientific studies (Li et al.,
2013; Marthandan et al., 2016; Rohde et al., 2014), particularly within mitochondrial
disease (Distelmaier et al., 2015; Millis and Pious, 1973; Woś et al., 2016).
Fibroblasts are easily attainable from a skin biopsy and readily established (Villegas
and McPhaul, 2001). With proper preparation, the minimally invasive method can
allow for a high cell yield, with minimal contamination frommorphologically different
keratinocytes (Takashima, 2001). Studies involving other cell types, such as myoblasts,
often struggle with fibroblast contamination (Chowdhury et al., 2015; Froehlich et al.,
2014) which can affect study results when samples are each comprised of differing
proportions of cell types. Despite the many advances in iPSCs models with three
LHON specific models developed (Bahr et al., 2020), in-house work has seen difficulty
in reprogramming iPSCs, with variable differentiation success. Given the breadth of
other work throughout this project, iPSCs were not chosen as a model due to time and
availability constraints.
Most importantly, fibroblasts have been previously identified and used as a model
for LHON in a range of experiments (Angebault et al., 2011; Jankauskaitė et al., 2017;
Pisano et al., 2015; Yu-Wai-Man et al., 2017), with fibroblasts behaving as expected for
a Complex I disorder. They have not previously been modelled in LHON against the
extensive range of biological mechanisms that this project seeks to investigate.
This chapter seeks to further establish specific patient-derived LHON fibroblast cell
lines and comprehensively characterise them with the goal of identifying biological
pathways which could have a role in disease onset and suitability for that cell line
within drug testing. Cells must be characterised to confirm that they are behaving as
expected for a LHONmodel before interrogation of further biochemical pathways. Ac-
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curate characterisation of disease mechanisms will allow for identification of involved
pathways which may allow for novel treatment strategies which minimise, or ideally
prevent, disease progression. Furthermore, functional analysis in cell models could
confirm hypothetical genes identified in the genetic studies discussed in Chapter 2.
Characterisation covers a number of interrelated systems to identify pathologi-
cal mechanisms which may precipitate visual loss in LHON patients including: mi-
tochondrial copy number, ATP production, cellular oxygen consumption, calcium
homeostasis, mitochondrial membrane potential, the mitochondrial network and ER-
mitochondrial interactions. These mechanisms are implicated in mitochondrial bio-




Skin biopsies were collected from the forearm of LHON patients and healthy control
volunteers by Doctors Patrick Yu-Wai-Man (University of Cambridge) and Hannah
Steele (Newcastle University); many thanks to those involved in both sample collection
and donation. Samples were transferred to Newcastle Biobank where primary fibrob-
last cell lines were established. The patient cohort was composed of three unrelated,
healthy controls and five unrelated cases with both a clinical diagnosis of LHON and
confirmed homoplasmic, pathogenic primary mutations in mtDNA Complex I sub-
units. They carried one of the three primary LHON mutations which account for the
majority of LHON cases (Yu-Wai-Man and Chinnery, 2000); three patients are affected
by the m.11778G>A mutation, A1-11778, A3-11778 and A4-11778, and the remaining
two patients, A2-14484 and A5-3460, are affected by the m.14484T>C and m.3460G>A
mutations respectively, as indicated in Table 3.1. An unaffected carrier was also inves-
tigated in preliminary work, U1-11778, who was the mother to A1-11778.
Table 3.1: Details of primary fibroblast cell lines functionally characterised.
Cell Line Status Gender Age
C1 Control Female 45
C2 Control Female 26
C3 Control Female 34
U1-11778 m.11778G>A carrier Female 53
A1-11778 m.11778G>A mutant Male 20
A2-14484 m.14484T>C mutant Male 33
A3-11778 m.11778G>A mutant Male 42
A4-11778 m.11778G>A mutant Male 45
A5-3460 m.3460G>A mutant Male 36
3.2.2 Cell Culture
To establish cell lines, cryovials acquired fromNewcastle Biobank were quickly thawed
in a 37°C water bath until samples approached phase transition from solid to liquid.
These were then removed and transferred into a T25 CELLSTAR Filter Cap Cell Culture
Flask (690175; Greiner Bio-One) with Growth Medium (GMEM), comprised of Mini-
mum Essential Media (21090-055; GIBCO) (MEM) supplemented with 10% (v/v) Fetal
Bovine Serum (F7524; Sigma-Aldrich) (FBS), 1% (v/v) MEM Vitamins Solution (100x)
(11120037; GIBCO), 1% (v/v) L-Glutamine (200 mM) (25030024; GIBCO), 1% (v/v)
Penicillin-Streptomycin (10,000 U/mL) (15140122; GIBCO), 1% (v/v) Sodium Pyruvate
(100 mM) (11360070; GIBCO) and 1% (v/v) MEMNon-Essential Amino Acids Solution
(100X) (11140035; GIBCO).
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Cells were given 3-4 hours to adhere before washing in Phosphate Buffered Saline
(Dulbecco A) (BR0014G; Oxoid Ltd.) (PBS) and replacing the media.
Cell lines were initially cultured in T25 CELLSTAR Filter Cap Cell Culture Flasks
and fed every 2-4 days as necessary before transferral to T75 CELLSTAR Filter Cap Cell
Culture Flasks (658175; Greiner Bio-One).
Cellswere trypsinised for passaging and collection using 10%Trypsin-EDTA (0.5%),
no phenol red (15400054; GIBCO) in PBS for 5 minutes at 37°C before inactivation with
GMEM.
Cells were pelleted by centrifugation at 1300 RCF for 5 minutes at 24°C for live cells
and 4°C for protein and DNA collection.
Pelleted cellswere resuspended and frozen in 10% (v/v)Dimethyl Sulfoxide (D8418;
Sigma-Aldrich) (DMSO), filter sterilised with Polyethersulfone Syringe Filter (28145-
501; VWR), in 90% (v/v) FBS using aMr. Frosty™ (5100-0001; Thermo Fisher Scientific)
for a minimum of 24 hours at -80°C before long-term storage in gas phase liquid
nitrogen.
To count cells, cells were resuspended in 1 ml GMEM and a 10% (v/v) cell suspen-
sion, (v/v) 40% GMEM and 50% (v/v) Trypan Blue Solution (T8154; Sigma-Aldrich)
solution was prepared for cells to be counted as a monolayer on a BS748 Improved
Neubauer Cell Counting Chamber (AS1000; Hawksley) before counting and calculat-
ing cells·µl-1.
All cell lines were stored at 37°C, 5% CO2, and routinely screened for mycoplasma.
Experiments were performed on cells from passage 5 to passage 15.
3.2.3 DNA Extraction
Following count, cells were seeded at 1x106 into a T75 CELLSTAR Filter Cap Cell
Culture Flask and incubated at 37°C for 2 days until they reached 70-80% confluency
before being pelleted in PBS and frozen at -80°C.
Cellswere later resuspended in 200µl PBS and theDNAwas extractedusingDNeasy
Blood & Tissue Kit (69506; QIAGEN), following the manufacturer’s instructions.
3.2.4 mtDNA Copy Number
QuantificationofmtDNAcopynumberhaspreviouslybeendescribedbyour lab (Grady
et al., 2014; Pyle et al., 2016), however, the sequence location of the MT-ND1 forwards
Quantitative Polymerase Chain Reaction (qPCR) primer contains the m.3460G>A pri-
mary LHONmutation, so this assaywould not be appropriate for quantification of copy
number in LHON samples and an altered methodology was necessary. Optimisation
of B2M qPCR primers were also carried out during validation of a new copy number
multiplex.
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Determination of Novel Multiplex
MT-RNR2 qPCR primers were designed following in-house meta-analysis of public
and private data collections to analyse 20,000 humanmtDNA sequences for mutations.
Primer and probe sequences were identified by screening the mitochondrial genome
for regions of genetic stability as characterised by genetic homogeneity and few muta-
tions. The regions were then subsequently screened for ideal primer and probe sites
and further checked on EMPOP (The European DNA Profiling Group et al., 2016) for
external confirmation of population sequence data.
The region around the previous lab standard B2M probe was then screened for
suitable primer sites and new primers were identified and screened usingNCBI dbSNP
(Sherry et al., 2001) to check for variation in the sequence identity.
All primers and probes were tested using Integrated DNA Technologies Inc. (IDT)
OligoAnalyzer 3.1 (IntegratedDNATechnologies, 2017) for in silico predictions for hair-
pins, self-dimers andhetero-dimerswith other components of theMT-ND4/B2M/RNR-2
triplex, alongside checking for similar melting temperatures and ~50% GC content.
Primers were then synthesised by IDT and checked for an optimum annealing
temperature via gradient PCR (Polymerase Chain Reaction), as shown in Tables 3.2 and
3.3. All PCRwas carried out using a Veriti™ 96-Well Thermal Cycler (4375786; Applied
Biosystems™).
Table 3.2: qPCR reaction composition whereMT-ND4/B2M/MT-RNR2 are amplified with their
respective forward and reverse primers. Primer sequence identity shown in Appendix Table S8.
Volume Component
5 µl 5x MyTaq Reaction Buffer (BIO-37111; Bioline)
0.2 µl MyTaq HS DNA Polymerase (BIO-21111; Bioline)
1 µl 10 µM Forward qPCR primer (MT-ND4/B2M/MT-RNR2)
1 µl 10 µM Reverse qPCR primer (MT-ND4/B2M/MT-RNR2)
1 µl 25-50 ng DNA
16.8 µl dH2O
Table 3.3: Thermocycling program with a variable annealing temperature of 49°C - 61°C.
Temperature/Capture Time
Initial Denaturation 95°C 1 min
Amplify
95°C 15 s
35 cycles49°C - 61°C (Gradient) 15 s
72°C 10 s
Final Extension 72°C 5 min
Hold 4°C ∞
Primers and probes were then tested in a singleplex SYBR Green assay as shown in
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Tables 3.4 and 3.5. This was followed by singleplex, duplex and triplex TaqMan assays,
which were designed as shown in Tables 3.6 and 3.7.
To determinewhether Cq values decreased between single-, du- and triplex, 2-sided
T-Tests were calculated for homoscedastic data of the Cq values between assays.
Table 3.4: qPCR reaction composition for each well where matching forward primers were used with
their reverse primer and standard DNA in a singleplex. Primer and probe sequence identity shown in
Appendix Tables S9 and S10.
Volume Component
10 µl 1x iTaq Universal SYBR Green Supermix (1725125; Bio-Rad)
0.6 µl 10 µMMT-ND4/New B2M/MT-RNR2 Forward primer
0.6 µl 10 µMMT-ND4/New B2M/MT-RNR2 Reverse primer
1 µl Standard MT-ND4/New B2M/MT-RNR2 DNA/Blank
7.8 µl dH2O
Table 3.5: SYBR Green qPCR thermocycling program.
Temperature/Capture Time
Initial Denaturation 95°C 3 min
Amplify
95°C 10 s
39 cycles58°C 1 min
Image Fluorescence -
Table 3.6: qPCR reaction composition for each well where water produces a reaction volume of 20 µl
but varies depending on singleplex (1 primer and probe set + their standard), duplex (2 primer and
probe sets + their standard) or triplex (3 primer and probe sets + their standard). Primer and probe
sequence identity shown in Appendix Tables S9 and S10.
Volume Component
10 µl iTaq Universal Probes Supermix (1725135; Bio-Rad)
0.4 µl 10 µMMT-RNR2 Probe
0.14 µl 10 µMMT-RNR2 Forward primer
0.14 µl 10 µMMT-RNR2 Reverse primer
0.4 µl 10 µM B2M Probe
0.6 µl 10 µMNew B2M Forward primer
0.6 µl 10 µMNew B2M Reverse primer
0.4 µl 10 µMMT-ND4 Probe
0.14 µl 10 µMMT-ND4 Forward primer
0.14 µl 10 µMMT-ND4 Reverse primer
1 µl MT-ND4/New B2M/MT-RNR2 PCR Amplified DNA Standard/Blank
× µl dH2O
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Table 3.7: qPCR thermocycling program.
Temperature/Capture Time
Initial Denaturation 95°C 3 min
Amplify
95°C 10 s
39 cycles58°C 1 min
Read Plate -
Generation of Standards
qPCR standards were amplified using PCR forMT-ND1,MT-ND4, B2M andMT-RNR2
as shown in Table 3.8 and Table 3.9.
Table 3.8: PCR reaction composition whereMT-ND1/MT-ND4/B2M/MT-RNR2 are amplified with
their respective forward and reverse primers. Primer sequence identity shown in Appendix Table S8.
Volume Component
5 µl 5x MyTaq Reaction Buffer
0.2 µl MyTaq HS DNA Polymerase
1 µl 10 µM Forward primer (MT-ND1/MT-ND4/B2M/MT-RNR2)
1 µl 10 µM Reverse Primer (MT-ND1/MT-ND4/B2M/MT-RNR2)
1 µl 25-50 ng DNA
16.8 µl dH2O
Table 3.9: qPCR standard PCR thermocycling program.
Temperature Time
Initial Denaturation 95°C 1 min
Amplify
95°C 15 s
35 cycles61°C 15 s
72°C 10 s
Final Extension 72°C 5 min
Hold 4°C ∞
10 PCR products were pooled and loaded with DNA Gel Loading Dye (6X) (R0611;
Thermo Fisher Scientific) then electrophoresed in a large, single well of a 1% agarose
gel (BIO-41025; Bioline) + 0.005% SafeView Nucleic Acid Stain (NBS-SV1; NBS Biolog-
icals) in a 1x dilution of Tris-Acetate-EDTA, 50x (129237; QIAGEN) buffer in dH2O for
90 minutes at 65 V. A GeneRuler 1 Kb Plus DNA Ladder (11511635; Thermo Fisher
Scientific) and negative controls were ran in separate wells. Gels were imaged on a
GelDoc-Ite (UVP) imaging systemwith VisionWorks LS (UVP) software for verification
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of product size and the PCR product was extracted using a QIAquick Gel Extraction
Kit (28706; QIAGEN), as per manufacturer protocol.
DNA concentration of standards and DNA extracted from cell pellet samples (as
described in Section 3.2.2)were thenmeasuredon an 8-Sample SpectrophotometerNan-
oDrop (ND-8000-GL; Thermo Fisher Scientific)) and copy number per µl was calculated
by:
Copy Number·µl-1  [C ÷ (L × 2 × 330)] × A
Where C is DNA concentration x 10-9 , L is the amplicon length in bp and A is
Avogadro’s number.
DNA standards were then rediluted to 1x1010 copies·µl-1 and a range of 1x108
copies·µl-1 to 1x102 copies·µl-1 were used to produce standard curves.
qPCR Assay
qPCR was performed as a triplex assay on a CFX96 Touch™ Real-Time PCR Detection
System (1855195; Bio-Rad) as shown in Tables 3.10 and Table 3.11; amplification tem-
perature of 58°C used in Table 3.7 was increased to 62°C after trialling the new triplex
with the optimum conditions of the old triplex and determining that this was also most
efficient for the new triplex. All qPCR assays were analysed in Bio-Rad CFX Manager
3.1.
Table 3.10: qPCR reaction composition for each well. Primer and probe sequence identity shown in
Appendix Tables S9 and S10.
Volume Component
10 µl iTaq Universal Probes Supermix
0.4 µl 10 µMMT-ND1 Probe
0.14 µl 10 µMMT-ND1 Forward primer
0.14 µl 10 µMMT-ND1 Reverse primer
0.4 µl 10 µM B2M Probe
0.6 µl 10 µM B2M Forward primer
0.6 µl 10 µM B2M Reverse primer
0.4 µl 10 µMMT-ND4 Probe
0.14 µl 10 µMMT-ND4 Forward primer
0.14 µl 10 µMMT-ND4 Reverse primer
1 µl Sample/Standard/Blank
6.04 µl dH2O
Results underwent QC to reduce standard deviation of triplicates below 0.3 by
removing outlying measurements, and copy number of mtDNA was calculated for
LHON patients and controls.
Mitochondrial copy numbers were then calculated using the calculation 2× (2−∆Ct )
whereby ΔCt represents the change in Ct value (the number of cycles taken to reach
the threshold fluorescence and register above background fluorescence) between MT-
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Table 3.11: qPCR final thermocycling program.
Temperature/Capture Time
Initial Denaturation 95°C 3 min
Amplify
95°C 10 s
39 cycles62°C 1 min
Read Plate -
ND1/MT-RNR2 and B2M (mitochondrial copy number), and MT-ND4 and B2M (copy
number of mitochondria unaffected by deletions).
Direct comparison of the lab standard, original triplex (Grady et al., 2014; Pyle et al.,
2016), for blood and fibroblast DNA samples were also measured. Finally, the copy
number of all patient fibroblast samples from Table 3.1 were measured across three
passages using the new assay.
3.2.5 ATP Production During Metabolic Stress
40,000 cells were seeded in 200 µl of GMEM into 12 wells of a 96Well Clear Polystyrene
TC-Treated Microplate (3599; Corning™) and also a 96 Well Solid White Polystyrene
TC-Treated Microplate (3917; Corning™) and incubated overnight at 37°C.
Cells were rinsed in PBS before replacing media with 200 µl ATP Assay Buffer
(156mMNaCl (S9888; Sigma-Aldrich), 3mMKCl (746436; Sigma-Aldrich), 2mMMgSO4
(M7506; Sigma-Aldrich), 1.25mM KH2PO4, 2mM CaCl2 (C1016; Sigma-Aldrich) and
20mM 4-(2-hydroxyethyl)-1-Piperazineethanesulfonic Acid (H3375; Sigma-Aldrich))
supplemented for one of four conditions: 5mM Glucose (G7021; Sigma-Aldrich), 5mM
Deoxyglucose (D8375; Sigma-Aldrich), 5mMGlucose andOligomycinA (75351; Sigma-
Aldrich) 2.5µg·ml-1 or 5mM Deoxyglucose and Oligomycin A 2.5µg·ml-1, as biological
triplicates and incubated at 37°C for 1.5 hours. Cells under Glucose conditions are
capable of undergoing glycolysis whilst Deoxyglucose conditions prevents cells from
producing ATP through glycolysis. Oligomycin A inhibits ATP synthase, further lim-
iting cells to rely on the limited ATP production allowed by Complexes I-IV.
90 µl of supplemented ATP Assay Buffer was removed from each well of the white
plate and 100 µl CellTiter-Glo Luminescent Reagent (G7570; Promega) (prepared ac-
cording to manufacturer instructions) was added. The plate was then slowly rocked on
a platform shaker (AQS Manufacturing Ltd) for 10 minutes and incubated in the dark
for a further 15 minutes. Luminescence was then measured with a 1000 ms integration
time on a Luminoskan™ Ascent Microplate Luminometer (5300330; Thermo Fisher
Scientific)).
The cells in the 96 Well Solid White Polystyrene TC-Treated Microplate were rinsed
with PBS and Protein Assay Dye Reagent Concentrate (5000006; Bio-Rad) was used to
perform a Bradford assay in accordance to manufacturer’s instructions.
ATP assay measurements were normalised to average mg protein·ml-1 across each
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cell line.
3.2.6 Cellular Oxygen Consumption
Seahorse XFe96 FluxPaks (102416-100; Agilent Technologies) were used to measure the
Oxygen Consumption Rate (OCR). A total of 20,000 cells were seeded into each well
of the Seahorse XF96 Cell Culture Microplate in 80 µl GMEM and the Seahorse XF96
Cartridge was rehydrated with 200 µl Seahorse XF Calibrant Solution 24 hours prior
to the experiment. Dulbecco’s Modified Eagle Medium, no glucose, no glutamine, no
phenol red (A1443001; GIBCO)was supplementedwith 5.5mMGlucose, 1mMSodium
Pyruvate (100 mM) and 2 mM L-Glutamine (200 mM) [pH 7] and cells were incubated
in 175 µl of this Seahorse media at 37°C in a non-CO2 incubator for 1 hour.
OCRwas measured on a Seahorse XFe96 Extracellular Flux Analyzer (Agilent Tech-
nologies) under basal conditions and following the sequential injection of: A) 1.5 µM
Oligomycin A to inhibit ATP synthase, B) 1 µM
CarbonylCyanide 4-(Trifluoromethoxy)phenylhydrazone (C2920; Sigma-Aldrich) (FCCP)
to uncouple the mitochondrial chain, C) 1.5 µMFCCP to ensure full uncoupling and D)
1 µMRotenone (R8875; Sigma-Aldrich) and 1 µMAntimycin A (A0149; Sigma-Aldrich)
to inhibit Complexes I and III respectively, preventing oxidative phosphorylation to
measure non-mitochondrial respiration. Protein Assay Dye Reagent Concentrate was
used to perform a Bradford assay in accordance to manufacturer’s instructions to nor-
malise OCR to mg of protein using Wave Desktop 2.1.2.0 (Agilent Technologies, 2017).
Wells with measurements more than 2 standard deviations from themean of the group
were excluded, leaving aminimumof 12 technical replicates of each cell line to calculate
basal respiration, ATP production, proton leak, maximal respiration, spare respiratory
capacity and non-mitochondrial respiration, with measurements indicated in Figure
3.1.
Statistical analysis was then performed using a two-tailed unpaired t-test for ho-
moscedastic data between patients and controls.
3.2.7 Calcium Homeostasis
Using cells seeded 24 hours previously at 100,000 in a 35 mm Glass Bottom Dish
(HBST-3522; WillCoWells), cells were incubated at room temperature with 0.4% Rhod-
2, AM, cell permeant (R1245MP; Life Technologies), reconstituted in DMSO, in 1 ml
GMEM for 30 minutes before washing twice in PBS and imaging on a Nikon A1r point-
scanning confocal microscope at x60 magnification, using a 1.40 numerical aperture
oil objective, in 1 ml Tyrode’s solution (136.9 mM NaCl, 2.7 mM KCl, 1.1 mM MgCl2
(M8266; Sigma-Aldrich), 417 µM NaH2PO4 (S3264; Sigma-Aldrich), 11.9 mM NaHCO3
(792519; Sigma-Aldrich), 10 mM Glucose and 2 mM CaCl2 [pH 7.4]). 1 minute after
Z-project recording, 100 µM Histamine (H7125; Sigma-Aldrich) was applied and cells
were recorded for a further 4 minutes.
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Figure 3.1: Seahorse XF cell mito stress profile showing proportions of mitochondrial function from
assay relating to drug injections. Adapted from Seahorse Bioscience (2015).
Histamine stimulation triggers PLC to release intracellular Ca2+ and induces the
influx of extracellular Ca2+ (Li et al., 2012a); Rhod-2, AM then binds Ca2+ and fluores-
cence intensity increases more than 100-fold upon binding where it is then sequestered
by the mitochondria and a maximal measurement of mitochondrial Ca2+ uptake can be
measured.
Videos were then analysed using Fĳi (ImageJ 1.52i) (Schindelin et al., 2012) by nor-
malising for background intensity and calculating the average intensity and maximum
entropy to highlight mitochondria (recognised nuclear elements manually removed)
and the pixel units of the particles were analysed to calculate the calcium in the cell of
each frame. Relative maximum calcium uptake was then calculated by comparing av-
erage fluorescence prior to histamine applicationwhen compared tomaximal intensity.
A two-tailed t-test for heteroscedastic data was then performed.
3.2.8 Mitochondrial Membrane Potential
Using cells seeded 24 hours previously at 100,000 in a 35 mm Glass Bottom Dish,
cells were incubated at at 37°C with 10nM Tetramethylrhodamine Methyl Ester (T668;
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Thermo Fisher Scientific) (TMRM) in 1 ml GMEM for 40 minutes in the dark before
washing twice in PBS and imaging on aNikon A1r point-scanning confocal microscope
at x60 magnification, using a 1.40 numerical aperture oil objective, in 1 ml Tyrode’s
solution. Cells were imaged for 1 minute before treatment with FCCP and recorded for
a further 15 seconds.
Videos were then analysed using Fĳi (ImageJ 1.52i) (Schindelin et al., 2012) by
isolating a single cell and subtracting background noise. Mitochondria were selected
by averaging intensity of time stacks and thresholding automatically on isodata before
analysing particles. The multi-measure tool was used to quantify intensity and F
was calculated as the mean of TMRM basal intensity (first 10 stacks; 2.404 seconds)
and F0 was calculated as post treatment intensity (last 10 stacks; 2.404 seconds) with
measurements presented as F/F0, ΔΨm. Experiment was replicated as biological
triplicates.
3.2.9 Mitochondrial Network and ER-Mitochondrial Interactions
Cells were prepared for both mitochondrial network analysis and concurrent visualisa-
tion of ER:Mitochondrial network interactions by seeding 100,000 cells in 35 mm Glass
Bottom Dishes and transiently transfecting Green Fluorescent Protein (GFP)-Sec61β
(Voeltz et al., 2006) 24 hours later.
LB Agar (22700025; Sigma-Aldrich), supplemented with 50 µg·ml-1 Kanamycin Sul-
phate (11815-032; Invitrogen) on 90 mm Agar Plates (101IRR; Thermo Fisher Scientific)
was prepared aeseptically and air dried before storage at 4°C. Upon use, plates were
warmed to 37°C and 25 µl of JM109 Competent Cells (L2001; Promega), previously
transformed with GFP-Sec61β (Voeltz et al., 2006) (pAc-GFPC1-Sec61beta was a gift
from Tom Rapoport (Addgene plasmid #15108)), were thawed from -80°C and plated
before overnight incubation at 37°C.
White colonies were picked and prepared using QIAprep SpinMiniprep Kit (27104;
QIAGEN) according tomanufacturer instructions before restriction digestionwith XBaI
(R0145T; New England Biolabs) using CutSmart Buffer (New England Biolabs) condi-
tions for 1 hour.
Digestions were loaded with DNA Gel Loading Dye (6X) then electrophoresed on
a 1% agarose gel + 0.005% SafeView Nucleic Acid Stain and plasmids containing GFP-
Sec61βwere stored at -20°C until use.
To detect ER, the cell lines were transiently transfected ~24 hours prior to imaging,
using Opti-MEM (31985062; Thermo Fisher Scientific), GeneJuice Transfection Reagent
(70967; Merck Millipore) and 1 µg of plasmid DNA, confirmed for GFP-Sec61β. Mi-
tochondria were detected by loading 75 nM MitoTracker Red FM (M22425; Thermo
Fisher Scientific) at 37°C for 30 minutes in the dark before washing twice with PBS and
imaged in Tyrode’s solution supplemented with 25 mM HEPES.
MitoTracker Red stains mitochondria in live cells and GFP-Sec61β transfection re-
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sults in expression of a GFP tagged Sec61 complex within the ER, therefore allowing
concurrent visualisation.
Cellswere immediately imaged followingwashingusingaNikonA1rpoint-scanning
confocal microscope at x60 magnification, with a 1.40 numerical aperture oil objective.
The high speed Piezo Z Drive took 69 Z-stacks, spanning the full cell depth, at 0.11 µM
increments. Number of cells quantified are available in Table S20.
Figure 3.2: Cell stacks were imaged and adjacent cells were cropped in Huygens Essential Software
(SVI). The cleaned image was then deconvolved to separate the red and green channels, ER and
mitochondria respectively, before reconstructing the 3D image.
Huygens Essential Software (SVI) was used to deconvolve both channels of the
original figure using an optimised 40 iteration CMLE deconvolution with a signal to
noise ratio of 20, thresholding quality at 0.05 and automatic brick layout. Background
was automatically estimated to reconstruct the stacks as a 3D image, as demonstrated
in Figure 3.2.
Mitochondrial Network
Following collection of data from primary cell lines, prepared as described in Section
3.2.9, and shown in Figure 3.2, the mitochondrial network was further analysed in
Huygens Essential Software (SVI).
The Advanced Object Analyzer was used for each deconvolution to segment the
objects, thresholding each channel at 10% with a 10% seed and garbage volume of 100.
Thresholding and seed values were recorded as detailed in Section 3.2.9 and the objects
were then analysed to quantify the mitochondrial network.
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ER-Mitochondrial Interactions
Cells were prepared and measured as described in Subsection 3.2.9 before Huygens
Essential Software (SVI) was used to calculate the relationship between the ER and
mitochondrial network using the Colocalization Analyzer (Bravo et al., 2011).
Using the 10% thresholding values recorded in Section 3.2.9, both themitochondrial
and ER channels were thresholdedwith a threshold range of 0 and a colocalisationmap
of the Manders’ M1 and M2 coefficients were computed.
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3.3 RESULTS
3.3.1 mtDNA Copy Number
Newly designed primers were checked for successful amplification of the target gene
and optimum annealing temperature via gradient PCR as seen in Figure 3.3. B2M
appears to successfully amplify across the whole temperature gradient from 49-61°C
whilst MT-ND4 amplifies more successfully from 53.6-61°C and MT-RNR2 from 51.3-
58.6°C. As such, an annealing temperature of 58°C was chosen to amplify all three
genes in triplex.
Figure 3.3: Gradient PCR of B2M, MT-ND4 and MT-RNR2 primers with indicated annealing
temperatures to determine optimum triplex assay temperature. B2M is expected to amplify a fragment of
141 bp, MT-ND4 107 bp andMT-RNR2 126 bp.
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Figure 3.4: Singleplex standard curves produced using SYBR Green showing B2M (A), ND4 (B) and
RNR2 (C) efficiency.
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SYBR Green was used to confirm that all three genes would successfully amplify at
58°C, as confirmed in Figure 3.4.
Given that the primers were redesigned for amplification of B2M, another SYBR
Green assay was used to determine whether the new primers increased efficiency of
amplification. As shown in Figure 3.5, using the newly designed primers increases
efficiency from 87.4% to 90.4% when compared to the original primers. Melt curve
analysis was also used in Figure 3.6. The new B2M primers melt at a slightly higher
temperature and there is a single melting peak, indicating no off-target amplification
when compared to the original B2M primers.
A singleplex assay of standards was used to ensure successful amplification using
the Taqman probe system with good efficiencies of 98.2%, 93.8% and 92.3% of B2M,
MT-RNR2 and MT-ND4 genes respectively, as shown in Figure 3.7.
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Figure 3.5: Singleplex standard curves produced using SYBR Green on original (A) and newly
designed B2M (B) primer sets to determine comparable efficiencies.
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Figure 3.6: Comparison of SYBR Green melt curves and peaks for the original and new B2M qPCR
assays. Original B2M melt curve (A), melt curve for new B2M amplification (B), original B2M melt
peak (C) and melt peak for new B2M amplification (D).
Figure 3.7: Standard curves produced using Taqman probe system in a singleplex each showing
MT-ND4, B2M and MT-RNR2 on the Cy-5, FAM and HEX channels respectively.
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Figure 3.8: Standard curves produced using Taqman probe system in a duplex of showingMT-ND4
and B2M on the Cy-5 and FAM channels (A), B2M andMT-RNR2 on the FAM and HEX channels (B)
and MT-ND4 and MT-RNR2 on the Cy-5 and HEX channels (C).
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Aduplexwas next set up to determine the efficiency of each gene setwhen amplified
in each possible combination. Figure 3.8 (A) shows good amplification of B2M andMT-
ND4 in combination and (B) shows good amplification of B2M and MT-ND4, however,
(C) shows a lowered efficiency of MT-RNR2 and MT-ND4 in duplex, possibly due to
competition of the primers and probes. This was predicted given that the MT-ND4
forward and reverse primers were predicted in silico to bind the MT-ND4 probe with
a ΔG value of -9.76/-53.42 kcal·mole-1 and -8.7/-53.42 kcal·mole-1 respectively where
the latter figure represents the free energy of the probe binding its perfect complement.
Further, the MT-RNR2 reverse primer was predicted to bind the MT-ND4 probe with
ΔG value of -9.76/-53.42 kcal·mole-1 and the combination of these appears to inhibit
the efficiency.
Figure 3.9: Standard curves produced using Taqman probe system in a triplex, respectively showing
MT-ND4, B2M and MT-RNR2 on the Cy-5, FAM and HEX channels respectively.
A triplex assay was then set up, as shown in Figure 3.9, to determine that all
efficiencies were >90%. The inhibition shown in duplex is less evident in the triplex
(Figure 3.9), however, the triplex efficiency was still lower than that of the original
triplex.
Tables S11 andS12 show the significance of difference inCt score between singleplex,
duplex and triplex. There is an increase in the number of cycles required to reach the
threshold, particularly between MT-ND4 and MT-RNR2 (p = 0.015 from singleplex to
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duplex of MT-ND4 and MT-RNR2 and p = 0.012 for MT-RNR2 in triplex). Between the
duplex to triplex, augmentingwithMT-RNR2 also has a p-value of 0.020, indicating that
Ct is affected in triplex settings; however, Ct scores are stable in the other combinations.
Mitochondrial copy number and major arc deletion were measured in triplicate as
shown in Figures 3.10 and 3.11. A control deletion sample was included, a transmito-
chondrial cybrid of ~70% heteroplasmic level, containing a single large-scale mtDNA
deletion which spans the major arc from positions m.7,982-15,504 (Diaz et al., 2002).
Figure 3.10: Amplification and standard curves produced using Taqman probe system in a triplex of the
original laboratory standard (A) and (C) compared to the new triplex (B) and (D) in blood DNA
extractions. B2M, MT-RNR2 and MT-ND4 on channels FAM, HEX and Cy5 respectively.
Figure 3.10 shows the comparison of the original laboratory standard assay for
mtDNA copy number quantification to the new qPCR assay in blood samples. The an-
nealing temperature was raised to 62°C, which was the previous lab standard optimum
temperature, to run the qPCR DNA and deletion controls alongside six control blood
samples, with both the original and new qPCR assays on the same plate.
The new B2M primers resulted in a great increase of fluorescence for the FAM
channel when comparing Figure 3.10 (A) to (B). Switching to MT-RNR2 also results
in a more consistent Relative Fluorescence Units (RFU) for the HEX channel with
final amplification cycles plateauing in a narrower range. MT-ND4 remains consistent
between the two qPCR assays. The channels in 3.10 (D) also show a narrower range in
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a more consistent efficiency than when compared to 3.10 (C). Increasing the annealing
temperature from 58°C to 62°C also results in an overall efficiency increase in Figure
3.10 (D) when compared to Figure 3.9.
The change in Ct across channels between the old and new assays through a range of
test samples are summarised in Table 3.12. Overall, it shows thatMT-ND4 amplification
was unaffected by the change in assay design,MT-RNR2 amplifies faster thanMT-ND1
in both blood and fibroblast DNA samples, and that B2M amplifies cycles faster in
fibroblast and particularly blood DNA samples.
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Table 3.12: Ct scores between original and new qPCR triplex for channels Cy5 (ND4), HEX (ND1/RNR2) and FAM (B2M) in blood and fibroblasts. Channel mean
indicates mean of technical replicates after QC; sample mean indicates the mean difference between the original assay and the new one alongside the Ct score percentage
change.
Cy5 Ct Mean HEX Ct Mean FAM Ct Mean
DNA
Sample
Original New Diff % Ct
Shift
Original New Diff % Ct
Shift





21.60 21.40 -0.20 -1% 21.57 20.88 -0.69 -3% 28.26 25.29 -2.97 -11%
Ctrl Del 20.01 19.89 -0.12 -1% 18.26 17.81 -0.45 -2% 33.00 25.59 -7.41 -22%
DNA 1 16.42 16.30 -0.12 -1% 16.46 15.71 -0.75 -5% 24.35 20.99 -3.36 -14%
DNA 2 20.07 20.14 0.07 0% 20.00 19.66 -0.34 -2% 29.71 25.08 -4.63 -16%
DNA 3 19.56 19.51 -0.05 0% 19.60 19.03 -0.57 -3% 25.18 23.52 -1.66 -7%
DNA 4 17.13 17.11 -0.02 0% 17.13 16.55 -0.58 -3% 27.54 22.05 -5.49 -20%
DNA 5 17.18 17.15 -0.03 0% 17.16 16.57 -0.59 -3% 22.31 21.76 -0.55 -2%
DNA 6 20.76 20.56 -0.20 -1% 20.33 19.82 -0.51 -3% 28.97 24.83 -4.14 -14%




21.91 21.90 -0.01 0% 21.84 21.26 -0.58 -3% 26.74 25.79 -0.95 -4%
Ctrl Del 19.89 19.81 -0.08 0% 18.29 17.73 -0.56 -3% 27.07 25.28 -1.79 -7%
C1 21.46 21.52 0.06 0% 21.39 20.97 -0.42 -2% 28.59 27.31 -1.28 -4%
C2 21.31 21.41 0.10 0% 21.28 20.84 -0.44 -2% 28.37 27.20 -1.17 -4%
C3 22.71 22.88 0.17 1% 22.63 22.23 -0.40 -2% 28.84 28.26 -0.58 -2%
A2-
14484
21.50 21.43 -0.07 0% 21.42 20.86 -0.56 -3% 29.10 27.46 -1.64 -6%
A3-
11778
23.26 23.21 -0.05 0% 23.15 22.63 -0.52 -2% 32.26 30.05 -2.21 -7%
A4-
11778
22.51 22.32 -0.19 -1% 22.31 21.71 -0.60 -3% 29.50 27.90 -1.60 -5%
Mean -0.01 0% -0.51 -2% -1.40 -5%
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Figure 3.11: Amplification and standard curves produced using Taqman probe system in a triplex of the
original laboratory standard (A) and (C) compared to the new triplex (B) and (D) in fibroblast DNA
extractions. B2M,MT-RNR2 and MT-ND4 on channels FAM, HEX and Cy5 respectively.
Figure 3.11 shows the comparison of the original laboratory standard assay for
mtDNA copy number quantification to the new qPCR assay in fibroblast samples. The
annealing temperature was maintained at 62°C to run the qPCR DNA and deletion
controls alongside six fibroblast samples, with both the original and new qPCR assays
on the same plate.
As with 3.10, the new triplex in Figure 3.11 shows an increase in fluorescence for
B2M but this is less than the difference in the fibroblast DNA samples. The MT-RNR2
also results in slightly more consistent RFU for the HEX channel andMT-ND4 remains
consistent between the two qPCR assays again. Finally, the channels in 3.11 (D) also
show a more consistent efficiency in the channels when compared to 3.11 (C).
Ct scores for Figures 3.10 and 3.11 are included in Table 3.12. As expected, as
the MT-ND4 primers and probes remained unchanged, there is very little change of
Cy5 Ct Score. Switching from MT-ND1 to MT-RNR2 improved the assay’s ability to
detect mtDNA, with the Ct score reaching the detection threshold more than half a
cycle earlier. Altering the B2M primer positions also greatly improved detection by
reducing the qPCR product size from 231 bp to 141 bp; this had a varied response
in the difference of detection in blood with a mean detection 3.78 cycles sooner. In
fibroblasts, the response was more consistent and it took a mean 1.40 cycles fewer to
detect. There is a good correlation between the copy number of samples between the
old and new assays, particularly for fibroblasts, as shown in Figure 3.12 and Table S13,
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although the correlation is not as strong in blood samples and there is a discrepancy
in the ability of the assays to reliably measure copy number in blood compared to
fibroblasts.
Figure 3.12: Copy number using Taqman probe system in a triplex of the original laboratory standard,
MT-ND1 against the new triplex,MT-RNR2 in blood (A), blood, excluding high concentration sample
(B), fibroblasts (C), all blood and fibroblast samples (D), and blood and fibroblasts, excluding high
concentration sample (E).
Using DNA extracted from primary control and LHON fibroblast cell lines, mito-
chondrial copy number andmajor arc deletion were measured in triplicate as indicated
previously with a control deletion (Diaz et al., 2002) and control blood DNA sample,
with results shown in Figure 3.13. Error bars indicate standard error of mean across
biological triplicates of the cell line at three different passages; Figure S10 shows the
individual Ct scores for each replicate.
Table S14 shows that there was not a significant deletion of the major arc in any of
the samples but the cell lineA4-11778 did show a significant reduction ofmitochondrial
copynumberwhen compared to the controls (p = 0.036). This significancewas exclusive
to this cell line as after grouping by mutation or disease status there was no significant
difference from controls.
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Figure 3.13: Mitochondrial copy number (A, C, E, G) and respective major arc deletion percentile (B, D, F, H) of LHON fibroblasts. Figures A and B show all
individual samples, including control deletion sample. Figures C and D collapse cell lines C1, C2 and C3 as controls, Figures E and F collapse cell lines A1-11778,
A3-11778 and A4-11778 as according to LHON primary mutation, and figures G and H collapse all LHON samples against controls. Error bars represent standard
error of the mean between three biological replicates collected at different passages. * Indicates p ≤ 0.05.
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3.3.2 ATP Production During Metabolic Stress
Cells cultured on the 96 Well Solid White Polystyrene TC-Treated Microplate were
rinsed with PBS and Protein Assay Dye Reagent Concentrate was used to perform a
Bradford assay in accordance to manufacturer’s instructions.
CellTiter-Glo Luminescent Reagent was used in a cell viability assay to quantify
the ATP produced by cells after treatments with Glucose, Deoxyglucose, Glucose and
Oligomycin A, and Deoxyglucose and Oligomycin A in a 96 Well Clear Polystyrene
TC-Treated Microplate. Luminescence detection quantifies light produced by a ther-
mostable luciferase which illuminates in the presence of ATP; a greater luminescence
is indicative of cells capable of producing more ATP under stress. The concurrent
Bradford assay was performed and free ATP was normalised to available protein, the
results of which are shown in Figure 3.14.
Table S15 shows that the only significant treatment for reducing ATP production
is Deoxyglucose, an inhibitor of glycolysis, in cell line A4-11778 (p = 0.017), however,
there is no significance once grouping according to the disease causingmutation. Once
grouping bydisease status, there are no significant differences between cases or controls
on any of the measurements.
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Figure 3.14: Relative luminosity, representing ATP, normalised to mg protein. Individual cell lines after grouping the three controls (A) and grouping by mutation
(B). Bars show luminosity under different drug treatments; error bars represent standard error of the mean between three biological replicates assayed at different
passages. * Indicates p ≤ 0.05.
113
3.3.3 Cellular Oxygen Consumption
20,000 cells were seeded per well of a Seahorse XF96 Cell Culture Microplate prior to
measurement ofOCRon a SeahorseXFe96 Extracellular FluxAnalyzer under both basal
conditions and following sequential inhibitory drug injections. OCR measurements
were normalised in Wave Desktop to mg of protein as shown in Figure 3.15.
Table S16 shows significance values. Measurements of basal respiration, ATP pro-
duction, maximal respiration and spare respiratory capacity were significantly reduced
in cell lines A1-11778, A4-11778 and A5-3460 (respectively, ATP production p = 0.028,
1.19e-05 and 0.001; maximal respiration p = 0.013, 0.021 and 0.009; spare respiratory ca-
pacity p = 0.016, 0.032 and 0.012) with non-mitochondrial respiration also significantly
reduced in A5-3460 (p = 0.049). After grouping cell lines A1-11778, A3-11778 and
A4-11778 together, only basal respiration and ATP production remained significantly
reduced compared to controls (p = 0.002 and 1.25e-04 respectively).
Finally, grouping by case:control status, basal respiration and ATP production are
seen to be extremely significantly reduced when compared to controls (p = 0.003 and
2.74e-04 respectively). There is a general reduction in maximal respiration, however
this is not significant given the variance in the control cell lines’ maximal respiration
level.
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Figure 3.15: OCR (pmol µ min -1 mg -1) was measured over 93 minutes. Basal respiration was determined before subsequent injections of Oligomycin A, FCCP, and
Rotenone and Antimycin A to allow calculation of measurements as shown in Figure 3.1. Individual cell lines after grouping the three controls (A) and grouping by
mutation (B). Error bars represent standard error of the mean between three biological replicates assayed at different passages. * Indicates p ≤ 0.05, ** indicates p ≤
0.005, *** indicates p ≤ 5.0e-04.
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3.3.4 Calcium Homeostasis
Maximal mitochondrial calcium intake was calculated after histamine stimulation rel-
ative to controls using fluorescence intensity, as shown in Figure 3.16. After focus-
ing the confocal microscope to the monolayer of cells, the laser was moved to non-
photobleached cells, as such, the number of cells visible on the microscope varied
between cell lines. A minimum of 3 cells of each cell line were used in each passage in
triplicate, with counts available in Table S18.
Significance of results are shown in Table S17. There were no significant differences
between cases and controls, except for cell line A5-3460 (p = 0.004).
Figure 3.16: Mitochondrial maximal calcium uptake, showing individual affected cell lines (A),
grouping by mutation (B) and grouping by disease state (C). Bars show maximal mitochondrial calcium
uptake after stimulation; error bars represent standard error of the mean between three biological
replicates imaged at different passages. ** indicates p ≤ 0.005.
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3.3.5 Mitochondrial Membrane Potential
Confocal microscopy visualised cells treated with TMRM to determine the ΔΨm.
TMRM fluorescence intensity is proportional to ΔΨm (Joshi and Bakowska, 2011) and
after treatment of FCCP, baseline ΔΨm can be calculated as shown in Figure 3.17. No
significant difference was found between controls and diseased cell lines, as shown in
Figure 3.17 and Table S19. There were no significant differences between cases and
controls on any of the measurements taken across any groupings.
Figure 3.17: F/F0 (fluorescence / background fluorescence) as a measurement of ΔΨm. Individual
patient cell lines after grouping the three controls (A), grouping by mutation (B) and grouping by
disease state (C). Error bars represent standard error of the mean between a minimum of three biological
replicates assayed at different passages.
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3.3.6 Mitochondrial Network and ER-Mitochondrial Interactions
Figure 3.18: XBaI restriction digestion of miniprepped plasmids designed for transfecting GFP-Sec61β
into fibroblasts to visualise ER. GFP-Sec61β is a 5,008 bp plasmid.
Figure 3.18 shows the partial digestion of the 5,008 bpGFP-Sec61β plasmid digestion
with XBaI. GFP-Sec61β contains one restriction site for XBaI and a faint band of linear
DNA is shown at ~5000 bp. The partial digest also shows other species of the same
plasmids running more slowly through the gel around 11,000 bp and >20,000 bp.
Minipreps from colonies 1, 3, 4, 5, 6 and 7 all incorporated the plasmid; colony 2 did
not.
Mitochondrial Network
Figure 3.19 shows that cell lines A1-11778 and A4-11778 have a significant reduction
in average and maximum mitochondrial network volume (average volume p-value =
0.047 and0.013 andmaximal volumep-value= 0.036 and0.036 respectively). A1-11778’s
total volume is also significantly reduced when compared to controls (p-value = 0.006),
however, after grouping with cell line A3-11778 as the m.11778G>A mutation, this is
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no longer significant. Cell line A5-3460 shows a significant increase in mitochondrial
network length (p-value= 0.024), withmitochondriamore likely to be joined together, as
indicated by the concurrent significant reduction in the number of fragmentswithin the
mitochondrial network (p-value = 0.016). However, after grouping the m.11778G>A
mutation cell lines (Figure 3.20) or all cell lines (Figure 3.21), this significance is no
longer detectable. Full significance tables and cell counts are available in the appendix,
Table S21 and Table S20 respectively.
Figure 3.19: Average mitochondrial length (A), maximal mitochondrial length (B), minimal
mitochondrial length (C), total mitochondrial length (D), average mitochondrial volume (E), maximal
mitochondrial volume (F), minimal mitochondrial volume (G), total mitochondrial volume (H) and
mitochondrial network fragments (I) of the mitochondrial network for individual cell lines with control
cell lines grouped. Error bars represent standard error of mean between a minimum of three biological
replicates measured at different passages with cell counts available in Table S20. * Indicates p ≤ 0.05.
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Figure 3.20: Average mitochondrial length (A), maximal mitochondrial length (B), minimal
mitochondrial length (C), total mitochondrial length (D), average mitochondrial volume (E), maximal
mitochondrial volume (F), minimal mitochondrial volume (G), total mitochondrial volume (H) and
mitochondrial network fragments (I) of the mitochondrial network for individual cell lines grouped by
mutation status. Error bars represent standard error of mean between a minimum of three biological
replicates measured at different passages with cell counts available in Table S20.
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Figure 3.21: Average mitochondrial length (A), maximal mitochondrial length (B), minimal
mitochondrial length (C), total mitochondrial length (D), average mitochondrial volume (E), maximal
mitochondrial volume (F), minimal mitochondrial volume (G), total mitochondrial volume (H) and
mitochondrial network fragments (I) of the mitochondrial network for individual cell lines grouped by
disease status. Error bars represent standard error of mean between a minimum of three biological
replicates measured at different passages with cell counts available in Table S20.
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ER-Mitochondrial Interactions
Cells were prepared as described in Subsection 3.2.9 with Huygens Essential Software
(SVI) used to calculate the co-localisation between the ER and mitochondrial network
(Bravo et al., 2011). Figure 3.22 shows a significant increase in cell line A2-14484
in the Pearson Correlation between the ER and mitochondrial network, and Man-
ders’ coefficient M2 which represents the mitochondrial:ER co-localisation (p-value =
0.001 and 3.36e-04). A4-11778 has a significant reduction in Manders’ coefficient M1
(ER:mitochondrial co-localisation) (p = 0.036), however, this is no longer significant
after grouping the m.11778G>A cell lines together in Figure 3.23. After grouping all
LHON cell lines together, M2 remains significantly increased (p = 0.025) as shown in
3.24. Full significance tables and data grouped by mutation available in Table S22.
Figure 3.22: Pearson Correlation (A), Manders’ coefficient M1 (B) and Manders’ coefficient M2 (C) as
measured, showing controls grouped and LHON patients separate. Error bars represent standard error
of the mean between a minimum of three biological replicates analysed at different passages, counts of
cells analysed are available in Table S20. * Indicates p ≤ 0.05, ** indicates p ≤ 0.005, *** indicates p ≤
5.0e-04.
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Figure 3.23: Pearson Correlation (A), Manders’ coefficient M1 (B) and Manders’ coefficient M2 (C) as
measured, showing controls grouped and LHON patients grouped by mutation. Error bars represent
standard error of the mean between a minimum of three biological replicates analysed at different
passages, counts of cells analysed are available in Table S20. ** indicates p ≤ 0.005, *** indicates p ≤
5.0e-04.
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Figure 3.24: Pearson Correlation (A), Manders’ coefficient M1 (B) and Manders’ coefficient M2 (C) as
measured, showing controls and LHON patients grouped. Error bars represent standard error of the
mean between a minimum of three biological replicates analysed at different passages, counts of cells
analysed are available in Table S20. * Indicates p ≤ 0.05.
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3.4 DISCUSSION
3.4.1 mtDNA Copy Number
Increased mtDNA copy number has previously been declared protective towards
LHON onset as observed in fibroblasts, peripheral white blood cells and skeletal mus-
cle (Bianco et al., 2017; Giordano et al., 2014), with unaffected carriers showing a higher
copy number than affected carriers or wild type controls, although this has been de-
bated as to whether it is neuroprotective or arises as a result of carrying a LHON
mutation (Finsterer, 2017; Yen et al., 2002). Increased copy number has independently
been shown to ameliorate cardiomyopathy and COX deficiency symptoms within a
heteroplasmic mitochondrial disease mouse (Filograna et al., 2019).
Preliminary results using the original laboratory standard assay for mtDNA copy
number quantification (Grady et al., 2014; Pyle et al., 2016) did indicate that an unaf-
fected mother had a greatly increased copy number when compared to her affected
son, another m.11778G>A affected patient and also wild type controls (Figure S9). No
further investigation was specifically taken into copy number in unaffected carriers due
to limited availability of unaffected carrier cell lines.
Modification to the qPCR strategy was then implemented; the in-house mtDNA
probe set was suboptimal for LHON mutations as a primer binding site sequence
location matched the LHON position 3460 primary mutation inMT-ND1. Quantifying
copy number in LHON samples with this mutation would result in an artificially low
copynumber being calculateddue to themismatch of theprimer to themutant sequence
when compared to healthy controls.
This was overcome by relocating the mtDNA major arc probe set to MT-RNR2.
The original in-house B2M primers were also replaced with new primers, arranged
in a different position around the original probe, to prevent triplex primers being
complimentary to one another as well as shortening the amplified fragment length
and improving efficiency. The new probe set was successfully verified in efficacy from
singleplex through to triplex (Figures 3.7 - 3.9). Both probe sets’ efficiency greatly
increased, withMT-RNR2 amplifying a mean of 0.54 cycles earlier and B2M 3.78 cycles
earlier in blood and 1.40 cycles earlier in fibroblast samples as shown in Table 3.12.
Given the variance of the blood copy number measurements for B2M it is possible
that the fibroblast measurement is more accurate, but this still indicates a detection
improvement by reaching the threshold 1.40 cycles earlier. In addition to this, from in-
house meta-analysis of mtDNA (kindly provided by Doctor Gavin Hudson (Newcastle
University)), it was significantly less likely for a SingleNucleotide Polymorphism (SNP)
to be present in the MT-RNR2 primers/probe (1/386.5 rather than 1/8.9); dbSNP
(Sherry et al., 2001) was used to ensure that the new B2M primers were similarly not
relocated over common SNPs.
SYBRGreenmelt curve analysis ofB2M (Figure 3.6) shows that theB2Moptimisation
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does not form novel primer dimers and the single melt peak indicates that only B2M is
being successfully amplified.
ThenewqPCR techniquewas shown to be successful for quantifyingLHONmtDNA
copy number with the new assay more sensitive and less likely to be affected by other
mtDNA sequence variability.
Using this assay to quantify LHON fibroblast copy number, results show a trend
in the reduction of mitochondrial copy number in affected carriers when compared to
wild type, however, this only reaches significance in the cell line A4-11778 (p = 0.036).
As one of the three m.11778G>A cell lines, this significance is lost after grouping by
mutation or looking at all LHON cell lines as a whole grouping.
No LHON cell lines showed deletion of the major arc; deletion is normalised to a
control DNA blood sample - the negative deletion in LHON samples suggests that the
control itself has some degree of heteroplasmy in the minor arc, with the negative dele-
tion control showing a deletion of 65% rather than the expected 70%. Whilst mtDNA
damage does occur under normal conditions (Richter et al., 1988) and is exacerbated
by oxidative stress (Yakes and Van-Houten, 1997) with deletions occurring as part of a
natural process of ageing (Phillips et al., 2014), large scale deletions were not expected.
3.4.2 ATP Production During Metabolic Stress
The mitochondrial respiratory chain, described in Section 1.2.1, is the principal source
of ATP in the cell. LHON mutations which inhibit Complex I can limit the oxidation
of NADH and electron transfer to CoQ10 (Lenaz et al., 2006) which in turn affects
the downstream processes and limits resources available for production of ATP. This
bioenergetic failure is known to prove fatal to cells, particularly cells with a high energy
demand, such as RGCs (Osellame et al., 2012).
ATP is also known to act as a signalling molecule by ATP release from nerves to
muscle tissue. Quite specifically, ATP has been shown to act as a neurotransmitter
within the eye, down the optic signalling cascade, from the rod and cone cells to the
brain (Khakh and Burnstock, 2009).
As such, impingement of ATP production and concentration could be causative of
the LHON phenotype.
Figure 3.14 (A) does show a general decrease in most cell lines under glycolytic
conditions, where it is thought that glycolysis can alleviate ATP deficiency by pro-
ducing more ATP via glycolysis. In treating the cells with Deoxyglucose, glycolysis is
inhibited and ATP should be produced by the mitochondrial respiratory chain. All cell
lines produce less free ATP under this condition and whilst A4-11778 is significantly
reduced when compared to controls, it did also have the lowest ATP measurement
under glycolytic conditions.
Oligomycin A further inhibits the mitochondrial respiratory chain by blocking the
proton channel of Complex V. During treatment with Glucose and Oligomycin A, cells
126
are dependent upon glycolysis and whilst insignificant, there is an upward trend of
LHON cell lines when compared to controls. It is possible that due to Complex I defect
that the trend reversal when compared to controls indicates LHON cell lines are more
accustomed to glycolytic dependency.
Upon treatment with both Deoxyglucose and Oligomycin A, both glycolysis and
Complex V are inhibited resulting in no production of ATP, free ATP in all cell lines is
greatly reduced as cells quickly use their ATP reserves.
Baracca et al. (2005) found a severe reduction in osteosarcoma-derived rho0 cells’
ATP production however they did not find a reduction in cellular ATP content, indi-
cating, like the data collected here, that a possible compensatory mechanism allows
alleviation of low cellular ATP levels in LHON cell lines.
3.4.3 Cellular Oxygen Consumption
Mitochondrial respiration was determined using the Seahorse XFe96 Extracellular Flux
Analyzer which assessed basal respiration, proton leak, ATP production, FCCP stim-
ulated maximal respiratory capacity and spare respiratory capacity of mitochondria,
alongside non-mitochondrial respiration in three control and five patient cell lines.
All LHON cell lines show a reduction in respiration, with several measurements
being significant, particularly the maximal respiration and spare respiratory capacity;
basal respiration and ATP production are also reduced in most cell lines, similar to that
which was expected from other studies (Giorgio et al., 2012).
Figure 3.15 confirms a severe reduction in respiration, similar to that which has been
seen before (Baracca et al., 2005; Brown et al., 2000). Section 3.3.2 shows that cell lineA5-
3460 has the greatest free ATP under glycolytic conditions, however, whilst measuring
ATP production in Section 3.3.3, A5-3460 actually produces significantly less ATP than
control cell lines. The results between the ATP Assay and Seahorse measurements
differ in this cell line, as excluding A5-3460, the shape of the graph under glycolytic
conditions (Figure 3.14) matches the shape of the graph for ATP production (Figure
3.15), indicating that ATP production could have a correlation to free cellular ATP. This
is despite the ATP assay measurements indicating that there is not exclusively a direct
relationship between the two as the cell lines respond differently during inhibition.
This could be a biochemical response difference between the cells’ responses, or that
the Seahorse quantification is a more accurate measurement of cellular respiration
across a range of conditions.
Interestingly, there is a range in the measurement of non-mitochondrial respiration
response. Three individual cell lines are significantly reduced whilst others increase,
however, after grouping by mutation, this is no longer significant. A5-3460 behaves
differently between theATPassay andSeahorsemeasurements, however, bothA1-11778
and A4-11778, which show the lowest cellular ATP measurements under glycolytic
conditions, also have the lowest non-mitochondrial respiration. It has previously been
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shown that m.3460G>A fibroblasts have reduced sensitivity to rotenone (Cock et al.,
1999), which potentially suggests that m.3460G>A mutations are more sensitive to
further Complex I inhibition than other causative LHON mutations.
Non-mitochondrial respiration includesNADPHoxidases’ activity (BrandandNicholls,
2011) and given that NADPH oxidases produce ROS (Jiang et al., 2011) and inactivate
Complex I (Kozieł et al., 2013), it is possible that LHON Complex I dysfunction results
in downregulation of NADPH oxidase activity to prevent further oxidative stress and
Complex I inhibition.
This was specific to the A5-3460 cell line and measurements of all cases indicated
that this is not significant. This could be a peculiarity of the specific A5-3460 cell line,
or indicative of a broader trend in the more severe m.3460G>A mutation which was
not detectable in this experimental design.
All cell lines were cultured with antibiotics which can induce mitochondrial dys-
function and oxidative damage (Kalghatgi et al., 2013) by mitochondrial targeting, sim-
ulating the cellular phenotype of LHON. As such, these results could be exacerbated
by further respiratory chain damage and ROS production.
LHON affects RGCs which experience variable ATP demand depending upon the
frequency of which they must send action potentials. As such, it is important for them
to maintain spare respiratory capacity and have a high maximal availability to manage
increases in energy demands (Brand and Nicholls, 2011); the reduction in maximal and
spare respiratory capacity within LHON patients indicates that the cells are already
close to their bioenergetic limit and that they are unable to respond to further stress.
3.4.4 Calcium Homeostasis
Cells were tested for their response to histamine application which stimulates cells
basal mitochondrial calcium load into their maximal uptake. This can be quantified
by using Rhod-2, AM, which is a rhodamine-like fluorophore that is passively loaded
into cells during incubation. Once inside the cell, the esterified AM group is cleaved to
inhibit cellular removal and allow for fluorescence visualisation.
The experiment requires precise timing to ensure equal loading between cell lines
and as some were approaching senescence, their calcium uptake could have been
affected in the experiment. It has been acknowledged that care should be taken when
acquiring mitochondrial calcium data via Rhod-2, AM imagery (Fonteriz et al., 2010).
Rhod-2, AM is known to cause modification to mitochondrial morphology and
mitochondrial calcium concentration, however, this effect is "slow and limited" at 1 µM
(Fonteriz et al., 2010) and Rhod-2, AMwas only applied at 177 nM for this experiment,
indicating that the cells would not be affected for their 30 minute incubation.
There is a high variability between cell lines with the majority of the mutant cell
lines responding within the response range of the controls. The A3-11778 cell line
shows the lowest uptake of calcium, however, this response does not occur in the other
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m.11778G>A cell lines; A4-11778 shows a slight decrease but this is well within the
range of the controls and A1-11778 is instead insignificantly increased in comparison to
controls. The m.3460G>A mutation, A5-3460, is shown to significantly (0.004) increase
the mitochondrial calcium uptake following histamine stimulation, however, following
case:control cell groupings, this result is no longer significant. It is, however, possible
that the increased biochemical response of A5-3460 is indicative of the phenotypically
more severe clinical presentation (Zhuo et al., 2012).
Calcium is known to have a role in neuronal degeneration (Brini et al., 2014) and pre-
viously, LHON cybridmodels’ calcium deregulation has beenminimisedwithMinocy-
cline treatment, when compared to controls (Haroon et al., 2007), however, this study
shows that only one m.3460G>A cell lines shows dysregulation of maximal mitochon-
drial calciumuptake following stimulation,which could again be specific to theA5-3460
cell line, or indicative increased m.3460G>A mutational burden.
As awhole, maximal calcium intake does not appear to differentiate LHON samples
from healthy controls in this study.
3.4.5 Mitochondrial Membrane Potential
TMRMis accumulatedwithin thematrix of polarisedmitochondria (Kholmukhamedov
et al., 2013) and is released once treatedwith FCCP,which uncouples themitochondria,
resulting in a loss of the proton gradient and fully depolarising the mitochondrial
membrane (Dispersyn et al., 1999; Joshi and Bakowska, 2011).
Methodology for measurement of ΔΨm is well characterised (Joshi and Bakowska,
2011; Perry et al., 2011) and ΔΨm has a role in cellular permanence. Membrane per-
meability greatly increases by formation of the mPTP (Rao et al., 2014) and subsequent
loss ofΔΨm. This change inΔΨm has been shown to cause matrix remodelling which
triggers the release of cytochrome c, resulting in apoptosis (Gottlieb et al., 2003). There
is conflicting evidence regarding this, with other authors indicating that apoptosis is in-
dependent ofΔΨm and dependent on other factors, with a decrease inΔΨm occurring
as a result of apoptosis, as opposed to a cause (Ly et al., 2003).
As reviewed in Section 1.3.1, fusion has been seen to generally minimise likelihood
of apoptosis from occurring. MIM fusion requires an established ΔΨm to take place
(Youle and Karbowski, 2005) and loss ofΔΨm selectively inhibits MIM fusion (Benard
and Karbowski, 2009). Subsequently, this shift in the balance between fusion and
fission would result in comparatively higher rates of mitochondrial fission - which is
more likely to shift the cell fate balance towards cell death rather than survival.
Surprisingly, LHON cell lines showed no significant difference in ΔΨm to control
cell lines but rather had a slight trend for increased ΔΨm which would indicate that
they should actually be more resistant to apoptosis.
Other studies have shown that ΔΨm does decrease in LHON (Jiang et al., 2016),
however, no change was found here, or in a study by Wong et al. (2002).
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3.4.6 Mitochondrial Network
There is a great deal of variability between cell lines’ response in experiments; LHON
causative mutation has previously been indicated to affect disease severity (Howell,
1998; Yu-Wai-Man and Chinnery, 2000) however this was difficult to determine; for
both the m.3460G>A and m.14484T>C mutation any significant differences could be
a result of a specific cell line behaving atypically rather than that behaviour being
indicative of that mutation.
MitoTracker Red, which was used to stain the mitochondria, permanence is depen-
dent upon ΔΨm, however, as shown in Section 3.3.6, there is no significant difference
between the ΔΨm of cases and controls so this should not affect the mitochondrial
network measurements.
Mitochondrial network structure has been previously implicated in othermitochon-
drial optic neuropathies (Alavi and Fuhrmann, 2013) and it was possible that this could
also factor into LHONdisease severity (Kirches, 2011), however, whilst LHON cell lines
tend to have a slightly smaller mitochondrial network volume, comprised of fewer frag-
ments, as a whole this is not significant and differences could be exclusive to individual
cell lines.
Mitochondrial fusion defects dramatically reduce cell growth rate and respiration,
much like a LHON defect, however, they also result in a heterogenous mitochondrial
population with reduced ΔΨm which was not seen in Section 3.4.5, indicating that
cellular fusion does not directly factor in LHON (Chen et al., 2005). This is compounded
by Figure 3.21 (E) showing no reduction in mitochondrial volume between cases and
controls. That being said, Figure 3.19 shows that there is a trend towards lowered
mitochondrial volume in m.11778G>A cell lines with cell lines A1-11778 and A4-11778
both significantly reducedwhileA3-11778mitochondrial networkvolume is unaffected.
The correlation between the mitochondrial network response andΔΨm response does
not appear to align with the cell lines’ behaviour in each assay responding in the same
direction, however.
LHON samples instead appear to have a higher rate of fusion than controls, with
fewer fragments in the mitochondrial network, as seen in Figures 3.19, 3.20 and 3.21 (I),
particularly in them.3460G>Amutation sample, which again indicates that this sample
responds differently to treatment compared to the other LHON samples.
It could be possible that LHON samples could upregulate fusion as a neuroprotec-
tive measure, however, further work would be needed to validate this.
3.4.7 ER-Mitochondrial Interactions
ER-mitochondrial interactions have been shown to be vital in a range of cellular func-
tions, including Ca2+ signalling, the UPRER and linking in to mechanisms such as
apoptosis, fusion and fission, as reviewed in Section 1.3.3.
ER-mitochondrial interactions have also been previously implicated in other mito-
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chondrial optic neuropathies (Alavi and Fuhrmann, 2013) with further evidence of ER
involvement in the metabolomic profile of LHON (Chao de la Barca et al., 2016). Man-
ders’ coefficient is commonly used to measure the interaction of the ER-mitochondria,
as a measure of the proportion of contact between the ER structure to the mitochondria
(Bravo et al., 2011).
As a whole, LHON appears to significantly increase the co-localisation of the mi-
tochondria to the ER (M2), however, this primarily appears to be in cell lines with the
m.3460G>A or m.14484T>C mutation; it is insignificantly elevated in one cell line with
a m.11778G>Amutation, but insignificantly lowered in the other two. Tunicamycin, an
ER stress inducer which upregulates the unfolded protein response, causes an increase
in mitochondrial-ER interactions (M2 coefficient) in HeLa cells (Bravo et al., 2011); the
increase of M2 in LHON cell lines suggests that ER stress could be a factor in LHON
disease development or progression, as indicated previously by Chao de la Barca et al.
(2016) but that this could be dependent upon the disease causing mutation.
In healthy cells, it is estimated that ~5–20% of the total mitochondrial surface is
in contact with the ER at any given moment (Friedman et al., 2011); the M2 value in
the control fibroblasts is ~27%, suggesting that these cell lines as a whole shows more
connections between the ER to the mitochondria than previous studies have shown,
but this ~5–20% figure then suggests that the LHONm.14484T>C and m.3460G>A cell
lines are further increasing interactions between the organelles in comparison.
Mitochondrial-ER contact points have also been shown to often be trigger points
for mitochondrial fission events (Friedman et al., 2011), however, despite the high
proportionofmitochondria in contact to theER, thenumber ofmitochondrial fragments
in these cell lines was not increased in comparison to controls, as shown in Figure 3.19.
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Chapter 4 | Retinal Characterisation of
Mitochondrial Disease Mouse
4.1 INTRODUCTION
Review of both subcellular systems and genetics in LHON has not yet yielded a defini-
tive cause for the variable disease penetrance.
As such, an alternate methodology of investigating the role of mtDNA mutations
at a macro systems level was considered. The mouse is known to be a good model for
optic disease; there are some minor differences with anatomy, such as the murine optic
nerve head opening at the nadir of the eye whilst it is off-centre in humans (Albrecht
May, 2008; May and Lütjen-Drecoll, 2002), but despite this, it remains a popular model
as it is more similar than many other species (Albrecht May, 2008; Krebs et al., 2017;
Veleri et al., 2015).
There have been rodentmodels of LHONdescribed, both a rat model (Marella et al.,
2010) using the yeast NDI1 gene, a homolog of human MT-ND4, and a mouse model
of human MT-ND4 by allotopic expression (Qi et al., 2007). Allotopic expression has
been known as an attempted strategy LHON treatment, described in Section 1.5.5 but
late stage phase III trials have been unsuccessful (GenSight Biologics, 2019).
LHONmutant m.13997G>A has also been created by fusing a cytoplast to a female
mouse embryonic stem cell line which was injected into blastocysts with subsequent
female carriers backcrossed for 10 generations (Lin et al., 2012). A further 150 cell lines
have been described for transmitochondrial mice, with LHON m.11186G>A tested for
disease phenotype (Fayzulin et al., 2015), although the LHON heteroplasmic mutation
m.11186G>A also contains a secondary homoplasmic m.15581C>T mutation in the
mtDNA too (Fayzulin et al., 2015).
Recently, a transgenicMitoMouseofhumanm.11778G>Awas createdbymitochondria-
targeted adeno-associated virus zygote injection with female carriers backcrossed onto
healthy males for 8 generations (Yu et al., 2015).
These mouse models did appear to reliably exhibit features of LHON and respond
to potential drug treatments (Lin et al., 2012; Marella et al., 2010; Qi et al., 2007; Yu et al.,
2015, 2018a), indicating that the systems based methodology for investigating LHON
disease onset could be most effective.
The human based MitoMouse created by Yu et al. (2015) is of particular interest for
being the firstmousemodel with both the human genotype and phenotype exhibited in
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themouse. Their later study ofmitochondrially targeting theMT-ND4 genewith adeno
associated viral vector indicates that LHON gene therapy could produce a favourable
clinical response.
Mutant models often have a lower fitness and reproductive capability compared to
wildtype and as such, there is limited availability of mitochondrially defective mice
so we were not able to characterise a specific LHON model. Instead, the well charac-
terised tRNAALA mouse was identified as a viable option for retinal characterisation for
novel optic defects in tRNAALA m.5024C>T andMT-ND6m.13715C>T (Kauppila et al.,
2016). tRNAALA m.5024C>T and MT-ND6 m.13715C>T are transcribed on the same
molecule and hence exist at the same level of heteroplasmy within the mouse. Further,
m.13715C>T is a non-synonymous variant in MT-ND6 - a subunit which is known
to also be involved in LHON, with the LHON m.14484T>C mutation also affecting
MT-ND6.
m.5024C>T affects the mitochondrially encoded MT-TA gene which encodes
tRNAALA. tRNAALA has a role in translation by decoding alanine codons and trans-
ferring an alanine amino acid to the newly synthesising amino acid chain as appro-
priate. The mouse was originally created by Professor James Stewart’s research group
(Max Planck Institute for Biology of Ageing), which originated from a cross of ’mt-
DNA-mutator’ mice (Trifunovic et al., 2004), and was kindly gifted to Professor Michal
Minczuk (University of Cambridge) who collaborated with us for retinal characterisa-
tion. Atpresent, themicehavebeen shown tohave reducedbodymass, cardiomyopathy
and impaired mitochondrial translation. Highly proliferating tissues also bias against
high mutant heteroplasmy levels, indicating that heteroplasmy in the eye - with little
proliferation - could increase above other tissue types (Kauppila et al., 2016).
The mouse has also been used in experiments which have targeted and corrected
mutant mtDNA burden in vivo, with both mitochondrially targeted TALENs and ZFNs
shown to be effective at reducing heteroplasmy levels (Bacman et al., 2018; Gammage
et al., 2018b). Despite the newer technology of CRISPR becoming highly prevalent and
popularised, it is likely not an effective strategy for mtDNA gene therapy treatments
(Gammage et al., 2018a).
This project sought to determine methodology and further characterise the
m.5024C>T + m.13715C>T disease mouse to ascertain whether a phenotype of reti-
nal neuropathy could be identified and characterised. Given the variable heteroplasmy
in the mouse, and the known response to TALENs and ZFNs, the long term aimwas to
later ascertain whether gene therapy treatments could then alleviate any retinal neu-
ropathy by reducingmutantmitochondrial burdenwithin a retinal phenotype (Bacman
et al., 2018; Gammage et al., 2018b). LHONoften exists as a homoplasmic disease, how-
ever, there are cases with reduced heteroplasmy in affected individuals (Jacobi et al.,
2001; Krylova et al., 2020). As such, the variable heteroplasmy in the m.5024C>T +
m.13715C>T could be used to create a scale both for the initial mutational burden and
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Tables 4.1 and 4.2 describe the mice which were respectively used for validating het-
eroplasmy levels between different tissue regions and retinal characterisation.
The work was performed in collaboration with Professor Michal Minczuk (Univer-
sity of Cambridge) who kindly shared the mice, Doctor Payam Gammage (University
of Glasgow, formerly, University of Cambridge) and Beverly McCann (University of
Cambridge) who originally raised the mice and determined ear heteroplasmy levels,
alongside Doctor AndrewOsborne (University of Cambridge) who collected ERGmea-
surements (Figure 4.3) and retinal tissue.
Table 4.1: Details of quantified heteroplasmy mice.









WT1 0% Male 2 months
WT2 0% Male 2 months
WT3 0% Male 2 months
M1 81% Male 9 months
M2 80% Male 9 months
M3 51% Male 24 months
M4 72% Male 24 months
M5 68% Male 24 months
Eye Collection
Mice were culled and eyes were extracted by Doctor Andrew Osborne.
4.2.2 Mitochondrial Heteroplasmy Level
DNA Isolation
Eyes from mice described in Table 4.1 were freshly collected and further dissected by
Doctor Andrew Osborne, separating the retina and sclera of the left eye and leaving
the right eye as whole tissue.
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Table 4.3: ERG measurements of characterised mice (Table 4.2) and wildtype mice. Measurements are
average of both eyes taken through three biological time point triplicates for mutant mice and a single
time point of four individual mice for wildtype (WT). pSTR (max), b-wave (max) and a-wave (min)




















35.65 27.14 -4.55 -0.71 667.54 616.88 -493.59
M3 24
months
12.71 6.75 0.89 1.20 260.70 238.75 -234.35
M4 24
months
9.89 7.76 0.93 2.13 307.99 285.22 -203.57
M5 24
months
12.05 10.18 -0.46 1.54 194.59 173.81 -183.48
DNA was then extracted from each tissue type using DNeasy Blood & Tissue Kit
as per manufacturer’s protocol and DNA was quantified using 8-Sample Spectropho-
tometer NanoDrop.
Pyrosequencing
Four technical replicates of each sample were PCR amplified using PyroMark PCR Kit
(978703; QIAGEN) as per manufacturer’s protocol, using the PCR reaction composition
described in Table 4.4.
Table 4.4: PCR reaction composition for pyrosequencing where water produces a reaction volume of 20
µl for pyrosequencing and 25 µl for electrophoresis. Primer sequence identity shown in Appendix Table
S23.
Volume Component
12.5 µl PyroMark PCR Master Mix, 2x
2.5 µl CoralLoad Concentrate, 10x
1.5 µl 25 mMMgCl2
5 µl Q-Solution, 5x
0.5 µl 10 mM Forwards Primer
0.5 µl 10 mM Reverse Primer
x µl 25-50 ng DNA
x µl RNase-free water
A pyrosequencing protocol was created in PyroMark Q24 Software (9019062; QI-
AGEN) and samples were then prepared using PyroMark Q24 Vacuum Workstation
(9001516; QIAGEN) and quantified on a PyroMark Q24 (9001514; QIAGEN)), both as
per manufacturer’s protocol.
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Table 4.5: Pyrosequencing standard PCR thermocycling program.
Temperature Time
Initial Denaturation 95°C 15 min
Amplify
94°C 30 s
45 cycles60°C 30 s
72°C 30 s
Final Extension 70°C 10 min
Hold 4°C ∞
4.2.3 Eye Preparation
Eyes described in Table 4.2 were further treated within the animal facility, by Doctor
Andrew Osborne, by fixing the fresh eyes in 4% Paraformaldehyde (P6148; Sigma-
Aldrich) immediately following collection.
Eye Sections
24-48 hours post fixation at 4°C, the left eyes of the mice described in Table 4.2 were
transferred into 30% Sucrose (S0389; Sigma-Aldrich) in PBS overnight until the tis-
sue had sunk to the bottom of the 1.5 ml Microcentrifuge Eppendorf Safe-Lock Tube
(0030120086; Eppendorf). The eyes were then transferred into Embedding Capsule
(Flat Ended) (AGG3759; Agar Scientific) containing O.C.T. Compound (4583; Sakura
Europe) and carefully orientating the pupil to be perpendicular to the bottom of the
Embedding Capsule (Flat Ended) before snap freezing on dry ice. These were stored
at -20°C until cryosectioning.
Samples were sectioned on an OTF5000 Cryostat Microtome (Bright Instruments)
with a 3P Anti-Roll System CE, Glass 70 mm (14047742497; Leica Microsystems), tak-
ing 11 µm sections and collecting onto Microscope Slides (630-1985; Gerhard Menzel
GMBH) in a series of 6 slides, each containing a range of sections across the whole
eye. Samples were left to air dry for 4 hours before transferral into a -20°C freezer until
staining.
Samples were equilibrated to room temperature before staining. They were then
washed for 15 minutes, three times, in PBS on a Mini Orbital Shaker SO5 (Stuart
Scientific) at a slow speed before drying, demarcating the outer slide boundary with
a Microscope Slide Marking Pen (Magnacol) and applying 500 µl blocking buffer (2%
Bovine Serum Albumin (A0149; Sigma-Aldrich), 0.3% Triton and 5% Normal Goat
Serum (G9023; Sigma-Aldrich) in PBS). This was incubated on the orbital shaker for
one hour before the blocking buffer was replaced with the primary antibody.
One series of slideswere stainedwithMouseAnti-βIII TubulinmAb (G7121; Promega)
and another with Mouse mAb Anti Rhodopsin (1D4, C-Terminal) (kindly gifted from
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Professor Mike Cheetham (University College London), who received it as a gift from
Professor Robert Molday (University of British Columbia)) at a dilution of 1:500 for
Mouse Anti-βIII Tubulin mAb and 1:1000 for Mouse mAb Anti Rhodopsin (1D4, C-
Terminal), both in blocking buffer. 400 µl of the primary antibody solution was incu-
bated in the dark overnight at 4°C on the orbital shaker.
All subsequent steps proceeded whilst limiting light exposure to the slides. The
slideswerewashed three times, each for 15minutes on the orbital shaker and secondary
antibodies were prepared for both series of slides. Goat anti-Mouse IgG (H+L) Highly
Cross-Adsorbed Secondary Antibody, Alexa Fluor 555 (A-21424; Invitrogen) at a 1:500
dilution in blocking bufferwas prepared for both theMouseAnti-βIII TubulinmAb and
Mouse mAb Anti Rhodopsin (1D4, C-Terminal). Both secondary solutions also added
a 1:8000 dilution of DAPI Solution (1 mg/mL) (62248; Thermo Fisher Scientific) and
500 µl of each secondary antibody to the slides before incubating at room temperature
for two hours on the orbital shaker.
The slideswere thenwashed three times, each for 20minutes, with PBSon the orbital
shaker prior tomountingwith FluorSave Reagent (345789; MerckMillipore) and an SLS
Select Coverslips No 1, 24x50mm (MIC3234 ; Scientific Laboratory Supplies).
The prepared slides were then kept in darkness and dried overnight before storing
at 4°C until imaging.
Flat Mounts
2 hours post fixation at room temperature, the right eyes from the M3:M5 mice, as
described in Table 4.2 were transferred into 50 mm Single Vent Shallow (10mm) Petri
Dish (SC266; Sterilin) filed with PBS. The cornea was punctured using a Hypodermic
Needle 27G (0.4 x 20 mm) (Terumo) and the retina was dissected out using Dumont #5
Forceps Biologie Dumostar (11295-10; InterFocus) and Vannas Spring Scissors, Straight
3mm Cutting Edge (15000-00; InterFocus). Cuts were made from the edge of the retina
towards optic nerve head, located in the centre of the mouse retina, to form the ’petals’
of the flattened tissue. This was then placed onto a Membrane Filter, 0.8 µm pore
size, gridded (AABG01300; MF-Millipore™) and the filter was placed into a Nunc
Cell-Culture Treated Multidish (142475; Thermo Fisher Scientific) with 500 µl of PBS.
Retinas were stored at 4°C until staining.
For staining, retinas were equilibrated to room temperature and washed twice, for
10 minutes, in 250 µl PBS with 0.5% Triton and placed on a slowmoving orbital shaker.
Retinas were permeated by freezing for 10 minutes at -70°C in 350 µl PBS with 0.5%
Triton. Care was taken to ensure that the entire retina was submerged prior to freezing.
This is vital for staining nuclear proteins.
The retinas were quickly thawed at room temperature by adding 500 µl PBS with
0.5% Triton and slowly shook until they finished thawing. They were washed twice for
an additional 10 minutes in 250 µl PBS with 0.5% Triton on the orbital shaker.
139
Retinas were blocked in 500 µl Blocking Buffer (2% BSA, 2% Triton and 10%Normal
Donkey Serum (D9663; Sigma-Aldrich) in PBS) for 1 hour on the orbital shaker before
incubating in the primary antibody within darkness. A 1:300 dilution of Goat Brn-3a
Antibody (C-20) (sc-31984; Santa Cruz Biotechnology) in Blocking Buffer was used for
2 hours on the orbital shaker at room temperature before shaking overnight at 4°C.
During all subsequent stages, care was taken to minimise sample light exposure.
The next morning, retinas were rinsed for 5 minutes in 1 ml PBS with 2% Triton
and a further three 30 minute washes took place using 1 ml PBS with 0.5% Triton, all at
room temperature on the slow orbital shaker.
A 1:500 dilution of Donkey anti-Goat IgG (H+L) Cross-Adsorbed Secondary Anti-
body, Alexa Fluor 555 (A-21432; Invitrogen) secondary antibody in PBS with 2% Triton
was added before incubating for two hours on the orbital shaker. They were then
washed three times for 30 minutes in 1 ml PBS on the orbital shaker. For the final 30
minute wash, a 1:10,000 dilution of DAPI Solution (1 mg/mL) was added.
The retinas were carefully transferred, RGC layer upwards, onto a microscope slide.
A fine paint brushwas used to smooth the tissue and a Kimwipes Delicate TaskWipers,
1-Ply (06-666; Kimberly-Clark Professional) was used to blot excess liquid. FluorSave
Reagent was carefully added and an SLS Select Coverslips No 1, 24x50mm placed on
top, taking care to prevent bubbles and air dried overnight.
The prepared slides were then kept in darkness and stored at 4°C until imaging.
4.2.4 Quantification
Sections
Sections were imaged using a Zeiss LSM 880 AxioObserver confocal microscope (Carl
ZeissMicroImaging) equippedwith aNikonPlan-Apochromat 63x/1.4 numerical aper-
ture oil immersionobjective, averagingfluoresence across two image replicates. A range
of tile scans, with 15% image over lap, Z-stacks, with 0.95 µm steps through the section,
and tiled Z-stacks were taken.
CZI files were imported into ZEN 2.6 18299.3 (blue edition) (Carl Zeiss Microscopy
GmbH), stitched as necessary, and best fit channel scalingwas applied. Each individual
channel was then exported as uncompressed TIFF file format.
TIFF files were imported into Fĳi (ImageJ 1.52i) (Schindelin et al., 2012) and a maxi-
mum projection was performed on stacks for RGC counting and length measurements.
ONL and INL cells were quantified from a single stack slice. Cells were converted
to a binary mask following signal multiplication, Gaussian blurring - to remove noise
- raising contrast and multiplying again. ONL and INL were auto thresholded via
"default white" and "triangle white" methods respectively with a further Gaussian blur
and image contrasting.
The binary mask was opened (eroded then dilated), cell holes were filled and a
watershedwas applied to separate any conjoined cells. Within the 11 µm section, RGCs
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existed in a monolayer, so the length in which the cells were counted was measured.
ONL and INL cells were dense and a region was highlighted, measured and the cells
within the region counted by analysing particles larger than 50 or 150 pixel units for
ONL and INL respectively.
Retinal cell layers’ length was also measured in Fĳi, using the maximal projection of
Rhodopsin stained sections to measure the PRs, ONL and OPL. Tubulin stained slides’
maximum projections were used to measure the INL, IPL and RGC layer.
All quantification steps were performed blinded to the sample identity as control
or mutant.
Whole Mounts
Whole mounts were imaged on a Dragonfly Spinning Disk Imaging System (Andor
Technologies Ltd.) comprised of a Nikon Ti-E microscope, Nikon Plan-Apochromat
40×/1.3 numerical aperture oil immersion objective and an Andor iXon EMCCD Cam-
era. Z-stacks were taken at 0.12 µm steps across the depth of the tissue, ~500 steps and
a staged montage was taken across the width and length of the tissue in a grid with
10% overlap between tiles, using Fusion Version 1.5.0.7 (Andor Technology Ltd.).
Imageswere initially reviewed in Imaris Bitplane 9.1.2 to stitch the tiles and quantify
RGC counts.
Individual tiles were imported into Fĳi (ImageJ 1.52i) (Schindelin et al., 2012) via
the Bio-Formats Importer and a maximum intensity projection was performed across
the Z-stacks on the Brn3-a channel. The individual tiles were then stitched together in
a grid, using a 10% overlap and fusion by linear blending with a regression threshold
of 0.15, maximum/average displacement threshold of 2.5 and absolute displacement
threshold of 3.5 (Preibisch et al., 2009). Following stitching, the images were converted
to binary masks and holes within the cells were filled. Images were cleaned by per-
forming a binary opening to remove isolated pixel noise and smooth the cell edges.
A watershed transformation was then used to create cell boundaries for cells which
appeared conjoined within the binary image. Particles larger than 100 pixel units were
then measured and analysed.
Total tissue cell counts were calculated, then a 1000x1000 pixel section was taken
in quadruplicate for points close to the optic nerve head, the outside edge of the
retina and the centre of the tissue, with care taken to avoid obvious venous routes and
secondary artefacts in the tissue structure. Cells were again quantified in this region
and the length across the entire flattened retina and optic nerve head were measured
in technical quadruplicate.




4.3.1 Mitochondrial Heteroplasmy Level
Table 4.6: m.5024C>T heteroplasmy levels of quantified heteroplasmic mice cohort in ear clippings,









S1 66% 66% 66% 66%
S2 56% 56% 56% 55%
S3 59% 62% 64% 64%
S4 63% 66% 65% 65%
Mitochondrial heteroplasmy level was compared between the ear and eye, with
further tissue stratification into whole eye, retina and sclera. As shown in Table 4.6,




As shown in Figure 4.1, staining patterns allowed for clear demarcation of retinal
layers. Methods for quantifying cell counts are shown in Figures 4.2, 4.3 and 4.4 for
ONL, INL and RGC layers respectively. Methodology allowed for clear demarcation
and identification of cells without human bias within the counting process.
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Figure 4.1: Measuring lengths of (A) PR layer, ONL and OPL, and (B) INL, IPL and RGC layer, in cells stained against Rhodopsin (1D4, C-Terminal) (red) and
DAPI (blue). Lines were drawn parallel to each layer and the length was measured perpendicularly to the line with triplicate measurements.
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Figure 4.2: Validation of ONL cell quantification in a single stack slice; original image (A), binary
mask after processing image B, mapping counted cells of binary mask back onto original image (C).
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Figure 4.3: Validation of INL cell quantification in a single stack slice; original image (A), binary mask
after processing image B, mapping counted cells of binary mask back onto original image (C).
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Figure 4.4: Validation of RGC cell quantification in a single stack slice; original image (A), binary mask
after processing image B, mapping counted cells of binary mask back onto original image (C).
146
Tissue Morphology
Tissue cross-sectionswere shown aswhole eye tile scans in Figures 4.5 and 4.6. Selected
regions from Z-stack tile scans are then magnified in Figures 4.7- 4.14.
Tissue morphology in wildtype samples (Figures 4.7, 4.8 and 4.9) were highly or-
dered with good separation between retinal layers.
Samples M1 and M2 (Figures 4.10 and 4.11) had several small spaces which appear
within the ONL and INL.
Sample M3 (Figure 4.12) was visibly more tortured across the whole eye and there
were a number of spaces in the ONL and INL.
Sample M4 (Figure 4.13) was visibly ragged across the whole eye and with lots of
spaces in the ONL and INL.
Sample M5 (Figure 4.13) was openly vacuous with spaces, variability is the size of
the layers and cell types transitioning between layers with less clear layer boundaries.
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Figure 4.5: Whole eye sectioned tile scan, stained against Rhodopsin (1D4, C-Terminal) (red) and
DAPI (blue). Red staining indicates the PR layer, with all cell nuclei stained by DAPI; gross
morphology of tissue structure shown.
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Figure 4.6: Whole eye sectioned tile scan, stained against Tubulin (βIII) (red) and DAPI (blue). Red
staining indicates the RGC layer, with all cell nuclei stained by DAPI; gross morphology of tissue
structure shown.
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Figure 4.7: WT1 retinal section stained against Rhodopsin (1D4, C-Terminal) (red)and DAPI (blue)
(A) and Tubulin (βIII) (red) and DAPI (blue) (B).
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Figure 4.8: WT2 retinal section stained against Rhodopsin (1D4, C-Terminal) (red)and DAPI (blue)
(A) and Tubulin (βIII) (red) and DAPI (blue) (B).
151
Figure 4.9: WT3 retinal section stained against Rhodopsin (1D4, C-Terminal) (red)and DAPI (blue)
(A) and Tubulin (βIII) (red) and DAPI (blue) (B).
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Figure 4.10: M1 retinal section stained against Rhodopsin (1D4, C-Terminal) (red)and DAPI (blue)
(A) and Tubulin (βIII) (red) and DAPI (blue) (B).
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Figure 4.11: M2 retinal section stained against Rhodopsin (1D4, C-Terminal) (red)and DAPI (blue)
(A) and Tubulin (βIII) (red) and DAPI (blue) (B).
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Figure 4.12: M3 retinal section stained against Rhodopsin (1D4, C-Terminal) (red)and DAPI (blue)
(A) and Tubulin (βIII) (red) and DAPI (blue) (B).
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Figure 4.13: M4 retinal section stained against Rhodopsin (1D4, C-Terminal) (red)and DAPI (blue)
(A) and Tubulin (βIII) (red) and DAPI (blue) (B).
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Figure 4.14: M5 retinal section stained against Rhodopsin (1D4, C-Terminal) (red)and DAPI (blue)
(A) and Tubulin (βIII) (red) and DAPI (blue) (B).
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Quantification
Figure 4.15: Measurements of retinal sections layer length in wildtype and individual heteroplasmic mice eye samples (A), then respective cell spacing area for the INL
and ONL (B) and length for cell spacing in the RGC layer (C).
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Figure 4.16: Measurements of retinal sections layer length in wildtype and grouped heteroplasmic mice
eye samples (A), then respective cell spacing area for the INL and ONL (B) and length for cell spacing in
the RGC layer (C).
Measurements of each retinal layer from mice described in Table 4.2 were taken as
shown in Figures 4.15 and 4.16 (A) and significance is shown in Table S24. The area
that a single cell occupies was also measured for the INL and ONL (B). The length that
a cell occupied was then measured for the RGC layer (C) and significance is shown in
Table S25.
There is no significant difference in the length of the PR layer in any sample, however,
ONL lengths are significantly different in samples M1, M4 and M5 (respectively p =
0.020, 0.046 and 0.042).
OPL and IPL length is significantly reduced in samplesM2,M4 andM5 (respectively
OPL p = 0.005, 0.007 and 0.001; IPL p = 0.003, 0.003 and 1.96e-04); OPL and IPL lengths
are significantly different in heteroplasmic samples as a whole (p = 0.008 and 0.028
respectively).
M4 INL length is significantly increased fromwildtype (p = 0.009) and bothM4 and
M5 are reduced in RGC layer (respectively p = 0.025 and 0.008).
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There is no significant difference in the length of which a single cell occupies in
the RGC layer between heteroplasmic samples and wildtype. The area in which cells
occupy in theONLand INL, however, are significantly increased in samplesM4,M5and
comparing heteroplasmic samples to wildtype (respectively, ONL p = 0.041 and 0.025;
INL p = 3.51e-06 and 0.015); M3 ONL is also significantly increased to the wildtype
controls (p = 0.042). Overall, both ONL and INL cell area is significantly increased (p




As seen in Figure 4.17, the Imaris Bitplane software did not successfully stitch the
individual tiles in the correct layout. It did successfully group the whole mount tiles
together, however, the outer boundary is clearly disordered and the venous internal
structure is disjointed.
Imaris Bitplane then selected regions of interest to quantify as shown in Figure 4.18
and an increased magnification of a region in Figure 4.19. Figure 4.19 shows that the
detected cells are not representative of the positioning or count of the real cells.
Figure 4.20 shows Fĳi stitching the tiles together and subsequent conversion to a
binary mask, following processing methodology. Outer flat mount boundary appears
precisely ordered and inner venous structure is continuous, indicating that both inner
and outer tiles are correctly stitched and that the binarymask is a good representation of
the original tissue. Figure 4.21 shows a magnification of the binary mask cell detection
and the cell counting appears to be more accurate than the regions quantified in Imaris
Bitplane.
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Figure 4.17: Imaris Bitplane software stitching together the individual tiles from whole mount tissue.
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Figure 4.18: Imaris Bitplane software assigning spots to detected cells.
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Figure 4.19: A magnification of a selected region of interest showing the real cells and cells detected by
Imaris.
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Figure 4.20: Fĳi stitching whole mount tiles into one image (A) and conversion to a binary mark (B).
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Figure 4.21: A magnification of the binary mask created in Fĳi after optimising and counting cells.
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Flat Mount Morphology
Figures 4.22, 4.23 and 4.24 show the final binary masks which were analysed for each
of the tissues, including tissue macro structure.
Figure 4.22: Final image for the M3 flat mount.
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Figure 4.23: Final image for the M4 flat mount.
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Figure 4.24: Final image for the M5 flat mount.
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Quantification
No comparatively healthy tissues were collected in this manner so no quantitative
statistical tests can be undertaken for this aspect of the project. Qualitative analysis will
be discussed in Section 4.4.3.
170
Figure 4.25: Quantified measurements of whole mounts by showing total RGC count (A), the total area
within the tissue covered by RGCs (B), average area (size) of RGCs within the tissue, error bars
represent standard error of mean across each cell (C). Looking at quadruplicate regions cocircular to the
optic nerve head in positions close to the optic nerve head (Central), close to the edge of the tissue (Edge)
and between the two positions (Mid), the average number of cells within a within a 1000x1000 pixel
region (105,625 µm2) (D), average area (size) of RGCs in the sampled area by region (E); error bars
represent standard error of mean across quadruplicate measures of the tissue in different samples.
Average retinal diameter (F) and average optic nerve head diameter (G); error bars represent standard
error of mean across quadruplicate measurements of the tissue through differing orientations.
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4.4 DISCUSSION
4.4.1 Mitochondrial Heteroplasmy Level
It was important to determine the heteroplasmy levels across the eyes of the mouse as
tissue preparation methods for microscopy work does not normally produce leftover
retinal tissue and the preparation methods make the sample unsuitable for subsequent
DNA sequencing.
As the heteroplasmic bottleneck occurs immediately following creation of the egg
cell and each time a cell divides, splitting the mitochondrial population into different
cells, cells of a different embryonic origin aremore likely to have differing heteroplasmy
levels than those which arose from a more recent cell division event. As such, the eyes
were separated into retinal and sclera, as they are of different embryonic developmen-
tal origin, namely, the anterior neural plate and periocular mesenchyme respectively
(Heavner and Pevny, 2012; Kanakubo et al., 2006).
The outer ear clipping, arising from the second arch neural crest in mice (Anthwal
and Thompson, 2016), is further developmentally distinct, and depending upon the
variability of mtDNA heteroplasmy across the differing samples, it could affect the
suitability of an ear clipping as a measure of retinal heteroplasmy.
As Table 4.6 shows, there is little difference in heteroplasmy levels across any of the
sampled regions, disregarding the minor variation which could inherently occur by
technical error and the sequencing methodology accuracy.
This means that ear clipping heteroplasmy measurements are an appropriate mea-
sure of heteroplasmy in the eye. This was particularly relevant for the m.5024C>T +
m.13715C>Tmouse as it has been shown tohave variable heteroplasmy levels (Kauppila
et al., 2016).
4.4.2 Sections
Cell quantification andmeasurements were takenwhilst blinded to the sample identity
so no human bias could occur from knowledge of sample mutational load. Further,
cell counting was undertaken by an automated process which identified and counted
the cells without further human input beyond highlighting the appropriate region of
interest for each retinal layer. The described methodologies appear to be an effective
and efficient manner of retinal cell quantification and size quantification.
Results indicate that the m.5024C>T + m.13715C>T mouse could have a cellular
ocular phenotypewith the tissuemorphology particularly disrupted in theM3,M4 and
M5heteroplasmicmice, of 51%, 72%and 68%heteroplasmy respectively. Unexpectedly,
M1 and M2, at 81% and 80% heteroplasmic burden, did not have such an obvious
cellular impairment and in all regions they appeared to have a better cellular structure
than the other mutant samples.
More contradictorily, the cellular response of M1 and M2 appeared to often act in
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an inverse direction of M3, M4 and M5 when comparing against controls as baseline
measurements. The most severe retinal defects appeared to be tortuosity of the retinal
tissue and gaping holes within the INL and particularly within the ONL. Unlike LHON
which preferentially affects RGCs (Sadun et al., 2000; Ventura et al., 2005; Yu-Wai-Man
et al., 2009), the m.5024C>T +m.13715C>Tmouse does not appear to have a significant
effect on RGCs’ morphology, spacing or quantity. Similarly, the PR layer is not affected
in size whilst LHON has been shown to affect colour perception (Yu-Wai-Man et al.,
2009).
M3:M5 have wider retinal layers, as seen in Figure 4.15 (A), particularly in the ONL
and INL, which could arise as a result of the m.5024C>T + m.13715C>T mutations.
Further, they have many vacuous spaces and a lower cell density, as seen in Figure 4.15
(B). M1 and M2 did not have such severe vacuity, as seen within Figure 4.15, however,
M1 did have a significant reduction of the INL and OPL length and significantly more
dense cells within the ONL; M2 also had a reduction of the IPL.
M3:M5 increase in size whilst reducing cellular density whereas M1 and M2 some-
times exhibited increased cell density and reduced layer size. M1 and M2 arise from
much younger mice (9 months) whilst M3:M5 are over twice the age (24 months) and
this could have affected expression as either a natural occurrence in elderly mice or
that the m.5024C>T + m.13715C>T mouse optic phenotype is only exhibited in elderly
mice, much like age-related macular degeneration.
ERGmeasurements were only collected in mice M3:M5, however, as shown in Table
4.3, mice do exhibit significant visual reduction when compared to wildtype mice in
both RGC, bipolar and PR response measurements.
4.4.3 Flat Mounts
Present methodology often takes a number of confocal microscope images to quantify
RGC density across whole mounts (Osborne et al., 2018), however, on a 40x magni-
fication, it is difficult to ascertain the exact microscope positioning in the tissue as
switching between 40x and a lower magnification requires the addition or removal of
oil and cleaning of the microscope, losing tissue positioning.
As such, this project sought to devise methodology whereby the whole retina RGC
count and distribution could be identified.
Staining of RGCs occurred as previously described (Osborne et al., 2018), however,
rather than single plane microscope images in selected regions, Z-stacks were taken
across the entirety of the tissue.
Some difficulty was observed in this, with M3 appearing to have a region which
was deeper than the Z-stack depth meaning that the total RGC cell count was likely
inaccurate. M4 also could have possibly underestimated cell counts by cropping an
outer edge of the tissue, however, despite this, the tissue can be clearly observed.
Initial analysis used proprietary Imaris Bitplane 9.1.2 software which came bundled
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with the Dragonfly Spinning Disk Imaging System microscope, however, both the
stitching and cell detectionquality appeared to be extremelypoor, as seen inFigures 4.17
and 4.19. In addition to this, the final tile scan was 80 GB in file size and computational
processing was met with difficulty.
As such, new methodologies were applied using Fĳi (ImageJ 1.52i) (Schindelin
et al., 2012). Tiles were first stitched together in 3D before a maximal projection was
applied to compress the file size. As seen in live tissue, and Figures 4.18:4.24, RGCs
exist in a monolayer which means that reducing the vertical dimension minimised loss
of information. It did lose the 3D structure which was available in Imaris Bitplane,
however, the tissue is already a flat mounted representation of the natural cup-like
structure and this reduction allowed functional analysis to continue. Further, the
improved cell counting methodology would allow for more accurate counting of the
cell counts.
It is possible that the cell counting in single confocal images could be as accurate,
however, it does not have the entire tissue view, or definitive positioning of tiles to
count in. The RGCs positioning leaves spaces for the circulatory system and tissue can
be damaged in collection, resulting in a number of spaces which would create artefacts
for the analysis.
Due to the extensive time on the microscope, the tissue was at risk of photobleach-
ing and subsequent imaging would not be as effective. For further work, it would be
recommended to increase the Goat Brn-3a Antibody (C-20) concentration as original
staining was not excessively bright or saturating the microscope’s detection limit. This
increased brightness could help remove the apparent fracturing of some cells in Figure
4.21 or a further image processing step of Gaussian blur and reduction of the pixel
threshold for cell detection could be applied. The present methodology could under-
estimate cells, however, it is automated and unbiased across the tissue so all samples
would be equally affected.
Due to limited time and sample availability, only samples M3, M4 and M5 were
analysed in this manner and nowildtypes were observed tomeasure a baseline against.
Despite this,M3 appears to have fewerRGCs than bothM4 andM5; whilst the total RGC
count couldbe anartefact of the reducedZ-dimensionality, Figure 4.25 (E), indicates that
this reduction occurred in both the central and edge of the tissue selected regions. No
regions were selected within the reduced Z-dimension region of M3. RGCs appeared
to also be smaller in M3 than M4 and M5; this could be indicative of different sub-
populations of RGCs, such as midget cells being more prevalent, however that was not
guaranteed by the limited staining.
Mice retinas have previously been estimated to have ~70,000 RGCs (Dräger and
Olsen, 1981), which is much greater than the total RGC counts in the heteroplasmic
samples (Figure 4.25 (A)), however, the staining methodology affects total RGC count
numbers; Brn3a was used as a marker of total retinal RGC count, however, Brn3a is
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expressed in theRGCsof theprincipal retinothalamic/retinocollicular pathwaymediat-
ing cortical vision but not the RGCs which serve subcortical visuomotor and circadian
functions (Quina et al., 2005). As such, it is likely an under-representation of total
retinal RGC count, but a more accurate representation of the effect of RGC in vision.
However, 85% of mouse retinal RGCs are believed to express Brn3a (Rodriguez et al.,
2014) so it still seems that the total RGC count is greatly reduced in the heteroplasmic
mice (~32,000 RGC in the most RGC populous retina after factoring that 15% would be
undetected by Brn3a staining) compared to the ~70,000 RGCs counted by Dräger and
Olsen (1981). Hedberg-Buenz et al. (2016) predicted ~55,000 RGCs per normal mouse
retina with an estimated ~16,000 RGCs in 16-month-old DBA/2J mice with glaucoma;
the heteroplasmic mice did not have such a significant reduction to total healthy RGC
counts, however, they definitely have fewer RGCs than healthy mice retinas. However,
there is variation in cell counts of the GCL between different mouse strains (Chen et al.,
2016).
The whole eyeball appeared to be of a similar size in all samples and it is difficult to
ascertain whether there was a difference in the size of the optic nerve head; the optic
nerve head was an ovaloid shape rather than circular, resulting in a large variability of
the measurements.
Despite the limited sample numbers, this appears to be an excellent methodology
for RGC counting and identification. Further samples, particularly of wildtypes, could
additionally validate this strategy for cell counting.
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Chapter 5 | Evaluation
5.1 LHON DISEASE PENETRANCE
This study further updated the penetrance of LHONon a range of different populations
and discovered that the LHON primary mitochondrial mutation and mother’s disease
status has a high significance in determining LHON penetrance. Further, whilst dif-
ferent mitochondrial mutations do have different penetrances, our cohort found that
overall penetrance in females is closer to ~20% rather than the previously estimated
~10% (Yu-Wai-Man et al., 2003, 2009). Penetrance has likely shifted given the improve-
ment in genetic diagnostic techniques and expansionof pedigrees to limit ascertainment
bias.
This further compounds that different mitochondrial mutations can be more severe
than others (Zhuo et al., 2012), with a higher penetrance in the m.3460G>A mutation
than the other variants which were observed in multiple families. It indicates that it is
further possible that different mtDNA and nDNA variants work in an additive model
to cause LHON disease onset (Caporali et al., 2018).
It would be interesting to further inspect this data for mitochondrial haplogroups
and ascertain whether it associates with primary LHON mutation, m.14484T>C is
particularly associated with an mtDNA founder effect in regions like French-Canada
(Howell et al., 2003; Macmillan et al., 2000b). Similarly m.11778G>A is associated with
East Asian founder events (Sudoyo et al., 2002). While no families of East Asian descent
were included within our cohort, the addition of pedigrees which are genetically more
distant would allow for a greater understanding of which variants control LHON
disease onset by alleles being identical by state within both cohorts. Prising apart the
significance of LHON primary mutation, nDNA background and haplogroup could
provide further evidence for new hypothesised genes which affect penetrance.
Haplogroup data is not presently available for several of the families in this study
and few samples have had nDNA characterised, so this was not possible within the
present study. DNA samples, however, are available for many of the patients so this
could be a beneficial future study to inspect both nDNA for genetic and epigenetic
modifications which affect LHON disease expression.
As we identified that mother’s disease status is highly significant in predicting
LHONdisease onset, it is possible that furthermtDNAandnDNAvariants are inherited
from the mother either on a genetic or epigenetic level as a result of being raised in a
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similar environment to the mother. As Biobanks expand and multigenerational DNA
samples become available, additional work which focuses on identifying alleles which
are identical by descent in affected mothers and offspring could map to genes which
explain the missing heritability in LHON.
We further investigated the statistical likelihood of an X-linked modifier gene mod-
erating LHON disease onset, as regularly previously hypothesised (Chen and Denton,
1991; Hudson et al., 2005; Phasukkĳwatana et al., 2010; Qu et al., 2010; Shankar et al.,
2008; Vilkki et al., 1991), by following the Bu and Rotter (1991) methodology. Similar
to Bu and Rotter (1991), we found it statistically significant that males in our cohort
developed LHON depending upon their inheritance of a mutant X-linked allele. The
penetrance and probability that a female will be affected was also similar between
studies (0.176 to Bu and Rotter’s (1991) 0.111 measurement).
Our cohort, however, had a much higher proportion of affected females (0.230
compared to 0.093) and the frequency of the hypothetical X-linked allele was much
more common (0.283 to 0.076). We find our value for the hypothetical gene frequency
to be far more likely than the original measurement as at a gene frequency of 0.076; we
would expect LHON penetrance to greatly reduce in generations following a LHON
patient as it is quite likely that the mutant X-linked allele would not be transmitted
multiple generations and that the father would likely contribute a healthy X allele
every time a daughter is born. The pedigree penetrance indicates that this is not the
case as we often see LHON onset in multiple subsequent generations, and an X-linked
gene of 28.3% population frequency could potentially be inherited from either parent.
In addition to this, a number of issues in the original studymethodology were iden-
tified and confirmedwith thanks byDoctors JoannaHowson (University of Cambridge)
and Ian Wilson (Newcastle University). This included their ascertainment bias correc-
tion, Chi-Squared test formula (different between pooled and individual male sibships
with one doubling the standard Chi-Squared test formula to make a four-tailed test)
and their goodness-of-fit test defining the null hypothesis to be that male LHON onset
to be dependent upon their inheritance of the mutant X-linked allele whilst this would
often be the alternate hypothesis given that an X-linked model has not previously
been robustly confirmed. Additionally, it assumes that all mitochondrial mutations
are of an equivalent burden and that X-inactivation is random, however, abnormal X
chromosomes are preferentially silenced (Shvetsova et al., 2019).
We are confident in the replication, however, statistical methods have developed in
the last 20 years andwewould like to pursue further analysis of our cohort using amore
robust, modern methodology which could allow for more confidence in the modelling
process. We would also like to further investigate the stratification by mutation type
instead of country of collection as our evidence suggests that the specific mutation has
a greater impact on the penetrance of LHON than where the pedigree was collected.
Further, we would like to further investigate how haplogroup background affects pen-
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etrance after stratifying by the specific LHON mutation as additive models of LHON
disease onset may arise by specific combinations, as evidenced by specific haplogroups
having a greater impact on LHON disease onset by specific mutation types (Carelli
et al., 2006; Hudson et al., 2007; Kaewsutthi et al., 2011).
Identification of LHON nDNA variants identified a number of novel hypothetical
modifier genes which are over-represented in a range of pathways when compared to
the expected proportion of each gene set to be returned, given the submitted gene list
count. Interestingly, comparing against MSigDB’s C2 curated gene sets of chemical and
genetic perturbations the gene sets returned were related to cell survival, and a gene
set which becomes hypermethylated in breast progenitor cells when pre-exposed to
estradiol (which targets ERB) (Cheng et al., 2008), linking to the investigation of ERB as
a target in LHON treatment (Giordano et al., 2011; Pisano et al., 2015).
Further gene sets included neurogenesis, cell signalling, oxidative stress, and cell
death when comparing against MSigDB’s C5 GO gene sets of biological processes.
Given that there are 7,350 potential gene sets which could be returned through this
analysis, the returned 26 gene set pathways appear to be quite similar and relevant
to LHON disease onset as a disease which affects RGCs through a Complex I defect,
or OXPHOS deficiency. Neurogenesis was also further confirmed by PANTHER’s
OverrepresentationTest, indicating that the identifiedgenes are relevant to neurological
pathways.
Somedifficultiesweremet through this investigation forpower constraints as Section
2.3.3 only had 1 unaffectedmale sample after QC, limiting the tests which could be used
to analyse the data. With only one male and 7 unaffected females, testing for disease
status in the whole data set would more readily detect the great difference between
methylation of the X chromosome between male and female samples. Additionally,
there was difficulty in obtaining clinical data so information about patients’ smoking
habits were not always available despite the significance that it had on methylation
patterns.
Further, BeadChips were initially prepared in 2010 and samples were not ran-
domised when plated, meaning that all families and similarly, primary LHON muta-
tion, were clustered together on the chips. This meant that including Family, Mutation
or Batch as a covariate normalised the effects of all three. The three BeadChips were
measured on the same day, on the same machine but another plate was measured
between the first and second BeadChip and looking at control probes a batch effect is
definitely observable (data not included). Following this, there is a great variability in
pipelines used to process BeadChips; the HumanMethylation27 BeadChip is the sec-
ond generation chip and themajority of papers and packages available on Bioconductor
(Huber et al., 2015) deal with the 450k array and quality control steps are now much
more rigorous than that which was initially used with the 27k array. Further, most
packages are not compatible with the 27k array so additional steps were necessary to
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improve the data quality, however some, such as normalising sample methylation to
methylation patterns of blood cell counts or predicted blood cell counts (Houseman
et al., 2012) were not possible.
As such, to compensate for this low power, candidate differential methylation re-
gression analysis looked at genes which appeared significantly methylated regardless
of the covariates included in the model as no methylation appeared significant in any
singular linear model following Benjamini–Hochberg correction for multiple testing.
Exome analysis was also limited by investigation of only three unaffected carrier
samples, compared to the 25 affected samples, which resulted in 3,833 genes being
returned as containing unique variants which were exclusively present in cases or
unaffected carriers.
Despite this, the cross-matching of the two analyses returned 29 hypermethylated
and 17 hypomethylated genes which contained unique variants between the LHON
patients and carriers that could be either causative or protective and downstream
pathway analysis predominantly returns gene sets which appear highly relevant to
LHON. Given the number of potential gene sets screened, if the discovered genes
occurred by chance, wewould also expect to see less logical gene set pathways returned
by chance but they mostly appear relevant. Further investigation into the variants
would need to be undertaken for confirmation, however, they are an optimistic starting
point, given the lack of success in other genetic screenings. Specifically investigating
gene function, multiple genes were directly known to cause retinal defects and further
genes impaired both mitochondrial and neuronal function, indicating that these genes
do seem to specifically affect mechanisms which are known to be involved in LHON.
We would like to validate our findings by investigating these genes for differential
variants and methylation patterns between LHON patients and an unaffected sibling
of the same sex, tomatch for nuclear background, haplogroup andmethylation patterns
which are caused by age and sex. Our candidate gene list is a novel finding for the
LHON research field and if validated, it could be a breakthrough in understanding
LHON disease onset.
In addition to this, we did some preliminary work investigating methylation pat-
terns of the mtDNA which successfully isolated high purity mtDNA without nuclear
contamination and bisulphite converted the samples. Unfortunately, this method had a
very low yield and samples failed NGSeq due to low sample concentration. Following
the success in investigating nDNAmethylation for potential LHONmodifier genes, we
would suggest that further investigation of mtDNA methylation as a factor in LHON
penetrance as an additivemodel should be performed (Caporali et al., 2018). Our exper-
imental design was successful in preparing high quality yields of pure mtDNA isolates
but found difficulty in preparing large yield volumes. We would recommend sequenc-
ing higher concentrations of sample and ensuring all stages after DNA extraction are
performed in laminar flow hood to prevent external mtDNA contamination.
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5.2 FUNCTIONAL CHARACTERISATION OF LHON FIBROBLASTS
Many different cellular pathways were characterised within this project. The most
useful of which is likely the qPCR work which identifies a novel qPCR methodology
for quantifying mitochondrial copy number within LHON fibroblasts. This removes
the bias from previously described methods which mostly use aMT-ND1 probe which
overlays the LHONprimarymutation, m.3460G>A, (Grady et al., 2014; Pyle et al., 2016).
Additionally, B2M primers were optimised, showing a much greater affinity and
sensitivity in quantifying the nDNA copy number.
Our new assay can be used to quantify mtDNA copy number in all of the common
LHONdisease causing variants without under representing any of themutationswhen
compared to each other.
Beyond the preliminary review of LHON asymptomatic carrier’s copy number in
Figure S9 and specifically the A4-11778 cell line’s copy number, there was no significant
difference between cases and controls.
A4-11778was also found to be particularly affected by deoxyglucose, indicating that
it favours ATP production through glycolysis rather than OXPHOS when compared to
the ratio in other cell lines. It also has a significant reduction of Manders’ coefficient
M1, indicating that most of the ER did not make contact with the mitochondrial net-
work. This could be a result of the decreased size of the mitochondrial network in
A4-11778, which was found to have reduced average and maximum mitochondrial
network volumes despite the overall increase in mtDNA copy number. A1-11778 had
a similar reduction in average and maximummitochondrial network volumes without
the increased mtDNA copy number or M1 or M2 measurements.
A5-3460 shows significantly increasedM2 value, mitochondrial network length and
reduced mitochondrial network fragments alongside an upregulated maximal calcium
uptake. Despite these changes, there is no difference in the ER-mitochondrial interac-
tions orΔΨm, suggesting that increased mitochondrial fusion occurs independently of
ER or Ca2+ signalling and ΔΨm.
ΔΨm was not found to be any different between cases and controls and there was
limited importance of ATP generation.
A2-14484 exhibits a significant increase in Manders’ coefficient M2 but is otherwise
indistinguishable from control cell lines. However, M2 values as a whole are increased
in LHON samples, indicating that LHON increases mitochondria-ER interactions.
The most dramatic responses were seen in LHON cellular oxygen consumption,
with greatly reduced basal respiration, ATP production, maximal respiration and spare
respiratory capacity in cell lines A1-11778, A4-11778 andA5-3460. For them.11778G>A
mutant group, basal respiration and ATP production remained significantly reduced
but A3-11778 maximal respiration and spare respiratory capacity was not impacted by
LHON. Non-mitochondrial respiration was also significantly reduced in A5-3460.
As a whole, the greatest LHON phenotype was seen in cell lines A4-11778 and A5-
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3460. A2-14484 had a very mild phenotype, which matches the favourable prognosis
for this mutation in patients (Riordan-Eva et al., 1995).
Patient blood samples indicated that they were homoplasmic for the LHON mu-
tation, as such, they should not have been affected by differing heteroplasmy levels
between biological replicates - improving the quality of the results.
Due to limited study scope and singular cell lines for both the m.3460G>A and
m.14484T>C mutations, it is impossible to determine whether any significant differ-
ences are cell line specific or a particular feature of that mutation.
The cell lines were also fibroblasts, which are asymptomatic to the LHONmutation
within affected LHON patient phenotypes, rather than the more sensitive neurological
cell types. It is possible that furtherwork could be done in iPSCswhichwould show this
neuronal sensitivity to LHONmutations. Three LHON iPSCmodels are now available
(Bahr et al., 2020) which would exhibit the tissue specificity of LHON and allow for a
more accurate representation of LHON disease phenotype characterisation. In Section
4, themousemodel for mitochondrial disease introduces a holistic systems approach to
seehow thepathwaysdirectly interactwith eachother, rather thandifferent assaysbeing
performed on different passages of cells. Additionally, with oestrogen implicated as
having a role in LHONdevelopment, amousemodel would allow for further pathways
to be analysed that are presently disregarded in isolated cell studies. Due to limited
LHON cell line availability, this could have been particularly impactful in this study
given that all control cell lines were of female origin compared to the affected cell
lines arising frommale patients; with the discordance in penetrance between male and
female LHON. Whilst within an isolated system and not exposed to mass influxes of
hormonal stimulation from other tissues, given the differential penetrance of LHON
between males and females, it would be beneficial to match the sex of case and control
samples or study males and females separately.
As awhole, this study succeeded in characterising specific LHONprimaryfibroblast
cell lines across a broad scope of biological responses.
Whilst we report a quantifiable difference in LHON cases to controls under Sea-
horse XFe96 Extracellular Flux Analyzer measurements, other pathways had a lim-
ited response and we would recommend that further cell work investigate established
iPSC lines. Given the specificity of cell types affected within LHON, with midget
RGCs primarily being affected, and the differences between fibroblast and neuronal
cell types, particularly myelination and mitochondrial distribution, it is possible that
further pathways are affected but that our model failed to exhibit symptoms due to cell
type differences.
Wewould recommend our novel qPCR assay for quantification of LHONmitochon-
drial copy number in future experiments. Our cells could also be directly investigated
with drug treatments to ascertain whether the treatment could prevent cell death, but
we would recommend limiting investigation to determining OXPHOS response and
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using a more sensitive model for investigation of other biological pathways.
5.3 RETINAL CHARACTERISATION OF MITOCHONDRIAL DISEASE
MOUSE
Cellular morphology indicates that the m.5024C>T + m.13715C>T mouse does have
an ocular phenotype. In collaboration with Doctors Andrew Osborne (University of
Cambridge) and PayamGammage (University of Glasgow), this was further confirmed
by ERG measurements in the live mice, as shown in Table 4.3. Wildtype comparisons
are only 5 months old and not strain-matched, so the measurements are not directly
comparable. Despite this, the visual reduction can be clearly seen and is further
confirmed bymeasurements by Brandli and Stone (2015) as indicative ofmeasurements
taken in mice retinas damaged by light. Of note, the heteroplasmic mice were much
older than the wildtype controls (roughly 9 or 24 months compared to two months).
Despite this, retinal thickness is often observed to shrink with age (Nieves-Moreno
et al., 2018) with certain layers being differentially affected in disease, such as the
thickening of the RPE in age-related macular degeneration (Brandl et al., 2019) and this
is the opposite of what we observed in our oldest mice, indicating that it may not be an
age related devolution.
Further work would be greatly improved by collection of mice at more similar life
stage to ensure that observed differences are not a result of the elderly mouse naturally
developing visual defects. Of note, the sectioned mutant tissue appeared greatly more
tortured than the wildtype and further work could measure the sum of angles across
the eye whilst normalising for the retinal curvature. Further, mutant tissue had a much
greater variability in the lengths of the retinal layers than the wildtype and analysis of
variance could further indicate that themutations destabilise a normally highly ordered
and regular tissue.
At present, a phenotype has been clearly observed and it would be interesting so see
whether this continues in additional samples and following genetic rescue by TALENs
or ZFNs (Bacman et al., 2018; Gammage et al., 2018b).
This would require a much larger mouse cohort to compare intraocular injection
of one retina against the untreated eye as flat mount and tissue section preparations
would then have to be observed in separate cohorts. We would recommend ageing the
mice to 24 months as our cohort found that the phenotype was most significant in the
elderly mice. Other mouse models of retinal disease have also found that phenotype
is age dependent (John et al., 1998) and given that our phenotype increased in severity
with age, it is possible that sacrificing the mice at an earlier date could fail to capture
the phenotype.
The new methodology for measuring RGC density and volume appears greatly
improved, allowing for total retinal cell counts and confidence in regional selection
accuracy. More interestingly, further staining could be applied and it would allow for
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a mosaic pattern of different sub-population of RGCs across the whole eye. As the
retina contains different populations of RGCs across the eye, it could be possible that
one sub-population is more affected by mitochondrial disease than the others.
Given that midget cells, which are more commonly positioned around the central
papillomacular bundle, are primarily affected in LHON (Pavlidis et al., 2006; Sadun
et al., 2000), this methodology could allow for validation of this hypothesis and visual-
isation of possible compensatory mechanisms.
Of note, Figure 4.25 (E) shows that the size of each RGC within the central region
are smaller in all three samples than the edge and middle RGCs, this could indicate
that there is a greater proportion of midget cells in the central region than the outer
regions, as previously described by Pavlidis et al. (2006); Sadun et al. (2000).
The RPE was also collected alongside the retina, however, extreme difficulty was
encountered by the dark tissue colouration. Brightfield microscopy was attempted to
observe the cell structure, however, it was not optimised and no conclusions could be
drawn. Our methodology allows for RPE collection but further optimisation would be
required to allow for whole RPE flat mount imaging.
The limited sample availability meant that no analysis between wildtype and
m.5024C>T + m.13715C>T mutant could be observed from flat mount macro struc-
ture and addition of wildtype samples would immediately improve analytic options.
Given that M3:M5 only has a heteroplasmy range of 21%, with three samples, it is not
possible to plot whether there is a heteroplasmy threshold or whether the differing
heteroplasmy affects the samples as a range of 21% difference in the mutational burden
is the equivalent that the sample with the lowest mutational burden (M3, 51%) contains
71% of the mutational burden captured in the sample with the greatest mutational
burden (M4,72%).
The characterisation of the m.5024C>T + m.13715C>T mouse has been particularly
interesting, and whilst replication is necessary, it has been confirmed to have a visual
defect which particularly affects cells within the ONL, OPL and INL in aged mice.
For this model, further investigation is needed to ascertain whether it arises as a late-
onset disease phenotype or a natural ageing progression. For LHON specific studies,
further work using one of the other LHONmice described in Section 4.1 could allow for
LHONspecific analysis and comparative analysis of the result of varyingmitochondrial
mutations on retinal phenotype.
We have established a technical framework which displays whole eye RGC dis-
tribution and counts; this could readily be adapted to co-stain the tissue for specific
neurological markers and subsets of RGC sub-populations could be further identified.
This framework could be applied to a specific LHON mouse model to characterise
disease and allow for drug treatment in a live, holistic system, and the characterisation
of the m.5024C>T + m.13715C>T mouse shows that it exhibits a previously unknown
retinal phenotype whilst aged.
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5.4 CONCLUDING REMARKS
LHON is a crippling disease for those affected and both patients and their families’
quality of life is greatly reduced. With extremely limited treatment strategies, further
investigation is necessary and this project sought to characterise LHONpenetrance and
identify novel predictive variants. Further, accurate characterisation of the phenotype
on a cellular level is necessary for drug design and to target involved mechanisms.
Whilst rare disease is often considered to be ‘simple’, this is clearly not the case
in LHON and identification of novel genetic features would also allow for improved
genetic counselling if it were possible to more accurately predict disease development.
As outlined in Section 1.6, this project sought to explore fundamental pathological
mechanisms which contribute to retinal defects by combining a systematic analysis of
pathophysiological mechanisms using in vitro models and analysis of the underlying
genomic traits associated with LHON.
We have identified 45 candidate genes which appear relevant in LHON disease
progression, with pathway over-representation showing that the majority of identified
pathways were clearly relevant and the others relate to a broader function in cellular
mechanisms. Whilst further assessment in a different cohort is necessary to fully val-
idate these candidate modifier genes, with 3/45 already known to specifically cause
optic neuropathy and others implicated in cell fate, oxidative phosphorylation, and
highly significant in neurogenesis, they do appear to be a favourable route of investi-
gation.
Given that affected mothers are more likely to transmit LHON to their offspring, it
is possible that some of the missing heritability of LHON is through heritable modifier
genes exerting a subtle influence in likelihood of disease onset.
We specifically characterised known LHON fibroblast cell lines and found that they
behaved as expected of LHON cell lines, with a significant reduction in respiratory
capabilities but limited significance in other measured assays. Given these limitations,
wewould recommend furtherwork to investigate othermodels, such as iPSCs, as tissue
specificity potentially limits the phenotype expression in other biological pathways.
We specifically validated a new qPCR assay to allow for accurate quantification
of mtDNA across the three most common LHON primary mutations - m.11778G>A,
m.3460G>A and m.14484T>C. This improved the likelihood of positioning the primers
and probes over a known SNP from ~1/8.9 to ~1/386.5 for one of the mitochondrial
primers and we also altered our B2M primer set to improve efficiency with the new
primer set reaching the detectable threshold 1.4-3.78 cycles earlier depending on the
sample DNA source.
Finally, we investigated a m.5024C>T + m.13715C>T mitochondrial disease mouse
for a retinal phenotype and identifieda reduction in retinal functionality both in vivo and
at a cellular level. Despite limited sample size, power calculations indicated that reduc-
tion in ERG measurements were so significant that live mice carrying the m.5024C>T
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+ m.13715C>T mutations are functionally affected with reduced vision. Cellular in-
vestigations were less significant with a phenotype appearing to only develop in aged
mice. This could be either late disease onset or natural visual loss through ageing
as wildtype controls were not age matched, but in addition to the highly disordered
tissue sections, we found a thickening of the retinal layers which is the opposite of the
common age-related retinal shrinkage. The technical frameworkwhichwas established
within this mouse model could readily be applied to other mouse models of retinal
disease, including a LHON specific one. It offers new opportunities to understand the
retinal mosaicism and evolution of retinal disease onset.
We cannot fully ascertain whether measurements occur as a result of genetic defects
or as a result of underlying disease pathogenesis, however, with identification of new
candidate genes for LHON and methods to quantify mitochondrial copy number and
characterise retinal phenotype within a mouse model, we are hopeful in eventual
improvement of diagnostic and treatment options.
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Figure S1: Counts of LHON affected patients by the age that they develop at within a cohort of 133
Italian and 111 British affected LHON patients. Splitting by gender (A) and further splitting by
country of origin (B).
Nuclear DNA Variants
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Table S1: 2-sample test for equality of proportions with Yates Correction between affected and






















Table S2: Illumina Infinium HumanMethylation27 BeadChip probe distribution, after quality control.
Chromosome Count Chromosome Count
1 2863 13 490
2 1682 14 824
3 1498 15 822
4 992 16 1192
5 1141 17 1575
6 1477 18 390
7 1241 19 1896
8 929 20 880
9 1063 21 311
10 1034 22 642
11 1714 X 1046
12 1511 Y 7
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Figure S2: Probes per chromosome (A) and percentages remaining (B) at different detection thresholds.
235
Figure S3: Negative control probes of the Illumina Infinium HumanMethylation27 BeadChips used
within this study. Note the final number in the sample identifier indicators which array it was loaded
onto and the variation of measurements between batches.
236
Figure S4: P-Value of methylation beta value per sample.
237
Figure S5: Density distribution of two colour channels; before (A) and after (B) quantile normalisation.
Figure S6: Global methylation patterns by disease status and gender.
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Table S3: Differentially hypermethylated genes in LHON patients compared to unaffected carriers,
emphasising hypermethylation in males compared to females out of a maximum of 40 tests.
Mitochondrial genes identified from MitoCarta 2.0 (Calvo et al., 2016; Pagliarini et al., 2008) and






ECT2 40 NA NA YES
C20orf102 NA NA NA NA
FGF20 NA NA NA NA
GJA7 NA NA NA NA
GNAI1 NA NA NA YES
IPO9 NA NA NA YES
KCNE1L NA 40 NA NA
TSPAN32 NA NA NA NA
WIRE NA NA NA NA
ZNF273 NA NA NA YES
CMTM6 NA NA NA YES
FLJ30834 40 NA NA NA
NSF NA NA NA YES
RAB32 NA NA YES YES
FZD1 40 NA NA NA
NFATC2IP 40 NA NA YES
GRB10 NA NA NA YES
HLA-C 39 NA NA YES
HGF 40 NA NA YES
PCDHGC4 NA NA NA YES
AIRE 40 NA NA NA
BMP8A NA NA NA NA
LOC349136 39 NA NA NA
MEGF10 40 NA NA YES
SCN4B 40 NA NA YES
SCUBE3 40 NA NA NA
SLC25A36 NA NA YES YES
SLC6A3 NA NA NA NA
TLX2 40 NA NA YES
NETO1 NA NA NA YES
C1orf85 NA NA NA YES
C20orf98 NA NA NA NA
LAMC2 NA NA NA NA
TMEM34 NA NA NA NA
C3orf15 NA NA NA NA
IRF6 40 NA NA YES
NIPA1 40 NA NA YES
THRB 40 NA NA YES
ADCY2 NA NA NA YES
GPR157 NA NA NA NA
LPPR4 39 NA NA NA
ITGA1 39 NA NA YES
RBP4 NA NA NA NA
GPM6A NA NA NA YES
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Table S4: Differentially hypomethylated genes in LHON patients compared to unaffected carriers,
emphasising hypomethylation in males compared to females out of a maximum of 40 tests.
Mitochondrial genes identified from MitoCarta 2.0 (Calvo et al., 2016; Pagliarini et al., 2008) and






BXDC1 NA 40 NA NA
EFNB1 40 NA NA YES
COPB2 NA NA NA YES
DNASE1L1 40 NA NA YES
EVL NA NA NA YES
GPR37L1 NA NA NA YES
IDH3G 40 NA YES YES
IGSF8 NA NA NA YES
IQSEC1 NA NA NA YES
LINS1 NA NA NA NA
RUNX3 NA NA NA NA
SLC6A18 NA NA NA NA
STK6 NA NA NA NA
TFAP4 NA NA NA YES
PHYH NA NA YES YES
RAB32 NA NA YES YES
SN NA NA NA NA
FLJ10996 NA NA NA NA
TNS3 NA NA NA YES
LOC317671 NA NA NA NA
DNAJB13 NA NA NA NA
C20orf75 NA NA NA NA
NANP NA 39 NA NA
Figure S7: Matches of LHON hypermethylated (red) and hypomethylated (genes) in MSigDB’s C2
curated gene sets of chemical and genetic perturbations (3302 gene sets).
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Figure S8: Matches of LHON hypermethylated (red) and hypomethylated (genes) in MSigDB’s C5 GO
gene sets of biological processes (7350 gene sets).
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Table S5: GO C2 curated gene sets of chemical and genetic perturbations gene sets which are
over-represented in genes which show differential methylation between LHON patients and carriers, and
contain exome variants which uniquely appear in patients compared to carriers in a dominant or
recessive model. k = cross-matched genes and K = number of genes in the gene set.





Benporath_Es_With_H3K27Me3 9 0.008 1.12E-06 3.71E-03
Hoebeke_Lymphoid_Stem_Cell_Up 4 0.041 2.60E-06 4.29E-03
Benporath_Eed_Targets 8 0.008 7.78E-06 8.57E-03
Nuytten_Nipp1_Targets_Dn 7 0.008 1.75E-05 1.45E-02
Ingram_Shh_Targets_Dn 3 0.048 3.34E-05 2.21E-02
Rodrigues_Thyroid_Carcinoma_Up 2 0.133 9.76E-05 4.85E-02
Verhaak_Aml_With_Npm1_Mutated_Dn 4 0.016 1.05E-04 4.85E-02
Meissner_Brain_Hcp_With_H3K27Me3 4 0.015 1.30E-04 4.85E-02
Boylan_Multiple_Myeloma_C_D_Dn 4 0.015 1.42E-04 4.85E-02
Rodrigues_Thyroid_Carcinoma_Anaplastic_Dn5 0.010 1.64E-04 4.85E-02
Cheng_Imprinted_By_Estradiol 3 0.027 1.76E-04 4.85E-02
Jackson_Dnmt1_Targets_Dn 2 0.100 1.76E-04 4.85E-02
Chiba_Response_To_Tsa_Dn 2 0.095 1.95E-04 4.94E-02
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Table S6: GO C5 Biological Process Complete gene sets which are over-represented in genes which
show differential methylation between LHON patients and carriers, and contain exome variants which
uniquely appear in patients compared to carriers in a dominant or recessive model. k = cross-matched
genes and K = number of genes in the gene set.





Neurogenesis 14 0.009 2.19e-10 1.26e-06
Neuron_Differentiation 13 0.010 3.43e-10 1.26e-06
Neuron_Development 10 0.009 8.55e-08 2.09e-04
Locomotion 12 0.006 2.47e-07 4.54e-04
Cellular_Response_To_Antibiotic 5 0.034 3.45e-07 5.07e-04
Response_To_Drug 9 0.009 5.37e-07 5.61e-04
Regulation_Of_Cell_Population_Proliferation 11 0.006 5.73e-07 5.61e-04
Cell_Motility 11 0.006 6.10e-07 5.61e-04
Response_To_Antibiotic 6 0.018 7.99e-07 6.53e-04
Positive_Regulation_Of_Signalling 11 0.006 1.11e-06 8.19e-04
Cellular_Response_To_Drug 6 0.017 1.46e-06 9.78e-04
Regulation_Of_Neuron_Differentiation 7 0.011 3.12e-06 1.91e-03
Cell_Cell_Signalling 10 0.006 3.39e-06 1.92e-03
Regulation_Of_Phosphorus_Metabolic_Process 10 0.006 4.42e-06 2.32e-03
Positive_Regulation_Of_Phosphorus_Metabolic_Process 8 0.007 9.28e-06 4.55e-03
Cellular_Component_Morphogenesis 8 0.007 1.14e-05 5.23e-03
Cell_Projection_Organization 9 0.006 1.34e-05 5.80e-03
Protein_Phosphorylation 10 0.005 1.63e-05 6.66e-03
Positive_Regulation_Of_Protein_Modification_Process 8 0.007 2.18e-05 8.45e-03
Negative_Regulation_Of_Response_To_Oxidative_Stress 3 0.054 2.35e-05 8.62e-03
Positive_Regulation_Of_Protein_Metabolic_Process 9 0.006 2.46e-05 8.62e-03
Response_To_Endogenous_Stimulus 9 0.006 2.65e-05 8.84e-03
Regulation_Of_Nervous_System_Development 7 0.008 2.83e-05 9.03e-03
Regulation_Of_Cell_Development 7 0.008 3.35e-05 1.03e-02
Cell_Part_Morphogenesis 6 0.009 4.91e-05 1.32e-02
Muscle_Organ_Development 5 0.012 5.02e-05 1.32e-02
Response_To_Forskolin 2 0.182 5.13e-05 1.32e-02
Positive_Regulation_Of_
Multicellular_Organismal_Process 9 0.005 5.15e-05 1.32e-02
Regulation_Of_Oxidative_Stress_Induced_Cell_Death 3 0.041 5.20e-05 1.32e-02
Regulation_Of_Protein_Modification_Process 9 0.005 6.31e-05 1.54e-02
Enzyme_Linked_Receptor_Protein_Signalling_Pathway 7 0.007 6.50e-05 1.54e-02
Regulation_Of_Cell_Differentiation 9 0.005 6.85e-05 1.57e-02
Striated_Muscle_Cell_Proliferation 3 0.037 7.10e-05 1.57e-02
Response_To_Platelet_Aggregation_Inhibitor 2 0.154 7.26e-05 1.57e-02
Response_To_Growth_Factor 6 0.008 7.68e-05 1.61e-02
Adenylate_Cyclase_Inhibiting_G_Protein
_Coupled_Receptor_Signalling_Pathway 3 0.034 9.39e-05 1.92e-02
Negative_Regulation_Of_Cell_Population_Proliferation 6 0.008 9.78e-05 1.94e-02
Cell_Death_In_Response_To_Oxidative_Stress 3 0.033 1.00e-04 1.94e-02
Cellular_Response_To_Oxygen_Containing_Compound 7 0.006 1.05e-04 1.97e-02
Cellular_Response_To_Ketone 3 0.032 1.10e-04 1.98e-02
Regulation_Of_Response_To_Oxidative_Stress 3 0.032 1.10e-04 1.98e-02
Cellular_Response_To_Hydrogen_Peroxide 3 0.030 1.29e-04 2.25e-02
Regulation_Of_Response_To_Drug 3 0.030 1.37e-04 2.34e-02
Positive_Regulation_Of_Rna_Biosynthetic_Process 8 0.005 1.45e-04 2.42e-02
Response_To_Oxygen_Containing_Compound 8 0.005 1.55e-04 2.54e-02
Positive_Regulation_Of_Nervous_System_Development 5 0.009 1.73e-04 2.77e-02
Cellular_Response_To_Oxidative_Stress 4 0.013 2.12e-04 3.32e-02
Negative_Regulation_Of_
Multicellular_Organismal_Process 7 0.005 2.39e-04 3.60e-02
Regulation_Of_Cell_Death 8 0.005 2.40e-04 3.60e-02
Negative_Regulation_Of_Cellular_Response_To_Drug 2 0.083 2.55e-04 3.75e-02
Activation_Of_Protein_Kinase_Activity 4 0.012 3.16e-04 4.55e-02
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Table S7: Genes contributing to GO C5 Biological Process Complete pathways which are
over-represented in PANTHER over-representation test.

















Investigating genes at an individual level, following gene summaries have been adapted
from GeneCards (Stelzer et al., 2016), Entrez (RefSeq) (McEntyre, 1998; O’Leary et al.,
2016) and UniProtKB/Swiss-Prot (Consortium, 2018) to identify relevant functional
details.
ADCY2
Adenylate Cyclase 2 is a Protein Coding gene. Among its related pathways are RET
signalling and Oocyte meiosis. GO annotations related to this gene include protein
heterodimerisation activity and phosphorus-oxygen lyase activity. This gene encodes a
member of the family of adenylate cyclases, which are membrane-associated enzymes
that catalyze the formation of the secondary messenger cyclic adenosine monophos-
phate. This enzyme is insensitive to Ca2+/calmodulin, and is stimulated by the G
protein beta and gamma subunit complex.
AIRE
Autoimmune Regulator is a Protein Coding gene. Diseases associated with AIRE
include Autoimmune Polyendocrine Syndrome, Type I, With Or Without Reversible
Metaphyseal Dysplasia andHypoparathyroidism, Familial Isolated. Among its related
pathways are Ubiquitin mediated proteolysis and Primary immunodeficiency. GO
annotations related to this gene include identical protein binding and transcription
regulatory region DNA binding. Mutations in this gene cause the rare autosomal-
recessive systemic autoimmune disease termed autoimmune polyendocrinopathywith
candidiasis and ectodermal dystrophy.
BMP8A
Bone Morphogenetic Protein 8a is a Protein Coding gene. Among its related path-
ways are G-Protein-Coupled Receptor (GPCR) Pathway and Nanog in Mammalian
Embryonic Stem Cell Pluripotency. GO annotations related to this gene include cy-
tokine activity and Transforming Growth Factor-β (TGF-β) receptor binding. This gene
encodes a secreted ligand of the TGF-β superfamily of proteins. Ligands of this family
bind various TGF-β receptors leading to recruitment and activation of SMAD family
transcription factors that regulate gene expression. Plays a role in calcium regulation
and bone homeostasis (By similarity). Signalling protein involved in regulation of
thermogenesis and energy balance.
CMTM6
CKLF Like MARVEL Transmembrane Domain Containing 6 is a Protein Coding
gene. Among its related pathways are Innate Immune System. GO annotations related
to this gene include cytokine activity. This gene belongs to the chemokine-like factor
gene superfamily, a novel family that is similar to the chemokine and transmembrane
4 superfamilies. Master regulator of recycling and plasma membrane expression an




Epithelial Cell Transforming 2 is a Protein Coding gene. Diseases associated with
ECT2 includeBreastCancer. Among its relatedpathways are SignallingbyRhoGTPases
and p75NTR receptor-mediated signalling. GOannotations related to this gene include
protein homodimerisation activity andGTPase activator activity. The expression of this
gene is elevated with the onset of DNA synthesis and remains elevated during G2 and
M phases. Drive tumour cell proliferation and invasion. Also stimulates genotoxic
stress-induced RHOB activity in breast cancer cells leading to their cell death.
FGF20
Fibroblast Growth Factor 20 is a Protein Coding gene. Diseases associated with
FGF20 include Renal Hypodysplasia/Aplasia 2 and Renal Agenesis, Bilateral. Among
its related pathways are Gastric cancer and Negative regulation of FGFR3 signalling.
GOannotations related to this gene include growth factor activity andfibroblast growth
factor receptor binding. The protein encoded by this gene is a member of the fibrob-
last growth factor family. The fibroblast growth factors possess broad mitogenic and
cell survival activities, and are involved in a variety of biological processes including
embryonic development, cell growth, morphogenesis, tissue repair, tumour growth
and invasion. This gene product is a secreted neurotrophic factor but lacks a typical
signal peptide. It is expressed in normal brain, particularly the cerebellum, and may
regulate central nervous system development and function. Homodimerisation of this
protein was shown to regulate its receptor binding activity and concentration gradient
in the extracellular matrix. Genetic variations of this gene have been associated with
Parkinson disease susceptibility.
FZD1
Frizzled Class Receptor 1 is a Protein Coding gene. Diseases associated with FZD1
include Exudative Vitreoretinopathy and Brachydactyly, Type B1. Among its related
pathways are Gastric cancer and Association Between Physico-Chemical Features and
Toxicity Associated Pathways. GO annotations related to this gene include GPCR
activity and transmembrane signalling receptor activity. Members of the ’frizzled’ gene
family encode 7-transmembrane domain proteins that are receptors for Wnt signalling
proteins. Functions in the canonical Wnt/beta-catenin signalling pathway.
GNAI1
G Protein Subunit Alpha I1 is a Protein Coding gene. Diseases associated with
GNAI1 include Pertussis and Cholera. Among its related pathways are Human cy-
tomegalovirus infection and GPCR Pathway. GO annotations related to this gene in-
cludeGTPbinding andobsolete signal transducer activity. Guanine nucleotide-binding
proteins function as transducers downstream of GPCRs in numerous signalling cas-
cades. The alpha chain contains the guanine nucleotide binding site and alternates be-
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tween an active, GTP-bound state and an inactive, GDP-bound state. Inhibits adenylate
cyclase activity, leading to decreased intracellular Cyclic Adenosine Monophosphate
(cAMP) levels (By similarity).
GPM6A
Glycoprotein M6A is a Protein Coding gene. GO annotations related to this gene
include calcium channel activity. Involved in neuronal differentiation, including dif-
ferentiation and migration of neuronal stem cells. Plays a role in neuronal plasticity
and is involved in neurite and filopodia outgrowth, filopodia motility and probably
synapse formation. GPM6A-induced filopodia formation involves Mitogen-Activated
Protein Kinase (MAPK) and Src signalling pathways. May be involved in neuronal
nerve growth factor-dependent Ca2+ influx. May be involved in regulation of endocy-
tosis and intracellular trafficking of GPCRs; enhances internalization and recycling of
µ-type opioid receptor.
GPR157
G Protein-Coupled Receptor 157 is a Protein Coding gene. Diseases associated
with GPR157 include Stromal Dystrophy. GO annotations related to this gene include
GPCR activity and transmembrane signalling receptor activity. Orphan receptor that
promotes neuronal differentiation of radial glial progenitors. The activity of this recep-
tor is mediated by a G(q)-protein that activates a phosphatidylinositol-calcium second
messenger.
GPR37L1
G Protein-Coupled Receptor 37 Like 1 is a Protein Coding gene. Among its related
pathways are Peptide ligand-binding receptors and Neuroscience. GO annotations
related to this gene include GPCR activity. Has been shown to bind the neuroprotec-
tive and glioprotective factor prosaposin, leading to endocytosis followed by a MAPK
phosphorylation cascade, however, other studies have shown that prosaposin does not
increase activity. Regulates baseline blood pressure in females and protects against
cardiovascular stress in males (By similarity). Mediates inhibition of astrocyte gluta-
mate transporters and reduction in neuronal N-methyl-D-aspartate receptor activity
(By similarity).
GRB10
Growth Factor Receptor Bound Protein 10 is a Protein Coding gene. Diseases
associated with GRB10 include Silver-Russell Syndrome and Spastic Paraplegia 17,
Autosomal Dominant. Among its related pathways are Beta-Adrenergic Signalling
and Signalling events Regulated by RET Tyrosine Kinase. GO annotations related to
this gene include SH3/SH2 adaptor activity and insulin receptor binding. This gene
encodes a growth factor receptor-binding protein that interacts with insulin receptors
and insulin-like growth-factor receptors. Over-expression of some isoforms of the
encoded protein inhibits tyrosine kinase activity and results in growth suppression.
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This gene is imprinted in a highly isoform- and tissue-specific manner, with expression
observed from the paternal allele in the brain, and from the maternal allele in the
placental trophoblasts.
HGF
Hepatocyte Growth Factor is a Protein Coding gene. Diseases associated with HGF
include Deafness, Autosomal Recessive 39 and Autosomal Recessive Non-Syndromic
Sensorineural Deafness Type Dfnb. Among its related pathways are Interleukin-7
signalling and RET signalling. GO annotations related to this gene include identical
protein binding and serine-type endopeptidase activity. This protein also plays a role in
angiogenesis, tumorogenesis, and tissue regeneration. Although the encoded protein
is a member of the peptidase S1 family of serine proteases, it lacks peptidase activity.
Mutations in this gene are associated with nonsyndromic hearing loss.
IDH3G
Isocitrate Dehydrogenase (NAD+) 3 Gamma is a Protein Coding gene. Diseases as-
sociated with IDH3G include Periventricular Heterotopia. Among its related pathways
are Pyruvatemetabolism andCitric Acid (TCA) cycle and Citrate cycle (TCA cycle). GO
annotations related to this gene include magnesium ion binding and oxidoreductase
activity, acting on the CH-OH group of donors, NAD or NADP as acceptor. Isocitrate
dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate.
These enzymes belong to two distinct subclasses, one of which utilizes NAD+ as the
electron acceptor and the other NADP+. Five isocitrate dehydrogenases have been re-
ported: three NAD+-dependent isocitrate dehydrogenases, which localize to the mito-
chondrial matrix, and two NADP+-dependent isocitrate dehydrogenases, one of which
is mitochondrial and the other predominantly cytosolic. NAD+-dependent isocitrate
dehydrogenases catalyze the allosterically regulated rate-limiting step of the tricar-
boxylic acid cycle.
IGSF8
Immunoglobulin Superfamily Member 8 is a Protein Coding gene. This gene en-
codes a member the EWI subfamily of the immunoglobulin protein superfamily. This
protein interacts with the tetraspanins CD81 and CD9 and may regulate their role in
certain cellular functions including cell migration and viral infection. The encoded
protein may also function as a tumour suppressor by inhibiting the proliferation of
certain cancers.
IPO9
IPO9 (Importin 9) is a Protein Coding gene. GO annotations related to this gene
include binding and protein transporter activity. Functions in nuclear protein import
as nuclear transport receptor. Serves as receptor for nuclear localization signals (NLS)
in cargo substrates. Is thought to mediate docking of the importin/substrate complex
to the nuclear pore complex (NPC) through binding to nucleoporin and the complex
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is subsequently translocated through the pore by an energy requiring, Ran-dependent
mechanism (PubMed:11823430).
IQSEC1
IQMotif And Sec7 Domain 1 is a Protein Coding gene. Among its related pathways
are Arf6 signalling events and EGF/EGFR Signalling Pathway. GO annotations related
to this gene include lipid binding and ARF guanyl-nucleotide exchange factor activity.
Guanine nucleotide exchange factor for ARF1 andARF6. Guanine nucleotide exchange
factor activity is enhanced by lipid binding. Accelerates GTP binding by ARFs of all
three classes. Guanine nucleotide exchange protein forARF6,mediating internalisation
of beta-1 integrin.
IRF6
Interferon Regulatory Factor 6 is a Protein Coding gene. Diseases associated with
IRF6 include Popliteal Pterygium Syndrome and Van DerWoude Syndrome 1. Among
its related pathways are Interferon gamma signalling and Innate Immune System. GO
annotations related to this gene include DNA-binding transcription factor activity. This
gene encodes a member of the interferon regulatory transcription factor (IRF) family.
Family members share a highly-conserved N-terminal helix-turn-helix DNA-binding
domain and a less conserved C-terminal protein-binding domain. The encoded protein
may be a transcriptional activator. Mutations in this gene are also associated with non-
syndromic orofacial cleft type 6.
ITGA1
Integrin Subunit Alpha 1 is a Protein Coding gene. Diseases associated with ITGA1
include Intestine Carcinoma In Situ and Colon Carcinoma In Situ. Among its related
pathways are Focal Adhesion and Dilated cardiomyopathy (DCM). GO annotations re-
lated to this gene include signalling receptor binding and collagen binding. This gene
encodes the alpha 1 subunit of integrin receptors. This protein heterodimerizes with
the beta 1 subunit to form a cell-surface receptor for collagen and laminin. The het-
erodimeric receptor is involved in cell-cell adhesion andmayplay a role in inflammation
and fibrosis.
LAMC2
Laminin Subunit Gamma 2 is a Protein Coding gene. Diseases associated with
LAMC2 include Epidermolysis Bullosa, Junctional, Herlitz Type and Epidermolysis
Bullosa, Junctional, Non-Herlitz Type. Among its related pathways are MET promotes
cell motility and Integrin Pathway. GO annotations related to this gene include hep-
arin binding. Laminins, a family of extracellular matrix glycoproteins, are the major
noncollagenous constituent of basement membranes. They have been implicated in a
wide variety of biological processes including cell adhesion, differentiation, migration,
signalling, neurite outgrowth and metastasis.
LINS1
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Lines Homolog 1 is a Protein Coding gene. Diseases associated with LINS1 include
Mental Retardation, Autosomal Recessive 27 andAutosomal RecessiveNon-Syndromic
Intellectual Disability. The Drosophila segment polarity gene lin encodes a protein,
lines, which plays important roles in development of the epidermis and hindgut. This
gene encodes a protein containing a lines-like domain.
MEGF10
Multiple EGF Like Domains 10 is a Protein Coding gene. Diseases associated with
MEGF10 include Myopathy, Areflexia, Respiratory Distress, And Dysphagia, Early-
Onset and Dysphagia. GO annotations related to this gene include endopeptidase
inhibitor activity. This gene encodes a member of the multiple epidermal growth
factor-like domains protein family. Necessary for astrocyte-dependent apoptotic neu-
ron clearance in the developing cerebellum (PubMed:27170117). Plays role in muscle
cell proliferation, adhesion and motility. Controls the balance between skeletal muscle
satellite cells proliferation anddifferentiation through regulation of the notch signalling
pathway. May also function in the mosaic spacing of specific neuron subtypes in the
retina through homotypic retinal neuron repulsion. Mosaics provide a mechanism to
distribute each cell type evenly across the retina, ensuring that all parts of the visual
field have access to a full set of processing elements.
NANP
N-Acetylneuraminic Acid Phosphatase is a Protein Coding gene. Diseases associ-
atedwithNANP include Parasitic Protozoa InfectiousDisease and Intracranial Abscess.
Among its related pathways are Synthesis of substrates in N-glycan biosythesis and
Transport to the Golgi and subsequent modification. GO annotations related to this
gene include hydrolase activity and N-acylneuraminate-9-phosphatase activity.
NETO1
Neuropilin And Tolloid Like 1) is a Protein Coding gene. GO annotations related
to this gene include ionotropic glutamate receptor binding. This gene encodes a trans-
membraneprotein containing twoextracellularCUBdomains followedbya low-density
lipoprotein class A (LDLa) domain. This protein is thought to play a critical role in spa-
tial learning and memory by regulating the function of synaptic N-methyl-D-aspartic
acid receptor complexes in the hippocampus.
NIPA1
NIPA Magnesium Transporter 1 is a Protein Coding gene. Diseases associated
with NIPA1 include Spastic Paraplegia 6, Autosomal Dominant and Spastic Paraplegia
6. Among its related pathways are Miscellaneous transport and binding events and
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine
compounds. GO annotations related to this gene include magnesium ion transmem-
brane transporter activity. This gene encodes a magnesium transporter that associates
with early endosomes and the cell surface in a variety of neuronal and epithelial cells.
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This proteinmayplay a role innervous systemdevelopment andmaintenance. Multiple
transcript variants encoding different isoforms have been found for this gene. Muta-
tions in this gene have been associated with autosomal dominant spastic paraplegia
6.
PCDHGC4
Protocadherin Gamma Subfamily C, 4 is a Protein Coding gene. GO annotations
related to this gene include calcium ion binding. This gene is a member of the pro-
tocadherin gamma gene cluster. Potential calcium-dependent cell-adhesion protein,
these neural cadherin-like cell adhesion proteins most likely play a critical role in the
establishment and function of specific cell-cell connections in the brain.
PHYH
Phytanoyl-CoA 2-Hydroxylase is a Protein Coding gene. Diseases associated with
PHYH include Refsum Disease, Classic and Retinitis Pigmentosa. Among its related
pathways are Peroxisome andMetabolism. GO annotations related to this gene include
electron transfer activity and cofactor binding. This gene is a member of the PhyH
family and encodes a peroxisomal protein that is involved in the α-oxidation of 3-
methyl branched fatty acids. Specifically, this protein converts phytanoyl-CoA to 2-
hydroxyphytanoyl-CoA.
RAB32
RAB32,MemberRASOncogene Family) is a ProteinCoding gene. Among its related
pathways are Vesicle-mediated transport and Sertoli-Sertoli Cell Junction Dynamics.
GO annotations related to this gene include GTP binding. The protein encoded by this
gene anchors the type II regulatory subunit of protein kinase A to the mitochondrion
and aids in mitochondrial fission. The encoded protein also appears to be involved in
autophagy and melanosome secretion.
RBP4
Retinol Binding Protein 4 is a Protein Coding gene. Diseases associated with
RBP4 include Retinal Dystrophy, Iris Coloboma, And Comedogenic Acne Syndrome
and Microphthalmia, Isolated, With Coloboma 10. Among its related pathways are
Metabolism of fat-soluble vitamins and the visual cycle I (vertebrates). GO annotations
related to this gene include protein heterodimerisation activity and retinol binding.
This protein belongs to the lipocalin family and is the specific carrier for retinol (vita-
min A alcohol) in the blood. It delivers retinol from the liver stores to the peripheral
tissues. In plasma, the RBP-retinol complex interacts with transthyretinwhich prevents
its loss by filtration through the kidney glomeruli. A deficiency of vitamin A blocks
secretion of the binding protein post-translationally and results in defective delivery
and supply to the epidermal cells.
RUNX3
RUNX Family Transcription Factor 3 is a Protein Coding gene. Diseases associated
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with RUNX3 include Testicular Yolk Sac Tumour and Cleidocranial Dysplasia. Among
its related pathways areWnt /Hedgehog /Notch andMeasles. GOannotations related
to this gene include DNA-binding transcription factor activity and RNA polymerase II
regulatory region sequence-specific DNA binding. This gene encodes a member of the
runt domain-containing family of transcription factors. A heterodimer of this protein
and a beta subunit forms a complex that binds to a number of enhancers and promoters,
and can either activate or suppress transcription.
SCN4B
Sodium Voltage-Gated Channel Beta Subunit 4 is a Protein Coding gene. Diseases
associated with SCN4B include Long Qt Syndrome 10 and Familial Atrial Fibrillation.
Among its related pathways are Cardiac conduction and L1CAM interactions. GO
annotations related to this gene include ion channel binding and voltage-gated sodium
channel activity. The protein encoded by this gene is one of several sodium channel
beta subunits. These subunits interact with voltage-gated alpha subunits to change
sodium channel kinetics.
SCUBE3
Signal Peptide, CUB Domain And EGF Like Domain Containing 3 is a Protein
Coding gene. Diseases associated with SCUBE3 include Lung Cancer. GO annotations
related to this gene include calcium ion binding. This gene encodes a member of
the signal peptide, complement subcomponents C1r/C1s, Uegf, bone morphogenetic
protein-1 and epidermal growth factor-like domain containing protein family.
SLC25A36
Solute Carrier Family 25 Member 36 is a Protein Coding gene. GO annotations
related to this gene include pyrimidine nucleotide transmembrane transporter activ-
ity. Mitochondrial transporter that imports/exports pyrimidine nucleotides into and
from mitochondria. Participates in mitochondrial genome maintenance, regulation of
mitochondrial membrane potential and mitochondrial respiration.
SLC6A18
Solute Carrier Family 6 Member 18 is a Protein Coding gene. Diseases associated
with SLC6A18 include Iminoglycinuria and Hyperglycinuria. Among its related path-
ways are Amino acid transport across the plasma membrane and Transport of glucose
and other sugars, bile salts and organic acids, metal ions and amine compounds. GO
annotations related to this gene include neurotransmitter:sodium symporter activity.
The SLC6 family of proteins, which includes SLC6A18, act as specific transporters for
neurotransmitters, amino acids, and osmolytes like betaine, taurine, and creatine. SLC6
proteins are sodium co-transporters that derive the energy for solute transport from
the electrochemical gradient for sodium ions.
TFAP4
Transcription Factor AP-4 is a Protein Coding gene. Diseases associatedwith TFAP4
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include Spinocerebellar Ataxia 12. Among its related pathways are Proteoglycans
in cancer. GO annotations related to this gene include protein homodimerisation
activity and protein heterodimerisation activity. Transcription factors of the basic
helix-loop-helix-zipper family contain a basic domain, which is used for DNA binding,
and HLH and ZIP domains, which are used for oligomerization. Transcription factor
AP4 activates both viral and cellular genes.
THRB
Thyroid Hormone Receptor Beta is a Protein Coding gene. Diseases associated with
THRB include Thyroid Hormone Resistance, Selective Pituitary and Thyroid Hormone
Resistance, Generalized, AutosomalDominant. Among its related pathways areNeural
StemCell Differentiation Pathways andLineage-specificMarkers andThyroid hormone
signalling pathway. GO annotations related to this gene include DNA-binding tran-
scription factor activity and enzyme binding. The protein encoded by this gene is a
nuclear hormone receptor for triiodothyronine. It is one of the several receptors for
thyroid hormone, and has been shown to mediate the biological activities of thyroid
hormone. Knockout studies in mice suggest that the different receptors, while having
certain extent of redundancy, may mediate different functions of thyroid hormone.
TLX2
T Cell Leukemia Homeobox 2 is a Protein Coding gene. Diseases associated
with TLX2 include Intestinal Pseudo-Obstruction and Neuronal Intestinal Dysplasia.
Among its related pathways are ALK2 signalling events and Cell Differentiation - In-
dex. This gene is a member of an orphan homeobox-containing transcription factor
family. Transcription activator that binds DNA elements via its homeobox. Required
for normal cell death of enteric neurons in the gastrointestinal tract.
TNS3
Tensin 3 is a Protein Coding gene. Diseases associated with TNS3 include Anisakia-
sis and Primary Syphilis. Among its related pathways are MET promotes Cell Motility
and Signalling by GPCR. GO annotations related to this gene include phosphatase
activity. May play a role in actin remodelling. Involved in the dissociation of the
integrin-tensin-actin complex. Seems to be involved in mammary cell migration.
TSPAN32
Tetraspanin 32 is a Protein Coding gene. This gene, which is a member of the
tetraspanin superfamily, is one of several tumour-suppressing subtransferable frag-
ments located in the imprinted gene domain of chromosome 11p15.5, an important
tumour-suppressor gene region. Alterations in this region have been associated with
Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical
carcinoma, and lung, ovarian and breast cancers.
ZNF273
Zinc Finger Protein 273 is a Protein Coding gene. Among its related pathways are
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Herpes simplex virus 1 infection and Gene Expression. GO annotations related to this
gene include nucleic acid binding. This nuclear protein is involved in transcriptional
regulation.
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FUNCTIONAL CHARACTERISATION OF LHON FIBROBLASTS
mtDNA Copy Number
Primers and Probes
Table S8: qPCR standard primer sequences and product size.
Gene Forward Sequence 5’-3’ Reverse Sequence 5’-3’ Product
Size (bp)
B2M CGCAATCTCCAGTGACAGAA GCAGAATAGGCTGCTGTTCC 1092
MT-ND1 CAGCCGCTATTAAAGGTTCG AGAGTGCGTCATATGTTGTTC 1040
MT-ND4 ATCGCTCACACCTCATATCC TAGGTCTGTTTGTCGTAGGC 1072
MT-RNR2 CAGTGACACATGTTTAACGGCGGAGGGGGGTTCATAGTAG 1026
Table S9: qPCR primer sequences and product size.



























Table S10: qPCR probe sequence, fluorophore and quencher.
Gene Fluorophore Quencher Sequence 5’-3’
B2M FAM BHQ_1 CCGTGTGAACCATGTGACTTTGTC
MT-ND1 HEX BHQ_1 ACCCGCCACATCTACCATCACCCTC
MT-ND4 Cy5 BHQ_2 CAACCAGCCAGAACGCCTGAACGCA
MT-RNR2 HEX BHQ_1 TACGACCTCGATGTTGGATCAGGACA
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qPCR Measurements
Table S11: T-Test values for change in Ct score between singleplex to duplex and triplex.
Duplex/Triplexed B2M ND4 RNR2
B2M - 0.013 0.458
ND4 0.276 - 0.015
RNR2 0.184 0.142 -
Triplex 0.057 0.071 0.012
Table S12: T-Test values for change in Ct score between duplex and triplex.
Duplex/Triplexed B2M ND4 RNR2
B2M - 0.405 0.020
ND4 0.135 - 0.289
RNR2 0.171 0.289 -
Table S13: Figure 3.12 graphs’ linear models showing the equation of the model, adjusted R-squared
value and the correlation between theMT-ND1 and MT-RNR2 copy number measurements.
Graph Formula Adjusted R-squared Correlation
A y = 141.215x - 9279.769 0.993 0.821
B y = 46.030x -2388.520 0.434 0.714
C y = 3.498x - 271.098 0.902 0.857
D y = 71.630x -7745.290 0.348 0.420
E y= 0.354x + 657.989 -0.088 0.275
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Figure S9: Preliminary qPCR copy number measurements for control DNA sample, control fibroblast
samples C1 and C2, unaffected sample U1-11778 and affected A1-11778. U1-11778 is the unaffected
mother of sample A1-11778 with the same mitochondrial background. Two biological replicates of each
sample were taken with three technical replicates and error bars indicate standard deviation.
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Figure S10: qPCR Ct measurement, showing each biological replicate inMT-RNR2 (A), B2M (B) and
MT-ND4 (C). A new dilution of Ctrl DNA 5 was prepared after the first replicate; demarcation
indicates that replicate 2 and 3 used the new dilution.
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Table S14: Welch two sample t-test significance of mtDNA copy number and percentage deletion.











Disease Grouped LHON 0.110 0.533
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ATP Production During Metabolic Stress
Table S15: Welch two sample t-test significance of ATP assay.






A1-11778 0.377 0.271 0.908 0.353
A2-14484 0.730 0.595 0.360 0.881
A3-11778 0.231 0.996 0.452 0.815
A4-11778 0.227 0.017 0.137 0.492
A5-3460 0.342 0.328 0.466 0.913
Mutation
Grouped
m.11778G>A 0.093 0.130 0.286 0.438
m.14484T>C 0.730 0.595 0.360 0.881
m.3460G>A 0.342 0.328 0.466 0.913
Disease
Grouped
LHON 0.629 0.908 0.316 0.642
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Cellular Oxygen Consumption














A1-11778 0.004 0.028 0.944 0.013 0.016 0.155
A2-14484 0.183 0.179 0.460 0.227 0.244 0.875
A3-11778 0.056 0.072 0.898 0.649 0.731 0.340
A4-11778 0.001 1.19e-05 0.414 0.021 0.032 0.820
A5-3460 0.002 0.001 0.737 0.009 0.012 0.049
Mutation Grouped
m.11778G>A 0.002 1.25e-04 0.743 0.066 0.091 0.873
m.14484T>C 0.183 0.179 0.460 0.227 0.244 0.875
m.3460G>A 0.002 0.001 0.737 0.009 0.012 0.049
Disease Grouped LHON 0.003 2.74e-04 0.669 0.083 0.113 0.652
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Calcium Homeostasis












Disease Grouped LHON 0.673


























Disease Grouped LHON 0.183
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Mitochondrial Network
Table S20: Number of cells used to quantify mitochondrial network and ER:mitochondrial


































A1-11778 0.267 0.221 0.760 0.251 0.047 0.036 0.299 0.006 0.360
A2-14484 0.464 0.524 0.847 0.060 0.710 0.939 0.851 0.890 0.058
A3-11778 0.530 0.330 0.714 0.746 0.848 0.775 0.919 0.645 0.912
A4-11778 0.466 0.403 0.696 0.471 0.013 0.036 0.571 0.285 0.760
A5-3460 0.058 0.024 0.092 0.131 0.174 0.458 0.895 0.617 0.016
Mutation Grouped
m.11778G>A 0.308 0.748 0.794 0.865 0.097 0.221 0.576 0.310 0.947
m.14484T>C 0.464 0.524 0.847 0.060 0.710 0.939 0.851 0.890 0.058
m.3460G>A 0.058 0.024 0.092 0.131 0.174 0.458 0.895 0.617 0.016
Disease Grouped LHON 0.637 0.237 0.600 0.377 0.773 0.673 0.748 0.635 0.203
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ER-Mitochondrial Interactions
Table S22: Welch two sample t-test significance of endoplasmic reticulum:mitochondrial





A1-11778 0.618 0.171 0.784
A2-14484 0.001 0.273 3.36e-04
A3-11778 0.175 0.272 0.197
A4-11778 0.180 0.036 0.153
A5-3460 0.081 0.416 0.082
Mutation Grouped
m.11778G>A 0.833 0.769 0.913
m.14484T>C 0.001 0.273 3.36e-04
m.3460G>A 0.081 0.416 0.082




PCR was used to amplify a 222 bp fragment spanning the m.5024 mutation site, us-
ing a biotinylated forward primer (5’-Biotin-TTCCACCCTAGCTATCATAAGC) and a
non-biotinylated reverse primer (5’-GTAGGTTTAATTCCTGCCAATCT). PCRproducts
were combined with dH2O, PyroMark PCR Kit (979006; QIAGEN) and 1 µl Strepta-
vidin Sepharose High Performance Beads (17-5113-01; GE Healthcare), and purified
and denatured using a PyroMark Q24 VacuumWorkstation.
Sequencing was carried out with PyroMark Gold Q24 Reagents (970802; QIAGEN)
according to manufacturer’s directions, using the sequencing primer
(5’-TGTAGGATGAAGTCTTACA).
Primers and Probes
Table S23: Pyrosequencing primer sequences and product size.








Table S24: Welch two sample t-test significance of differences in the length of retinal layers.
PR ONL OPL INL IPL RGC
Controls Grouped
M1 0.146 0.020 0.162 0.519 0.120 0.262
M2 0.626 0.172 0.005 0.087 0.003 0.127
M3 0.086 0.943 0.163 0.053 0.233 0.204
M4 0.079 0.046 0.007 0.009 0.003 0.025
M5 0.520 0.042 0.001 0.100 1.96e-04 0.008
Mutant Grouped 0.200 0.453 0.008 0.122 0.028 0.063
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Table S25: Welch two sample t-test significance of differences in the area (µm2) of which a single cell




M1 0.801 0.073 0.214
M2 0.154 0.809 0.874
M3 0.042 0.070 0.364
M4 0.041 3.51e-06 0.120
M5 0.025 0.015 0.316
Mutant Grouped 0.004 4.00e-04 0.320
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